

CURRICULUM VITAE

RICHARD T. MAZIARZ
415 NE Laurelhurst Place
Portland, Oregon 97232
Phone: (503) 231-2498

Business

Oregon Health and Science University
Adult Bone Marrow Transplant Program – UHN73C
3181 S.W. Sam Jackson Park Road
Portland, OR 97239
Telephone Number: (503) 494-4606
FAX Number: (503) 418-4054
Email: maziarzr@OHSU.edu

Personal

Date of Birth: October 30, 1953
Place of Birth: New London, Connecticut

Education

1974 B.S. University of Pennsylvania, Philadelphia, PA (Biology)
1979 M.D. Harvard Medical School, Boston, MA (Medicine)
1998-1999 American College of Physician Executives: Physicians in Management, Phase I, II, III
2007-2008 Foundation for Medical Excellence: Health Care Leadership for the 21st Century

Postdoctoral Training

Internships and Residencies

1979-1980 Intern in Internal Medicine, University Hospitals of Cleveland, Cleveland, OH
1980-1981 First-year Medical Resident, University Hospitals of Cleveland, Cleveland, OH
1981 Second-Year Medical Resident, University Hospitals of Cleveland, Cleveland, OH

Fellowships

1981-1985 Research Fellow in Immunology, Dana-Farber Cancer Institute, Boston, MA
1985-1987 Research/Clinical Fellow in Hematology, Brigham and Women's Hospital
1985-1988 Research Fellow in Medicine, Harvard Medical School
1986-1987 Clinical Fellow in Medical Oncology, Dana-Farber Cancer Institute

Appointments

1979-1981 Postdoctoral Fellow, Case Western Reserve Medical School, Cleveland, OH
1981-1985 Research Fellow in Pediatrics, Harvard Medical School, Boston, MA
1985-1989 Instructor in Medicine, Harvard Medical School
1987-1991 Associate Physician, Brigham and Women's Hospital
1989-1991 Assistant in Medicine, The Children's Hospital
1989-1991 Staff Physician (part-time), Brockton-West Roxbury VA Medical Center
1989-1991 Assistant Professor of Medicine, Harvard Medical School
1991-1993 Assistant Professor of Medicine, Oregon Health Sciences University
1992-1993 Assistant Professor of Microbiology & Immunology, Oregon Health Sciences University
1991- 2000 Staff Physician, Portland VA Medical Center
1991- Present Staff Physician, Oregon Health Sciences University
1992-1994 Acting Director, Bone Marrow Transplantation Program, OHSU
1992-1999 Program Leader, Experimental Therapeutics Program of Oregon Cancer Center
1993-1999 Associate Professor of Medicine, OHSU
1993- Present Associate Professor of Microbiology & Immunology, OHSU

Appointments (cont.)

1994- Director, Adult Blood & Marrow Transplantation Program, OHSU
1995-1996 Associate Director for Clinical Research (Interim), Oregon Cancer Center
1999- Professor of Medicine, OHSU
1999-2003 Program Leader, Transplantation/Immunology Program of Oregon Cancer Institute

Awards and Honors

1974 B.A., Cum laude, University of Pennsylvania
1985-1990 American Heart Association Clinician Scientist Award
2010,11,17 Portland Best Doctors
2005-2018 Castle Connelly Top Doctors for Cancer
2010-2018 Castle Connelly Top Doctors
2010 OHSU Technology Innovation Awards: Top Three License Award

Licensure and Certification

1982 Massachusetts Registration License No. 49120
1982 Diplomate, American Board of Internal Medicine, Certificate No. 89898
1988 Diplomate, Subspecialty of Hematology, American Board of Internal Medicine
1989 Diplomate, Subspecialty of Medical Oncology, American Board of Internal Medicine
1992 Oregon Registration License No. MD 17664

Editorial Review Boards

1990- AD HOC Reviewer, *Blood*
1990-1993 AD HOC Reviewer, *Cellular Immunology*
1991-1993 AD HOC Reviewer, *International Journal of Cancer*
1993-1996 Editorial Board, *Cellular Immunology*
1993 AD HOC Reviewer, *Journal of Cell Physiology*
2001- AD HOC Reviewer, *Experimental Hematology*
2002- AD HOC Reviewer, *Leukemia & Lymphoma*
2002- AD HOC Reviewer, *Bone Marrow Transplantation*
2003- AD HOC Reviewer, *Cancer*
2003 AD HOC Reviewer, *Mayo Clinic Proceedings*
2004- AD HOC Reviewer, *Biology of Blood & Marrow Transplantation*
2005- AD HOC Reviewer, *Experimental Hematology*
2008- AD HOC Reviewer, *Transplantation; Transfusion; Cytotherapy; Leukemia & Lymphoma*
2008-2013 Editorial Board, *Journal of Clinical Oncology*
2009-2011 Editorial Board, *The Open Leukemia Journal*
2011- Editorial Board, *Cytotherapy*
2014- Editorial Board, *Bone Marrow Transplantation*
2017- Editorial Board, *Advances in Cell and Gene Therapy*

OHSU Committee Assignments

1992-1994 Grant Review Subcommittee, Research and Development, Portland VAMC
1992-1993 Curriculum Committee, OHSU
1992-2003 Program Leaders Committee, Oregon Cancer Center
1994-1996 Research and Development Committee, Portland VAMC
1996-1998 Oncology Outreach Committee, OHSU Search Committee, DeArmond Chair for Cancer Research, OHSU
1999-2000 Clinical Trials Research Organization, OHSU
2000-2004 UMG Board of Directors, OHSU
2001-2002 OHSU Faculty Council
2002 UMG Subcommittee on Governmental Pension Plans
2002-2005 OHSUMG Pension Committee
2002-2004 OHSU Stem Cell Institute Steering Committee
2007 OHSU Faculty Engagement Committee
2007-2008 Search Committee, Hematology/ Medical Oncology Division Chair
2008-Present Knight Cancer Institute Oncology Quality Oversight Committee

2009-2014 FPP Quality & Risk Committee
 2012-2013 Search Committee, Hematology/ Medical Oncology Division Chair
 2013-2014 Search Committee, Acute Leukemia Program Leader
 2015- OHSU FFP Quality Review committee
 2017- KCI Immunotherapy Oversight committee
 2017- OHSU Hospital Medical Directors Performance Excellence team

Non-OHSU Committee Assignments

1986-1995 Class agent, Harvard Alumni Association, Medical School Class of 1979
 1986-1989 Admissions Committee, Harvard Medical School
 1994-1999 Advisor, Transplantation Group, Health Resource Commission, Oregon Health Plan
 1996, 1998 American Society of Hematology (ASH) Abstract Review for Bone Marrow Transplantation Submissions
 1996- Chair, Executive Committee, Northwest Marrow Transplantation Program
 1996- Clinical Oversight Committee, Northwest Marrow Transplantation Program
 1997 Member, Technology Assessment Panel for Autologous Bone Marrow Transplantation, Oregon Health Resource Commission
 1998 NIH Study Section, Experimental Therapeutics I, (Ad Hoc Review Panel on Bone Marrow Transplantation)
 1998 American Society of Hematology (ASH), Co-Chair: Scientific Session - Recurrence, Secondary Neoplasia and Long Term Complications after Transplantation
 1999 VAMC Merit Review Study Section (Ad Hoc Review on graft-versus-host-disease)
 2000 International Society for Experimental Hematology (ISEH), Co-Chair: Scientific Session- “Experimental Stem and Progenitor Cell Transplantation”
 2000 International Society for Experimental Hematology (ISEH), Chair: Corporate Symposium on “Transplantation of Hematopoietic Stromal and Mesenchymal Cells”
 2001 International Society for Hematotherapy and Graft Engineering (ISHAGE), Panelist, Mesenchymal Stem Cell Workshop on “Differentiation Capabilities and Models”
 2000 Amer Soc of Hem (ASH), Co-Chair: Scientific Session –“CML Clinical studies: novel agents, IFN, BMT”
 2001 International Society for Cellular Therapy (ISCT), Chair: Scientific Sessions, “Mesenchymal Stem Cells”, Barcelona, Spain.
 2003- 2004 American Society of Hematology (ASH), Member, Committee on Communications
 2004- Bone Marrow Transplantation Clinical Trial Network (BMT CTN) Steering Committee
 2005 CIBMTR/ ASBMT meetings: Chair: Scientific Session on GVHD/ GVL/ Supportive Care
 2005 CIBMTR/ ASBMT meetings: Planning committee for plenary speaker selection for annual meeting
 2006 BMT CTN Committee on Nonmyeloablative Stem Cell Transplantation
 2006 American Society of Hematology (ASH), Abstract Reviewer for Scientific Session, “Clinical Results- Allogeneic Matched Related Allogeneic Transplantation”
 2007- 2013 CIBMTR Clinical Trials Review & Advisory Committee
 2007-2008 BMT CTN “State of the Science” GVHD Planning Committee
 2007-2008 Coordinating Committee for Radiation Injury Network, Dept of Health Services
 2008- Steering Committee, RITN, NMDP
 2007 American Society of Hematology (ASH), Abstract Coordinating Reviewer for Scientific Session, “Clinical Results- Allogeneic Matched Related Allogeneic Transplantation”
 2007- 2013 CIBMTR Stem Cell Therapeutic Outcomes Database Advisory Group
 2007-2009 Efficacy Adjudication Board, Phase III Randomized GVHD Trial Study Group, OsirisTherapeutics
 2008 ASBMT Scientific Program Organizing Committee- Tandem Transplant Meetings 2009
 2008- 2010 ASBMT Reimbursement Committee
 2008 Tandem Transplant Meetings: Abstract Review Committee
 2008-2010 International Society of Cellular Therapy, Vice-President for North America Region
 2009-2014 Chair, CIBMTR Chronic Leukemia Working Committee
 2009-2010 Member, ASBMT Committee on Research Priorities
 2009-2010 Vice-Chair, NMDP Financial Working Group (Payers & Insurance) of the System Capacity Initiative
 2010 CIBMTR/ ASBMT meetings: Chair: Scientific Session on GVHD, Stem cell processing and MSC
 2010 Co-Chair, ISCT Industry Task Force
 2010-2013 ISCT, Advisory Board
 2010-2012 ISCT, Co-Chair Commercialization Committee
 2012- Member, ISCT Commercialization Committee

2010-2012 Chair, DSMB for Gamida, phase I trial ex vivo expansion of cord blood stem cells
2010-2012 Chair, NMDP Financial Working Group (Payers & Insurance) of the System Capacity Initiative
2010-2012 Member, NMDP Steering Committee of the System Capacity Initiative
2011-2012 Leader, BMT CTN Working Group on Affiliate Centers
2011- Present Member, BMT CTN GVHD Study Review Committee
2011- 2016 Member, BMT CTN Regimen Related Toxicity Committee
2011-2012 ISCT, Organizing Committee ISCT 2012
2012- 2016 Chair, ISCT Reimbursement Subcommittee
2012-2014 Chair, Payer Advisory Group, NMDP
2012 - 2016 BMT CTN, Chair, Toxicity and Supportive Care Committee
2013- 2014 BMT CTN “State of the Science” GVHD Planning Committee
2013- 2014 BMT CTN “State of the Science” Regimen related toxicity Committee
2013-2014 CIBMTR Publicly Available Data Task Force
2014- Payer Advisory Group on Barriers to Transplantation, NMDP
2016- NMDP – Emerging Reimbursement Working Group
2016- ASBMT- Chair, Health Economics & Value Special Interest Group
2018- Member, Financial Toxicity Working Group, NMDP
2018- Member, DSMB, Novartis Reach II Phase III trial of ruxolitinib in steroid refractory aGVHD
2018- Member, DSMB, Novartis Reach III Phase III trial of ruxolitinib in steroid refractory cGVHD
2018- Member, DSMB, Athersys Masters II Phase III trial of MAPC in treatment of acute thrombotic CVA
2018-2019 TCT Abstract Review committee, Regimen Related Toxicity

Major Research Interests

1. Molecular Immunology
2. Blood and Marrow Transplantation
3. Graft vs. Host Disease
4. Stem Cells and Regenerative Medicine

Teaching Experience

1979-1981 Clinical Instructor in Medicine, Case Western Reserve Medical School
1985-1991 Instruction of Medical Students on Hematology elective, Brigham and Women’s Hospital
1987-1991 Attending Physician, Hematology service, Brigham and Women’s Hospital
1987-1991 Attending Physician, Bone Marrow Transplant Service, The Children’s Hospital
1988-1991 Section Leader, Biochemistry/Physiology Block, Harvard Medical School
1989-1991 Member, Subcommittee on Clinical Tutorial Design of Biochemistry/Physiology Block, Harvard Medical School
1990-1991 Section Leader, Hematology Pathophysiology Block, Harvard Medical School
1990-1991 Supervisor, Postdoctoral Fellow (Dr. R. Lawton)
1990-1991 Supervisor, Harvard Medical School Transplant Immunology Honor Student (Dr. D. Araten)
1992- Lecturer, Hematology Pathophysiology Course, OHSU
1992- Lecturer, Immunology Course, OHSU
1992-1996 Attending Physician, General Medicine, Portland VA Medical Center
1996-2002 Attending Physician, Hematology/Medical Oncology service, Portland VA Medical Center
1991-1993 Subsection Director, BLOOD Pathophysiology Course, OHSU
1993-1995 Supervisor, Research Training Associate, (Dr. Marcus Braun)
1993-1995 Lecturer, Immunology Course, Reed College, Portland, Oregon
1994- Attending Physician, Bone Marrow Transplantation Services, OHSU
1994-1998 Supervisor, Postdoctoral Fellow (Dr. H. Guo)
2002-2003 Supervisor, Postdoctoral Fellow (Dr. B Hayes-Lattin)
2004-2006 Supervisor, Predoctoral Student (Mr. Cedar Fowler)
2006-2008 Supervisor, Postgraduate NP student (Ms. Molly McHenry)
2006-2008 Supervisor, Predoctoral Student (Ms. Valerie Nelson)
2010-2012 Supervisor, Postdoctoral Fellow (Dr. Avraham-Perets)
2011-2012 Supervisor, Postdoctoral Fellow (Dr. Tarun Bains)
2013-2014 Supervisor, Postdoctoral Fellow (Dr. Jonathan Brammer)

Principal Clinical and Hospital Service Responsibilities

1987-1991 Attending Physician, Hematology Service, Brigham and Women's Hospital
 1987-1991 Attending Physician, Bone Marrow Transplant Service, The Children's Hospital
 1989-1991 Attending Physician, Hematology/Oncology Service, Brockton-West Roxbury VAMC
 1990-1991 Attending Physician, General Medical Service, Brockton-West Roxbury VAMC
 1991- Attending Physician, Hematology/Medical Oncology and Bone Marrow Transplantation Services, OHSU
 1991- 2001 Attending Physician, Hematology and Medical Oncology Service, Portland VAMC
 1992-1994 Acting Director, Adult Autologous-Allogeneic Bone Marrow Transplant Program, OHSU
 1994- Director, Adult Autologous and Allogeneic Bone Marrow Transplant Program, OHSU
 1996- Director, OHSU Matched Unrelated Donor Transplant Program
 1996- Medical Director, Northwest Marrow Transplant Program
 1997- Director, Hematopoietic Cell Processing Laboratory, OHSU
 1998-2004 Director, OHSU Cell Apheresis Program
 2002-2013 Medical Director, OHSU Center for Hematologic Malignancies

Professional Organizations

1994- American Society of Hematology
 1994- Southwest Oncology Group
 1994- 2010 Puget Sound Oncology Consortium
 1994- American Society of Blood and Marrow Transplantation
 2000-2013 International Society of Experimental Hematology
 2008- International Society of Cellular Therapy

Research Grant Funding

1981-1984 National Research Service Award
 Project Title: Cellular Regulation of the Cytolytic T Cell Response
 Total Direct Costs: \$57,430

1985-1990 American Heart Association Clinician-Scientist Award
 Project Title: Cytolytic T Lymphocyte Recognition of Class I HLA Antigens
 Total Direct Costs: \$200,000

1988-1990 American Heart Association Initiation Grant
 Project Title: Cytolytic T Lymphocyte Recognition of Class I HLA Antigens
 Total Direct Costs: \$20,000

1988-1991 American Cancer Society Research Grant
 Project Title: Immune Response to MHC Class I Molecules
 Direct Costs: \$201,060

1989-1990 BWH Foundation Award
 Project Title: Multi-Drug Resistance in Hematologic Malignancies
 Direct Costs: \$30,000

1990-1991 Leukemia Research Foundation Grant
 Project Title: Leukemic Target Cell Ligands for Natural Killer Cells
 Total Direct Costs: \$23,998

1992-1993 Medical Research Foundation Award, Oregon
 Project Title: Neoplastic Cell Ligands for Natural Killer Cells
 Total Direct Costs: \$17,000

1992-1993 V.A. Research Advisory Group Award
 Project Title: Tumor Ligands for Non-MHC Restricted Killer Cells
 Total Direct Costs: \$82,200

1992-1994 American Cancer Society Grant, Oregon Division

Project Title: Immune Reactivity to Tumor-Specific, MHC-Restricted Peptides
Total Direct Costs: \$32,120

1993-1997 V.A. Merit Award
Project Title: Immune Response to Tumor-Specific MHC-Restricted Peptide
Total Direct Costs: \$299,644

1995-1997 OHSU Foundation Grant
Project Title: Control of Graft versus Host Disease
Total Direct Costs: \$43,000

1997-2000 NIH Project Title: Oregon Cancer Center - Experimental Therapeutics Program
Total Direct Costs: \$48,750

1997-2001 V.A. Merit Award
Project Title: Control of Graft vs. Host Disease in Bone Marrow Transplantation
Total Direct Costs: \$392,800

2000-2005 NIH Project Title: Oregon Cancer Center - Transplantation/ Immunology Program
Total Annual Direct Costs: \$12,300

2000-2001 Osiris Therapeutics
Project Title: Control of Graft vs. Host Disease in Bone Marrow Transplantation
Total Direct Costs: \$49,119

2000-2001 Chimeric Therapies, Inc.
Project Title: Immune Reconstitution after Unrelated Bone Marrow Transplantation
Total Direct Costs: \$64,000

2000-2001 American Red Cross
Project Title: Cellular Immune Therapy as Adjunct Therapy for STI571 in patients with CML
Total Direct Costs: \$100,000

2001-2002 American Red Cross
Project Title: Cellular Immune Therapy as Adjunct Therapy for STI571 in patients with CML
Total Direct Costs: \$134,000

2001-2002 Medical Research Foundation Award, Oregon
Project Title: Immune Therapy for Acute Leukemia
Total Direct Costs: \$25,000

2001-2006 National Institutes of Health
Principal Investigator: Hillard Lazarus, MD
Co-Investigator: Richard Maziarz, MD
Project Title: Phase III Trial of Unrelated Cord Blood +/- Mesenchymal Stem Cells
in Hematologic Cancers
Total Annual Direct Costs: \$48,953

2004-2006 Athersys, Inc.
Multipotent Adult Progenitor Cells in Transplantation
Principal Investigator: Richard Maziarz, M.D
Total Direct Costs: \$127,288.95

2005 ESP Pharma, Inc
IV busulfan in the treatment of patients with refractory hematologic malignancies with reduced intensity
allogeneic stem cell transplantation.

Principal Investigator: Richard Maziarz, M.D
Total Direct Costs: \$30,000

- 2006-2011 National Institutes of Health
Principal Investigator: Hillard Lazarus, MD
Co-Investigator: Richard Maziarz, MD
Project Title: BMT CTN Phase III Trial of Unrelated Cord Blood +/- Mesenchymal Stem Cells in Hematologic Cancers
Total Annual Direct Costs: \$48,953
- 2008 - 2011 Athersys, Inc.
A Phase I, Multicenter, Dose-Escalation trial evaluating maximum tolerated dose of single and repeated administration of allogeneic multi-stem in patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia.
Principal Investigator (Overall study PI): Richard T. Maziarz, MD
Total direct costs: \$198,700
- 2010 – 2011 Genzyme Corporation
Retrospective analysis of the outcomes of patients who experience delayed or suboptimal engraftment after autologous hematopoietic stem cell transplantation
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: \$96,050
- 2011- 2016 National Institutes of Health
Principal Investigator: Hillard Lazarus, MD
Co-Investigator: Richard Maziarz, MD
Project Title: BMT CTN Phase III Trial of Unrelated Cord Blood +/- Mesenchymal Stem Cells in Hematologic Cancers
Total Annual Direct Costs: \$48,953
- 2012 – 2013 Athersys, Inc.
Adherent stromal stem cells and impact on hematopoiesis
Total Direct Costs: \$141,068
- 2017- 2024 NIH
Principal Investigator: Richard Maziarz, MD
BMT CTN: OHSU Clinical Consortium
Project title: Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS
Total Direct Costs:

Clinical Research Contracts

1994-1995	Sandoz Pharmaceutical Corporation Project Title: A Phase II, Open-Label, Randomized Trial to Evaluate the Safety, Tolerability, and Biological Effects of the Sequential Administrations of SDZ ILE 964 (Recombinant Human Interleukin-3) followed by Leucomax7 (Granulocyte-Macrophage Colony Stimulating Factor) Versus Leucomax7 Alone, As An Adjunct to High-Dose Chemotherapy with Etoposide and Cytosin in Patients With Advanced Breast Cancer Total Direct Costs: \$12,480
1995-1997	Cell Therapeutics, Incorporated Project Title: CTI 1015 A Phase II Randomized Double-Blind Study of Lisofylline in Patients with <i>de novo</i> Acute Myeloid Leukemia Undergoing Induction Chemotherapy Total Direct Costs: \$8,400
1995-1996	Cell Therapeutics, Incorporated Project Title: CTI 1018 A Phase II Randomized Double-Blind Placebo-Controlled Trial of Lisofylline in Patients with Hematologic Malignancies Undergoing HLA-Identical Related Allogeneic Marrow Transplantation Total Direct Costs: \$19,200
1995-1996	Baxter Biotech Project Title: #92004302104-A CD34+ Cells from Mobilized Peripheral Stem Cell Collections for Hematologic Rescue of Patients Treated with High-Dose Chemo/Radiotherapy for B-Cell Malignancies Total Direct Costs: \$16,400
1995-1996	Baxter Biotech Project Title: #92004302103 Peripheral Blood Stem Cells (PBSC) or Isolated CD34+ Cells from Mobilized Peripheral Stem Cell Collections for Hematologic Rescue of Advanced Breast Cancer Patients Treated with High-Dose Chemotherapy Total Direct Costs: \$32,000
1996-1997	Cell Therapeutics, Incorporated Project Title: CTI-1029 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Lisofylline in Patients with Hematologic Malignancies Undergoing Bone Marrow Transplantation from HLA-Identical Siblings Total Direct Costs: \$23,250
1997-1998	Searle Project Title: #NG6-97-02-009 Phase III Study of Mobilization of Peripheral Blood Stem Cells by Subcutaneous Daniplestim Plus G-CSF in Patients with Breast Cancer Total Direct Costs: Pending, per patient basis (10 patients enrolled) (Transferred PI status after project established)
1997-1998	SEQUUS Protocol Number 07-26B, A Double-Blind, Randomized Study Comparing ABCD (Amphotericin B Colloidal Dispersion) and Fungizone in the Treatment of Febrile Neutropenic Patients Failing Broad Spectrum Antibacterial Therapy Total Direct Costs: \$17,500
1997-1999	JANSSEN Protocol Number ITR-USA-117, "A Randomized Trial of Fluconazole versus Itraconazole for the Prevention of Fungal Infections in Allogeneic Bone Marrow Transplant Patients." Total Direct Costs: \$131,898.00
1998-1999	Therakos, Inc. Protocol # 1995-01a, AUVAR Photopheresis System in Conjunction with UVADEX for the Treatment of Refractory Acute or Chronic Graft-vs-Host Disease Total Direct Costs: Pending, per patient basis

2000-2003 Medimmune, Inc.: Principal Investigator: Joseph Bubalo, Pharm D
A phase II study examining the use of Cytogam (anti-CMV hyperimmune globulin) vs standard IVIG (Immune Globulin) for the prevention of CMV reactivation in hypogammablobulinemic adult allogeneic bone marrow or blood stem cell transplants
Total Direct Costs: Pending, per patient basis

1999-2002 Chimeric Therapies
Protocol # HM01/HM02, "A multi-center open label, randomized, active controlled phase II/III clinical trial to evaluate the safety and efficacy of processed unrelated bone marrow in patients with acute or chronic leukemia" Total Direct Costs: \$33,250

1999-2002 Chimeric Therapies
Protocol # HM03, "A multi-center, non-randomized, single arm, phase I clinical trial to evaluate the efficacy of processed bone marrow from mismatched, unrelated donor (HLA 5/6) in acute or chronic leukemia patients who are older than 35 years of age"
Total Direct Costs: \$7,750

2001 – 2012 Biovitrum
KGF 960226-36 Long term follow up study
Total Annual Direct Costs: \$2,604

2002 Intrabiotics, Inc.: Principal Investigator: Richard Maziarz, MD
Protocol #PG-018, "A phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial to determine the efficacy and safety of iseganan HCL oral solution in reducing the incidence and severity of oral mucositis in patients receiving stomatotoxic chemotherapy
Total Direct Costs: \$76,800

2002 Shire, Inc.
Phase II Multi-Center study of Troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma
Principal Investigator: Richard Maziarz, M.D.
Total Direct Costs: \$6,813

2003 Protein Design Labs, Inc.
A Phase II, Multi-center Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab (Nuvion™) as Second-line Therapy for Glucocorticoid Refractory, Acute Graft-Versus-Host Disease
Principal Investigator: Richard Maziarz, M.D.
Total Direct Costs: \$6,092

2002 Osiris Therapeutics, Inc.
A Phase II/III Randomized, Placebo-Controlled, Double-Blind Study of Allogen™ Universal Cell in Recipients of Unrelated Donor Umbilical Cord Blood Hematopoietic Cell Transplantation
Principal Investigator: Richard Maziarz, M.D.
Total Direct Costs: \$5,600

2004- Wyeth, Inc
Observational trial in patients with ANLL receiving Mylotarg therapy
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: \$9950

2004 – 2008 BMT Clinical Trials Network
Clinical trials 0101-0102-0201-0202

Principal Investigator: Richard Maziarz, M.D.
Total Direct Costs: \$380,408

2004- Anormed, Inc.
AMD2104: Treatment with AMD3100 in multiple myeloma or non-Hodgkin's lymphoma patients to increase the number of peripheral blood stem cells when given with a mobilizing regimen of chemotherapy and G-CSF
Principal Investigator: Richard Maziarz, M.D.
Total Direct Costs: \$67,629

2003 Sanofi, Inc.
Evaluation of single agent rasburicase for 5 days versus sequential treatment with rasburicase from Day 1 through 3 followed by oral allopurinol from Day 3 through 5 (overlap on Day 3) versus single agent oral allopurinol for 5 days in the management of plasma uric acid in adult patients with leukemia, lymphoma, and solid tumor malignancies at risk for Hyperuricemia and tumor lysis syndrome
Total Direct Costs: To be determined on per patient basis; Current Direct Costs = \$81,200

2005-2006 Curagen, Inc.
A Phase II, Multimember, Randomized, Double-Blind, Placebo-Controlled Trial Of The Safety And Efficacy Of CG53135-05 Administrated Intravenously As A Single Dose For The Prevention Of Oral Mucositis In Patients Receiving Autologous Hematopoietic Stem Cell Transplant
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: Determined on per patient basis; Current Direct Costs = \$144,736

2005- 2009 Anormed, Inc.
AMD3100-3101: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) Plus Placebo to Mobilize and Collect $\geq 5 \times 10^6$ CD34+ Cells/kg in Non-Hodgkin's Lymphoma Patients for Autologous Transplantation
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: Determined on per patient basis; Current Direct Costs = \$168,023

2005- 2009 Anormed, Inc.
AMD3100-3102: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) Plus Placebo to Mobilize and Collect $\geq 5 \times 10^6$ CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: Determined on per patient basis; Current Direct Costs = \$73,437

2006 – 2012 Genzyme Corporation
Long-term observational follow up on NHL
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: \$39,645

2006 – 2012 Genzyme Corporation
Long-term observational follow up – MM
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: \$26,995

2006 - 2011 Genzyme Corporation
Expanded access study of Plerixafor and G-CSF for the mobilization and collection of peripheral blood stem cells for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma, Hodgkin's disease or multiple myeloma.
Principal Investigator: Richard Maziarz, MD
Total Direct Costs: \$52,200

2008 - 2011 Athersys, Inc.

A Phase I, Multicenter, Dose-Escalation trial evaluating maximum tolerated dose of single and repeated administration of allogeneic multi-stem in patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia.

Principal Investigator (Overall study PI): Richard T. Maziarz, MD

Total direct costs: \$198,700

2009 – 2012

Seattle Genetics

A pivotal study of SGN-35 in treatment of patients with relapsed or refractory Hodgkin's lymphoma (HL)

Principal Investigator: Richard Maziarz, MD

Total direct costs: \$196,044

2011-

Novartis

Armor trial: Randomized post HCT for FLT3ITD+ AML to midostaurin vs standard of care

Principal Investigator (Overall study PI): Richard T. Maziarz, MD

Total direct costs: \$139,351.68

2012 -

Fate Therapeutics

A Phase II, controlled trial of a single prohema-cb unit (*ex vivo* CXCR4-upregulated CD34⁺ hematopoietic progenitor cells, cord blood) as part of a double umbilical cord blood transplant following myeloablative conditioning for patients 15-55 years with hematologic malignancies.

Total Annual Direct Costs: \$73,823

2012 -

Fresenius Biotechnology

A randomized, prospective, double blind, placebo-controlled, Phase III study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GvHD in adult myeloid leukemia, acute myeloid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors.

Total Annual Direct Costs: \$158,338

2013-

Bellicum

A Phase I-II dose escalation study evaluating safety and feasibility of BPX-501 T cells after partially mismatched, related, T cell depleted HSCT

Total Direct Costs: \$281,741.88

2015-

Novartis

CTL019C2201: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTO019 in adult patients with relapsed or refractory diffuse large b cell lymphoma

Total Direct Costs: \$171,681.36

PI and Chair, Steering Committee for clinical trial

2016-

Fate Therapeutics

ProTmune: Phase I non-randomized/Phase 2 randomized study of graft treatment of URD myeloablative procedures

Principal Investigator (Overall study PI): Richard T. Maziarz, MD

Total direct costs: \$45,008.12

Patents

April 3, 2012

Maziarz, et al.
U.S. Patent

Immunomodulatory Properties of Multipotent Adult Progenitor Cells and Uses Thereof
#8,147,842

Publications

1. Bernabeu C, Finlay D, van de Rijn M, Maziarz RT, Biro PA, Spits H, de Vries J, Terhorst C. Expression of the major histocompatibility antigens HLA-A2 and HLA-B7 by DNA mediated gene transfer. *J Immunol* 1983; 131:2032-2038.
2. Duprez V, Maziarz RT, Weinberger O, Burakoff SJ. Thymectomized, irradiated and bone marrow reconstituted chimeras have normal cytolytic T lymphocyte precursors but a defect in lymphokine production. *J Immunol* 1984; 132:2185-2189.
3. Bernabeu C, Maziarz RT, Spits H, de Vries J, Burakoff SJ, Terhorst C. Coexpression of human HLA heavy chain and human beta-2 microglobulin in mouse L cells. *J Immunol* 1984; 133: 3188-3194.
4. Bernabeu C, Maziarz RT, Burakoff SJ, Terhorst C. Beta-2 microglobulin from serum associates to native and foreign MHC Class I antigens on the surface of mouse L cells. *Mol Immunol* 1985; 22:955-960.
5. Maziarz RT, Allen H, Strominger JL, Flavell R, Biro PA, Burakoff SJ. Recognition of interspecies hybrid class I histocompatibility antigens by antigen-specific cytolytic T lymphocytes. *Proc Natl Acad Sci USA* 1985; 82:6276-6280.
6. Reiss CS, Greenstein JL, Crimmins M, Liu L, Maziarz RT, Murre C, Burakoff SJ. Recognition of the alpha 1 and alpha 2 domains of H-2 molecule by allospecific cloned T cells. *J Immunol* 1986; 136:2191-2194.
7. Maziarz RT, Burakoff SJ, Reiss CS. Viral restricted cytolytic T lymphocyte recognition of human-mouse class I hybrid histocompatibility antigen. *Cell Immunol* 1986; 99:279-286.
8. Maziarz RT, Fraser J, Strominger JL, Burakoff SJ. The anti-human HLA monoclonal antibody W6/32 recognizes discontinuous epitope within the alpha 2 domain of murine H-2D^b. *Immunogenetics* 1986; 24:206-208.
9. Maziarz RT, Burakoff SJ, Bluestone J. The alpha-3 domain of class I MHC proteins influences cytotoxic T lymphocyte recognition of antigenic determinants located within the alpha-1 and alpha-2 domains. *J Immunol* 1988; 140:4372-4377.
10. Maziarz RT, Tepler I, Antin JH, Keroack MA, Churchill WH, Holmes W, Rapoport JM. Reversal of infection with *Mycobacterium avium* intracellularly by treatment with alpha-interferon in a patient with hairy cell leukemia. *Ann Intern Med* 1988;109:292-294.
11. Bierer BE, Emerson SG, Antin JH, Maziarz RT, Rapoport JM, Smith BR, Burakoff SJ. Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation. *Transplantation* 1988; 46:835-839.
12. Groh V, Fabbi M, Hochstenbach F, Maziarz RT, Strominger JL, Double-negative (CD4-CD8-) lymphocytes bearing T cell receptor alpha and beta chains in normal human skin. *Proc Natl Acad Sci USA* 1989; 86:5059-5063.
13. Tomkinson BE, Maziarz RT, Sullivan JL. Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. *J Immunol* 1989; 143:660-670.
14. Maziarz RT, Burakoff SJ, Faller DV. Regulation of endogenous and exogenous Class I genes in the human tumor cell line, K562. *Mol Immunol* 1990; 27:135-142.
15. Maziarz RT, Mentzer SJ, Burakoff SJ, Faller DV. Distinct effects of gamma-interferon and MHC class I surface antigen levels on resistance of the K562 tumor cell line to natural killer-mediated lysis. *Cellular Immunol* 1990; 130:329-338.
16. Allen H, Hsuan J, Clark S, Maziarz RT, Waterfield M, Flavell R, Haley J. Expression of EGF receptor in K562 cell line by transfection: activated receptor kinase in absence of EGF. *Biochem J* 1991; 217:785-790.

Publications (cont.)

17. Maziarz RT, Groh V, Prendergast M, Fabbi M, Strominger JL, Burakoff SJ. Non-MHC-restricted target cell lysis by a CD4-CD8- TCR alpha/beta T cell line, as well as by TCR gamma/delta T-cell lines, results from lymphokine-activated killing. *Int J Cancer* 1991; 48:142-147.
18. Levitz SM, Farrell TP, Maziarz RT. Killing of *Cryptococcus neoformans* by human peripheral blood mononuclear cells stimulated in culture. *J Infect Dis* 1991; 163:1108-1113.
19. Treseler CB, Maziarz RT, Levitz SM. Biological activity of interleukin-2 bound to *Candida albicans*. *Infection and Immunity*, 1992; 60:183-188.
20. Maziarz RT, Arceci RJ, Bernstein SC, Frazier L, Smith BR, Kasai M, Tantravahi R, Strominger JL. A gamma/delta T cell leukemia bearing a novel, t(8:14)(q24;q11) translocation demonstrates in vitro natural killer-like activity. *Blood* 1992; 79:1523-1531.
21. Kasai M, Maziarz RT, Aoki K, Macintyre E, Strominger JL. Molecular involvement of the PVT-1 locus in a T-cell leukemia bearing a variant t (8;14) (q24;q11) translocation. *Molecular and Cell Biology*, 1992; 12:4751-4757.
22. Araten DJ, Lawton T, Ferrara JM, Antin JH, Milford E, Carpenter CB, Maziarz RT. In vitro alloreactivity against host antigens in adult HLA mismatched bone marrow transplant recipient despite in vivo host tolerance. *Transplantation* 1993; 55:76-82.
23. Heinrich M., Dooley D, Freed A, Band L, Hoatlin M, Keeble W, Peters S, Silvey K, Ey F, Kabat D, Maziarz RT, Bagby GC. Constitutive expression of steel factor gene by human stromal cells. *Blood* 1993; 82:771-783.
24. Yoshino I, Peoples G, Goedegbuure P, Maziarz RT, Eberlein T. Association of HER2/neu Expression with sensitivity to tumor-specific CTL in human ovarian cancer. *J Immunol* 1994; 152:2393-2400.
25. Aoki K, Nakahara K, Ikegawa C, Seto M, Takahashi T, Minowada J, Strominger JL, Maziarz RT, Kasai M. Nuclear proteins binding to a novel target sequence within the recombination hotspot regions of Bcl-2 and the immunoglobulin D_H gene family. *Oncogene* 1994; 9:1108-1115.
26. Kasai M, Aoki K, Matsuo Y, Minowada J, Maziarz RT, Strominger JL. Lymphoid lineage specific nuclear binding proteins recognized novel sequence motifs at the site of interchromosomal rearrangements in T-ALL patient with t(8;14)(q24;q11) and t(1;14)(P34;q11). *International Immunology* 1994; 6:1017-1025.
27. Braun MP, Maziarz RT. Abscopal depression of G-CSF mobilized peripheral stem cells. *Bone Marrow Transplantation* 1994; 14:1005-1007.
28. Peters WP, Fay JW, Holland HK, Ahmed T, Bolwell BJ, Wolf J, Damon L, Long G, Schwartzberg LS, Goldberg SL, Friedman DJ, Lynch JP, Winberger BB, Taylor RF, Stadtmauer E, Rifkin RM, Broun ER, McCarthy PL, Zamkoff K, Petersen FB, Reed EC, Mills L, Schuster MW, Lazarus HH, Fruchtman SM, Hesdorffer CS, Douer D, Flomenberg J, Guarino MJ, Maziarz RT, Eifenbein GH, LeMaistre CF, Akard L, Cirrincione C. Autologous bone marrow transplantation in primary breast cancer: the American experience. *Bone Marrow Transplantation, Suppl 1*, 1995; 15:254-262.
29. Fields LL, White CR Jr, Maziarz RT. Rapid development of disseminated superficial porokeratosis after transplant induction therapy. *Bone Marrow Transplantation*, 1995; 15:993-995.
30. Valentine PJ, Meyer K, Rivera MM, Lipps C, Pauza D, Maziarz RT, So M, Heffron F. Induction of SIVmac251 p27 specific CD8⁺ CTLs and mucosal immunity in mice immunized with a recombinant AroA *Salmonella typhimurium*. *Vaccines*, 1996; 2:138-146.

Publications (cont.)

31. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz RT, Davey M, Palida F, Godfrey W, Engleman E, Fulton RJ, Offner H, Vandenbark AA. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. *Nature Medicine*, 1996; 2:183-189.
32. Bensinger WI, Rowley SD, Demiret T, Lilleby K, Schiffman K, Clift RA, Appelbaum FR, Fefer A, Barnett T, Storb R, Chauncey T, Maziarz RT, Klarnet J, McSweeney P, Holmberg L, Maloney DG, Weaver CH, Buckner CD. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. *Journal of Clinical Oncology*: 1996, 14:1447-1456.
33. Schiffman KS, Bensinger W, Appelbaum FR, Rowley S, Lilleby RA, Clift RA, Weaver C, Demiret T, Sanders JE, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Maziarz R, Klarnet JP, Storb R, and Buckner CD. Phase II Study of High-Dose busulfan, melphalan, and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. *Bone Marrow Transplantation*: 1996, 17:943-950.
34. Brunvand MW, Appelbaum FR, Soll E, Lilleby K, Clift RA, Gooley TA, Bensinger WI, Weaver CH, Rowley SD, Fefer A, Press OW, Storb R, Sanders JE, Martin PL, Chauncey T, Maziarz RT, Zuckerman N, Montgomery P, Dorn R, Weiden PL, Demiret T, Holmberg LA, Schiffman K, McSweeney PA, Maloney DG, and Buckner CD. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. *Bone Marrow Transplantation*:1996, 18:131-142.
35. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T cell activation antigen, OX-40 identifies alloreactive T cells in acute graft-versus-host-disease. *BLOOD*: 1997, 89:4652-4658.
36. Kasai M, Matsuzaki T, Katayanagi K, Omori A, Maziarz RT, Strominger JL, Aoki K, Suzuki K. The translin ring specifically recognizes DNA ends at recombination hot spots in the human genome. *J Biol Chem*: 1997, 272 (17): 11402-11407.
37. Bensinger WI, Schiffman KS, Holmberg L, Appelbaum FR, Maziarz R, Montgomery P, Rivkin S, Weiden P, Lilleby K, Rowley S, Petersdorf S, Klarnet JP, Nichols W, Hertler A, McCrowsky R, Weaver CH, Buckner CD. High-dose busulfan, melphalan, thiotepa, and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. *Bone Marrow Transplantation*: 1997, 19:1183-1189.
38. Rathbun RK, Faulkner GR, Ostroski MH, Christianson TA, Hughes G, Jones G, Cahn R, Maziarz R, Royle G, Keeble W, Heinrich MC, Grompe M, Tower PA, Bagby GC. Inactivation of the Fanconi Anemia Group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. *BLOOD*, 1997, 90: 974-985.
39. Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K., Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger W. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. *Biology of Blood and Marrow Transplantation*: 1997, 3: 261-266.
40. Holmberg LA, Demiret T, Rowley SD, Buckner CD, Goodman G, Maziarz R, Klarnet J, Zuckerman N, Harrer G, McCloskey R, Gersh R, Goldberg R, Nichols W, Jacobs A, Weiden P, Montgomery P, Rivkin S, Appelbaum FR, Bensinger WI. High dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cells (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. *Bone Marrow Transplantation*: 1998, 22:651-659.
41. Guo H, Tittle TV, Allen H, Maziarz RT. Brefeldin A-mediated apoptosis requires caspase activity and is inhibited by Bcl-2. *Experimental Cell Research*: 1998, 245:57-68.

Publications (cont.)

42. Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, Needles B, Wienske D, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, Dipersio J. Outcomes of high-dose chemotherapy and autologous stem cell transplant in stage III-B inflammatory breast cancer, *J Clin Oncology* : 1999, 17:2006-2014.
43. Nichols DJ, Maziarz RT, Haupt MT. Mechanical ventilation in hematopoietic stem cell transplant patients: is there need for reevaluation? *Chest* : 1999, 116:857-859.
44. Holmberg LA, Boeckh M, Hooper H, Weisenring W, Rowley S, Heimfeld S, Press O, Maloney D, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. *Blood*: 1999, 94:4029-4035.
45. Nichols C, Maziarz R. High Dose Chemotherapy—results of American studies. *Int J Cancer*: 1999, 83:841-843.
46. List AF, Maziarz RT, Stiff P, Jensen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Caranes C, Dahlberg S, Bianco JA, Singer JW. A randomized placebo-controlled trial of lysofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. *Bone Marrow Transplantation*: 2000, 25:283-291.
47. Yanovich S, Mitsky P, Cornetta K, Maziarz RT, Rosenfeld C, Krause DS, Lotz J-P, Bitran JD, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patient with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. *Bone Marrow Transplantation*: 2000, 25:1165-1174.
48. Gutierrez-Delgado F, Holmberg LA, Hooper H, Appelbaum FR, Livingston RB, Maziarz RT, Wieden P, Rivkin S, Montgomery P, Kawahara K, Bensinger W. High-dose chemotherapy and autologous stem cell transplantation as consolidation for noninflammatory high-risk breast cancer: *Bone Marrow Transplantation*: 2000, 26: 51-59.
49. Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open label trial of dolasetron for the control of nausea and vomiting associated with high dose chemotherapy with hematopoietic stem cell transplantation. *Biology of Blood and Bone Marrow Transplantation*, 2001, 7: 439-445.
50. Gutierrez-Delgado F, Maloney DG, Press OW, Golden J, Holmberg LA, Maziarz RT, Hooper H, Buckner CD, Appelbaum FR, Bensinger WI. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. *Bone Marrow Transplantation*, 2001, 28:455-461.
51. Araten DJ, Swirsky D, Karadimitris A, Notaro R, Nafa K, Bessler M, Thaler H, Castro-Malaspina H, Childs BH, Boulad F, Weiss M, Anagnostopoulos N, Kular A, Savage DG, Maziarz RT, Jhanwar S, Luzzatto L. Cytogenetic and Morphologic Abnormalities in Paroxysmal Nocturnal Hemoglobinuria. *British Journal of Hematology*, 2001, 115: 360-368.
52. Hayes-Lattin B, Curtin PT, Fleming WH, Leis JF, Stepan DE, Schubach S, Maziarz RT. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis. *Bone Marrow Transplantation*, 2002, 30:279-285.
53. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Brazier RB. Development of new clonal abnormalities in BCR-ABL negative cells following imatinib mesylate induced major cytogenetic responses in patients with chronic myelogenous leukemia. *Leukemia*, 2003, 17:481-487.

Publications (cont.)

54. Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI,

- Maziarz RT, Miller AM, Millone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang M. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. *BLOOD*, 2003, 101: 2476-2482.
55. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. A multicenter, randomized trial. *Annals of Internal Medicine*, 2003, 138: 705-713.
 56. Jones A, Maziarz RT, Domreis J, Gilster J, Deveney C, Sheppard B. Surgical complications of bone marrow transplant: a ten year perspective. *American Journal of Surgery*, 2003, 185: 481-484.
 57. Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz RT, Maloney D, Chauncey T, Appelbaum F, Bensinger W. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan, and thiotepa compared to a radiation-based regimen. *Bone Marrow Transplantation*, 2003, 32:279-285.
 58. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes C, Gibson J, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Horowitz MM, Vose JM. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. *BLOOD*, 2003 Nov 15;102 (10):3521-9. Epub 2003 Jul 31.
 59. Maziarz RT, Mesa RA, and Tefferi A. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: The question is "When?" *Mayo Clinic Proceedings*, 2003, 78:941-943.
 60. Medis R, Marlowe M, Partel R, Tomines E, Wetzsteon P, Curtin P, Maziarz R, Norman D, Endres RO. PCR-SSP typing of an apparently homozygous A31 individual reveals the serologically undetected HLA-A*2411N allele. *Human Immunology*, 2003, 64 (10 suppl), S56.
 61. Hayes-Lattin B, Seipel T, Gatter K, Heinrich M, Maziarz RT. Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic transplantation. *American Journal of Hematology*, 2004, 75:142-145.
 62. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcomes with cessation of imatinib mesylate after optimal response in chronic phase CML: a report of two patients. *Leukemia Research*, 2004, 28 (Suppl 1), 71-73.
 63. Leis JF, Stepan DE, Curtin PT, Peng B, Ford JM, Schubach S, Fleming WH, Druker BJ, Maziarz RT. Isolated central nervous system failure in patients with chronic myelogenous leukemia blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571): a pharmacokinetic analysis. *Leukemia and Lymphoma*, 2004, 45: 695-698.
 64. Walker L, Gatter KM, Harmon S, Maziarz RT. Late relapse of myelodysplasia after allogeneic transplantation concomitant with new presentation of invasive liposarcoma as a secondary neoplasm. *Bone Marrow Transplantation*, 2004, Apr 19 [Epub ahead of print] 33: 1215-1218.
 65. Winston DJ, Maziarz RT, Chandrasekar PH. Itraconazole versus fluconazole for antifungal prophylaxis (Letter). *Annals of Int Medicine*, 2004, 140: 581-582.
 66. Streeter P, Zhang X, Tittle TV, Schon CN, Weinberg AD, Maziarz RT. CD25 expression distinguishes functionally distinct alloreactive CD4⁺CD134⁺ (OX40⁺) T cell subsets in acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, 2004, 10:298-309.

Publications (cont.)

67. Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, Goldberg SL, Anaissie EJ, Bolwell BJ, Chao NJ, Shea TC, Brunvand MM, Vaughan W, Petersen F, Schubert M, Lazarus HM, Maziarz RT, Silverman M, Beveridge RA, Redman R, Pulliam JG, Devitt-Risse P, Fuchs HJ, Hurd DD. A phase II, randomized double-blind,

placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. *Leuk. Res.* 2004, 28:559-565.

68. Lee SJ, Zahrieh D, Agura E, MacMillan M, Maziarz RT, McCarthy P, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-vs-host disease: results of a randomized trial. *Blood.* 2004 Sep 1;104 (5):1559-64. Epub 2004 May 11.
69. Hayes-Lattin B, Maziarz RT. Natural history of mucormycosis (zygomycosis) in a neutropenic patient. *Images in Hematology, BloodMed, ePub, June, 2004.*
70. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, Agura E, Langston AA, Pulsipher M, Storb R, Maloney DG. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. *Blood.* 2004 Dec 1;104(12):3535-42. Epub 2004.
71. Leis J, Primack S, Schubach S, , Curtin P, Fleming W, Druker BJ, Maziarz RT. Management of life threatening pulmonary leukostasis with single agent STI571 during CML blast crisis. *Haematologica, 2004;89(9):ECR30.*
72. Bonyhadi M, Frohlich M, Rasmussen A, Ferrand C, Grosmaire L, Robinet E, Leis J, Maziarz RT, Tiberghien P, Berenson RJ. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. *J Immunol, 2005; 174: 2366-2375.*
73. Lazarus HM, Omer NK, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Frassoni F, Labopin M, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Moseley AB, Bacigalupo A. Co-transplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in patients with hematologic malignancy: a Phase I trial. *Biol Blood Marrow Transplant.* 2005; 11(5):389-98.
74. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Stuart M, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Ponisch W, Grommisch L, Storer B, Maloney D, Petersdorf E, McSweeney P, Chauncey T, Agura E, Epner E, Maziarz RT, Petersen F, Bruno B, Blume K, Storb R. Treatment for acute myelogenous leukemia by low dose total body irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors. *J Clin Oncology.* 2006 Jan 20; 24(3):444-53 [Epub ahead of print 2005 Dec 12]
75. Tallman MS, Waleska S, Perez MPH, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop MR, Christiansen N, Frankel SR, Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM. Pretransplant consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant.* 2006 Feb; 12(2):204-16.
76. Maris MB, Sandmaier BM, Storer B, Maloney D, Shizuru J, Agura E, Niederwieser D, Pulsipher M, Maziarz RT, McSweeney P, Wade J, Langston AA, Chauncey T, Bruno B, Blume K, Storb R. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. *Biol Blood Marrow Transplant.* 2006; 12:454-465.
77. Navarro WH, Loberiza Jr. FR, Bajorunaite R, van Besien K, Vose JM, Lazarus HM, Rizzo JD with the CIBMTR Lymphoma Writing Committee. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2006; 12:541-551.

Publications (cont.)

78. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boque C, Faber E, Nagler A, Pogliani E, Russel N, Violin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D for

the EBMT. The effect of prior exposure to imatinib on transplant-related mortality. *Haematologica*. 2006; 91:452-459.

79. Eldredge D, Nail LM, Maziarz RT, Hansen LK, Ewing D, Archbold PG. Explaining family caregiver role strain following autologous blood and marrow transplantation. *J Psychosocial Oncology*. 2006; 24:53-74.
80. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman S, McSweeney P, Maziarz RT, Pulsipher MA, Agura ED, Wade J, Sorror M, Maloney DG, Sandmaier B. Allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning after failed myeloablative HCT: factors affecting outcomes. *J Clin Oncol*. 2006 Sep 1; 24(25):4150-7. Epub 2006 Aug 8.
81. Zhong Y, Bakke AC, Fan G, Brazier R, Gatter KM, Leis JF, Maziarz RT, Huang JZ. Drug resistance in B-cell chronic lymphocytic leukemia predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay. *Cytometry B Clin Cytom*. 2007 May;72(3):189-95.
82. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PM, Sobocinski KA, Horowitz MM. Impact Of Imatinib Therapy On The Use Of Allogeneic Hematopoietic Progenitor Cell Transplantation For The Treatment Of Chronic Myelogenous Leukemia. *Brit J Hem*, 137:461-467, 2007.
83. Schuster MW, Anaissie E, Hurd D, Bensinger W, Mason J, McCarty J, Rifkin R, Maziarz R, Halvorsen Y, Annino V, Hahne W. Final analysis of the phase II, randomized, double blind, placebo-controlled trial of single-dose velaferrin (CG53135-05) for the prevention of oral mucositis. *J Supportive Oncology*. 2007; 5, suppl 2, 58-59.
84. Baron F, Sandmaier BM, Storer BE, Maris MB, Langston AA, Lange T, Petersdorf E, Bethge W, Maziarz RT, McSweeney PA, Pulsipher MA, Wade JC, Chauncey TR, Shizuru JA, Sorror ML, Woolfrey AE, Maloney DG, Storb R. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft vs host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. *Bio Blood Marrow Trans*. 2007 Sep;13(9):1041-8. Epub 2007 Jul 20.
85. Rezvani A, Storer B, Maris M, Sorror M, Agura E, Maziarz RT, Wade JC, Chauncey T, Forman SJ, Niederwieser DW, Shizuru J, Langston A, Pulsipher M, Storb R, Maloney DG. Non-myeloablative allogeneic hematopoietic cell transplant in relapsed, refractory, and transformed indolent non-Hodgkin lymphoma. *J Clin Oncol*. 2008; 26: 211-217. Epub 2007 Dec 3.
86. Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Buchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Dohner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML intergroup and the CIBMTR. *Biol Blood Marrow Transplant*. 2008 Feb;14(2):187-96. Epub 2007 Dec 20.
87. Sorror M, Storer B, Sandmaier BM, Maloney DG, Maris MB, Chauncey TR, Langston A, Maziarz R, Pulsipher M, McSweeney PA, Storb R. Hematopoietic cell transplantation-comorbidity index and Karnovsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. *Cancer*. 2008 May 1;112(9):1992-2001.
88. Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Keating A, Klumpp T, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor stem cell transplantation for adults with Philadelphia chromosome negative acute lymphoblastic leukemia in first complete remission: A Center of the International Blood and Marrow Transplant Research analysis. *Blood*. 2008 Jul 15;112(2):426-34. Epub 2008 Apr 8.

Publications (cont.)

89. Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, Macpartlin M, Willis SG, Lange T, Druker BJ, Kovacsovic T, Maziarz R, Gattermann N, Deininger MW. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. *Leukemia*. 2009 Feb;23(2):406-9. Epub 2008 Jul 10.

90. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. *Biol Blood Marrow Transplant.* 2008 Aug; 14(8):904-12.
91. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks KI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. *Blood.* 2008 Oct 15; 112(8):3500-7. Epub 2008 Jul 29.
92. Rezvani AR, Norasetthada L, Gooley T, Sorrow M, Bouvier ME, Sahebi F, Agura E, Chauncey T, Maziarz RT, Maris M, Shirzuru J, Bruno B, Bredeson C, Lange T, Yeager A, Sandmaier BM, Storb RF, Maloney DG. Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicenter experience. *Br J Haematol.* 2008 Nov; 143(3):395-403. Epub 2008 Aug 28.
93. Sorrow ML, Storer B, Sandmaier BM, Maris MB, Shizuru J, Maziarz R, Agura E, Chauncey T, Pulsipher M, McSweeney P, Wade J, Bruno B, Langston A, Radich J, Niederwieser D, Blume K, Storb R, Maloney DG. Five year follow up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation following non-myeloablative conditioning. *J Clin Oncol.* 2008; 26(30):4912-20. Epub 2008 Sep 15.
94. Du HY, Pumbo E, An P, Bagby GC, Maziarz RT, Reiss UM, Chirnomas D, Shimamura A, Vlachos A, Lipton JM, Goyal RK, Goldman F, Wilson DB, Mason PJ, Bessler M. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. *Blood.* 2009; 113(2):309-16. Epub 2008 Oct 17.
95. Burroughs L, O'Donnell P, Sandmeier BM, Storer B, Luznik L, Symons H, Jones R, Ambinder R, Maris M, Blume KG, Niederwieser DW, Bruno B, Maziarz RT, Pulsipher M, Petersen F, Storb RF, Fuchs EJ, Maloney DG. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant.* 2008 Nov; 14(11):1279-87.
96. Hahn T, McCarthy PL, Zhang MJ, Wang D, Aurora M, Sobocinski K, Frangoul H, Hale G, Horan J, Isola L, Maziarz RT, van Rood J, Gupta V, Halter J, Litzow M, Bolwell B, Bredeson C, Chen A, Gale RP, Holler E, Reddy V, Russell J, Tiberghien P, Verdonck L, Pavletic SA, Barrett J, Ringden O. Risk factors for grade II-IV acute graft vs. host disease after HLA-identical sibling transplants for adults with leukemia: A CIBMTR study. *J Clin Oncol.* 2008 Dec 10; 26(35):5728-34. Epub 2008 Nov 3.
97. Kovacovics-Bankowski M, Mauch K, Raber A, Streeter PR, Deans RJ, Maziarz RT, Van't Hof, W. Pre-clinical safety testing supporting clinical use of allogeneic adult stem cells. *Cytotherapy.* 2008; 10(7):730-42.
98. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. *Antimicrob Agents Chemother.* 2009 Feb; 53(2):428-34. Epub 2008 Nov 17. Erratum in: *Antimicrob Agents Chemother.* 2009 Jul; 53(7):3179.
99. Rotta M, Storer B, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey T, Appelbaum FR, Sorrow ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. *Blood.* 2009 Apr 2; 113(14):3383-91. Epub 2008 Nov 17.

Publications (cont.)

100. Kovacovics-Bankowski M, Streeter P, Mauch K, Van't Hof W, Deans R, Maziarz RT. Clinical scale expanded adult pluripotent stem cells prevent graft vs host disease. *Cell Immunol.* 2009; 255(1-2):55-60. Epub 2008 Nov 20.

101. Devetten MP, Hari P, Carreras J, Logan BR, van Beisen K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P. Unrelated donor reduced intensity and nonmyeloablative stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant.* 2009 Jan; 15(1):109-17.
102. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, Nelson V, Kovacovics T, Leis J, Calandra G, Maziarz RT. Rescue from failed HSC mobilization with G-CSF and AMD3100: an institutional experience. *Bone Marrow Transplant.* 2009 Jun; 43(12):909-17. Epub 2009 Feb 2.
103. Martin PJ, Storer BE, Rowley SD, Flowers ME a phase shift, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. *Blood.* 2009 May 21; 113(21):5074-82. Epub 2009 Mar 6.
104. DiPersio JF, Stadtmauer EA, Nadamane A, Micallef IN, Stiff PJ, Kaufman J, Maziarz RT, Chosing C, Fruhauf S, Horwitz M, Cooper D, Bridger G, Calandra G. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. *Blood.* 2009 Jun 4; 113(23):5720-6. Epub 2009 Apr 10.
105. Dugan MJ, Maziarz RT, Bensinger WI, Nadamane A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. *Bone Marrow Transplant.* 2010 Jan; 45(1):39-47. Epub 2009 Jun 1.
106. DiPersio JF, Micallef I, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nadamane A, McCarty J, Bridger G, Calandra G. Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma. *J Clin Oncol.* 2009 Oct; 27(28):4767-73. Epub 2009 Aug 31.
107. Gajewski, JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. Impending challenges in the hematopoietic stem cell transplant physician workforce. *Biol Blood Marrow Transplant.* 2009 Dec; 15(12):1493-1501. Epub 2009 Sep 23.
108. Maziarz RT, Sridharan P, Slater S, Meyers G, Post M, Erdman D, Peret T, Taplitz R. Control of an outbreak of parainfluenza virus 3 in hematopoietic stem cell transplant recipient. *Biol Blood Marrow Transplant.* 2010 Feb; 16(2):192-8. Epub 2009 Sep 23.
109. Adkisson HD, Milliman C, Zhang X, Mauch K, Maziarz RT, Streeter PR. Immune evasion by neocartilage derived chondrocytes: implications for biologic repair of joint articular cartilage. *Stem Cell Res.* 2010 Jan; 4(1):57-68. Epub 2009 Sep 25.
110. Loberiza FR, Lee SJ, Klein JP, Hassebroek A, Dehn JG, Frangoul HA, Hahn T, Hale G, Lazarus HM, LeMaistre CF, Maziarz RT, Rizzo JD, Majhail NS. Outcomes of hematological malignancies after unrelated hematopoietic cell transplantation according to place of residence. *Biol Blood Marrow Transplant.* 2010 Mar; 16(3):368-375. Epub 2009 Oct 29.
111. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M. Outcome of transplantation for myelofibrosis. *Biol Blood Marrow Transplant.* 2010 Mar; 16(3):358-367. Epub 2009 Oct 29.

Publications (cont.)

112. Baker KS, Davies SM, Majhail NS, Hassebroek A, Ballen KK, Bigelow CL, Frangoul HA, Hardy CL, Bredeson C, Dehn J, Friedman D, Hahn T, Hale G, Lazarus HM, LeMaistre CF, Loberiza F, Maharaj D, McCarthy P, Setterholm M, Spellman S, Trigg M, Maziarz RT, Switzer G, Lee SJ, Klein JP, Rizzo JD. Race and Socioeconomic Status

Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. *Bio Blood Marrow Transplant, Biol Blood Marrow Transplant*. 2009 Dec; 15(12):1543-54. Epub 2009 Sep 25.

113. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin, BM, , Ataergin SA, Bitran JD, Bolwell BJ, Cairo MS, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavolvsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B-cell lymphoma: a report from the CIBMTR. *Bio Blood and Marrow Transplant*. 2010 Jan; 16(1):35-45. Epub 2009 Oct. 4.
114. Micallef I, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G. Successful stem cell mobilization rescue by G-CSF plus Plerixafor (AMD3100) in patients with Non-Hodgkin's lymphoma: Results from the Phase III Study Rescue Protocol. *Bio Blood Marrow Trans*, 2009 Dec; 15(12):1578-86. Epub 2009 Oct 4.
115. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan EA, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. *Biol Blood Marrow Transplant*. 2010 Apr; 16(4):543-7. Epub 2009 Dec 2.
116. Litzow MR, Perez WS, Tarima S, Bolwell BJ, Cairo MS, Camitta BM, Cutler C, de Lima M, DiPersio JF, Gale RP, Keating A, Lazarus H, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini M, Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for the treatment of therapy-related myelodysplastic syndrome and acute myeloid leukemia: Result from the Center for International Blood and Marrow Transplant Research. *Blood*. 2010 Mar 4; 115(9):1850-7. Epub 2009 Dec 23.
117. Gajewski JL, Lill M, Horowitz M, Maziarz RT. BMT Workforce Shortage, Response to letter from Demetrios S.Theodoropoulos, MD, DSc. *Biol Blood Marrow Transplant*. 2010 Apr; 16(4):561-2. Epub 2010 Feb 6.
118. Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, Bredeson CN, Gupta V, Maziarz RT, Hale GA, Lizow MR, Logan B, Bornhauser M, Giller RH, Isola L, Marks DI, Rizzo JD, Pasquini MC. Second unrelated donor hematopoietic cell transplantation for primary graft failure. *Biol Blood Marrow Transplant*. 2010 Aug; 16(8):1099-106. Epub 2010 Feb 19.
119. McClune BL, Weisdorf DJ, Pedersen TL, deSilva GT, Tallman MS, Sierra J, DiPersio J, Keating A, Artz AS, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Miller A, Schiller G, Waller E, Bredeson C, Giralt S. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission and myelodysplastic syndrome. *J Clin Oncol*. 2010 Apr 10; 28(11):1878-87. Epub 2010 Mar 8.
120. Gyurkocza B, Storb R, Storer B, Chauncey T, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Peterson FB, Maris M, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier B. Non-myeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. *J Clin Oncol*. 2010 Jun 10; 28(17):2859-67. Epub 2010 May 3.
121. Fowler C, Dunlap J, Troyer D, Stenzel P, Epner E, Maziarz RT. Life threatening adenovirus infection in the setting of the immunocompromised allogeneic stem cell patients. *Adv Hematol*. 2010;2010:601548. Epub 2010 Jun 16.
122. Deans R, Gunter K, Allsopp T, Bonyhadi M, Burger S, Carpenter M, Clark T, Driscoll D, Field E, Huss R, Lardenoije R, Lodie T, Mason C, Neubiser R, Rasko J, Rowley J, Maziarz RT. A changing time: ISCT embraces its industry members. *Cytotherapy* 2010; 12(7):853-856.

Publications (cont.)

123. Meyers G, Maziarz RT. Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia. *Bone Marrow Transplant*. 2010 Oct;45(10):1479-88. Epub 2010 Jul 5.
124. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A,

Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D. Hematopoietic stem cell transplantation for acute leukemia in relapse or primary induction failure *J Clin Oncol*. 2010 Aug 10;28(23):3730-8. Epub 2010 Jul 12.

125. Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown, Jr. A, Laadem A, Seiter K. Control of plasma uric acid in adults for tumor lysis syndrome: Efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone: Results of a multicenter phase III study. *J Clin Oncol*. 2010 Sep 20;28(27):4207-13. Epub 2010 Aug 16.
126. Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. *Biol Blood and Marrow Transplant*. 2011 Mar; 17(3):341-350. Epub 2010 May 25.
127. Loren AW, Chow E, Jacobsohn DA, Gilleece M, Halter J, Joshi S, Wang Z, Gupta V, Hale GA, Marks DI, Stadtmauer E, Apperley J, Cahn JY, Schouten HC, Lazarus HM, Savani B, McCarthy PL, Jakubowski AA, Kamani NR, Hayes-Lattin B, Maziarz RT, Warwick AB, Sorror ML, Bolwell BJ, Socie G, Wingard JR, Rizzo DJ, Majhail NS. Pregnancy after hematopoietic-cell transplantation: A report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIMBTR). *Biol Blood Marrow Transplant*. 2011 Feb; 17(2):157-166. Epub 2010 Jul 23.
128. Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. *Ann Oncol*. 2011 Apr; 22(4):939-946. Epub 2010 Oct 8.
129. Espinoza-Aguilar L, Green JS, Forest GN, Ball ED, Maziarz RT, Strasfeld L, Taplitz RA. Novel H1N1 influenza infection in hematopoietic stem cell transplantation recipients: two centers' experience. *Biol Blood Marrow Transplant*; 2011 17(4):566-573. Epub 2010 Aug 10.
130. Wingard, JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gerstein ID, Mendizabal AM, Leather H, Confer DL, Baden LR, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, DiPersio JF, Boeckh M, Marr KA. Randomized, Double-blind trial of Fluconazole vs. Voriconazole for the prevention of invasive fungal disease after allogeneic hematopoietic cell transplantation. *Blood*. 2010 Dec; 116(24):5111-5118. Epub 2010 Sep 8.
131. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers M, Gupta V, Hsu J, Jagasia M, Kitko CL, Maziarz RT, Shaughnessy PJ, van Biesen K, Weisdorf DJ, Lee SJ. Comparison between short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. *Biol Blood Marrow Transplant*, 2011 Jan; 17(1):124-132. Epub 2010 Jul 2.
132. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Arat M, Baker KS, Bhatia S, Burns LJ, Cahn JY, Jacobsohn D, Gajewski JL, Gupta V, Hale GA, Halter J, Lazarus HM, Lee SJ, Marks DI, Maziarz RT, Reddy V, Ringden O, Savani BN, Sorror ML, Willert JR, Horowitz MM, Bolwell B, Wingard JR, Socie G. Secondary solid cancers after allogeneic hematopoietic-cell transplantation using busulfan-cyclophosphamide conditioning. *Blood*. 2011 Jan; 117(1):316-322. Epub 2010 Oct 6.
133. Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, Bridger G, Marulkar S, Hsu F, DiPersio JF. Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin's lymphoma or multiple myeloma. *Biol Blood Marrow Transplant*. 2011 Aug; 17(8):1146-1153. Epub 2010 Nov 29.

Publications (cont.)

134. Horwitz EM, Maziarz RT, Kebriaei P. MSCs in hematopoietic cell transplantation. *Biol Blood Marrow Transplant*, 2011 Jan; 17(1 Suppl):S21-S29.
135. Maziarz RT, Arthurs J, Horwitz E. The International Society for Cellular Therapy: Evolving to meet the demands of the regenerative medicine industry. *Regen Med*, 2011 Mar; 6(2):163-6.

136. Maziarz RT, Driscoll D. Hematopoietic stem cell transplantation and implications for cell therapy reimbursement. *Cell Stem Cell*. 2011 Jun 3; 8(6):609-612.
137. Sorrow M, Sandmaier B, Storer B, Franke G, Laport G, Chauncey T, Agura E, Maziarz R, Langston A, Hari P, Pulsipher M, Bethge W, Sahebi F, Bruno B, Maris M, Yeager A, Petersen F, Andersen N, McSweeney P, Hubel K, Mielcarek M, Georges G, Niederwieser D, Blume K, Maloney D, Storb R. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. *JAMA* 2011; 306(17):1874-1883.
138. Cooke L, Grant M, Eldredge DH, Maziarz RT, Nail LM. Informal caregiving in hematopoietic blood and marrow transplant patients. *European J Oncol Nursing*. 2011; 15(5):500-507. Epub 2010 July 28.
139. Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. *J Clin Pharmacol*. 2012; 52(4):586-589. Epub 2011 Mar 17,
140. Howard DH, Kenline C, Lazarus HM, LeMaistre CF, Maziarz RT, McCarthy PL, Parsons SK, Szwajcer D, Rizzo JD, Majhail NS. Abandonment of high dose chemotherapy/HCT for breast cancer following negative trial results. *Health Serv Res*. 2011; 46(6pt1):1762-1777. Epub 2011 Jul 25.
141. Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savioe ML, Halter J, Still PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredsen CN, Soiffer RJ, Weisdorf DJ. Classifying cytogenetics in patients with AML in complete remission undergoing allogeneic transplantation: A CIBMTR study. *Biol Blood Marrow Transplant* 2012; 18(2):280-288. Epub 2011 Jul 30.
142. Khoury H, Kukreja M, Goldman J, Wang T, Halter J, Arora M, Gupta V, Rizzieri D, George B, Keating A, Gale R, Marks D, McCarthy P, Woolfrey A, Szer J, Giral S, Lee S, Maziarz RT, Cortes J, Horowitz M. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis. *Bone Marrow Transplant*; 2012 47(6):810-6. Epub 2011 Oct 10.
143. Majhail NS, Brazauskas R, Hassebroek A, Bredeson C, Hahn T, Hale G, Horowitz MM, Lazarus HM, Maziarz RT, Wood W, Parsons SK, Joffe S, Rizzo JD, Lee SJ, Hayes-Lattin, B. Outcomes of allogeneic hematopoietic stem cell transplantation for adolescent and young adults compared to children and older adults with acute myeloid leukemia. *Biol Blood Marrow Transplant*, 2012 Jun;18(6):861-73. Epub 2011 Oct 29.
144. Majhail NS, Murphy EA, Denzen EM, Ferguson SS, Anasetti C, Bracey A, Burns L, Champlin R, Hubbard N, Markowitz M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Weisdorf DJ, Yolin Raley DS, Chell J, Snyder EL. The National Marrow Donor Program's symposium on hematopoietic cell transplantation in 2020: A health care resource infrastructure assessment. *Biol Blood Marrow Transplant* 2012; 18(2):172-182. Epub 2011 Dec 14.
145. Battiwalla M, Ellis K, Li P, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani B, Aljurf MD, Cairo MS, Drobyski WR, George B, Hahn T, Khera N, Litzow MR, Loren AW, Sabel W, Arora M, Urbano-Ispizua A, Cutler C, Flowers MED, Spellman SR. HLA DR15 antigen does not impact graft-versus-host disease or survival in

Publications (cont.)

- HLA-matched sibling transplantation for hematologic malignancies. *Biol Blood Marrow Transplant* 2012;18(8):1302-8. Epub 2012 Mar 10.
146. Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. *Biol Blood Marrow Transplant* 2012; 18(9):1446-54. Epub 2012 Mar 24.

147. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callender NS, van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Sexton M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. *N Eng J Med* 2012; 366(19):1770-1781.
148. Auletta JJ, Bartholomew AM, Maziarz RT, Deans RJ, Miller RH, Lazarus HM, Cohen JA. The potential of mesenchymal stromal cells as novel cellular therapy for multiple sclerosis. *Immunotherapy* 2012; 4(5):529-547.
149. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher M, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Carter SL, Horowitz MM, Confer DL. Peripheral blood stem cells versus bone marrow from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network protocol 201, a phase III, prospective, randomized trial. *N Engl J Med.* 2012; 367(16):1487-96
150. Chen AI, Bains T, Murray S, Knight R, Shoop K, Bubalo J, Fowler C, Slater S, Maziarz RT. Clinical experience with a simple algorithm for Plerixafor utilization in autologous stem cell mobilization. *Bone Marrow Transplant* 2012; 47(12):1526-1529. Epub 2012 May 7.
151. Tomblyn M, Kukreja M, Tarima S, Aljurf MD, Mohareb FA, Bolwell BJ, Cahn JY, Carabasi MH, Gale RP, Gress RE, Gupta V, Hale GA, Ljungman P, Maziarz RT, Storek J, Wingard JR, Young JA, Horowitz MM, Ballen KK. No effect of recipient or donor hepatitis B and/or C serostatus on outcomes of related donor allogeneic hematopoietic cell transplantation. *Transpl Infect Dis* 2012; 14(5):468-478. Epub 2012 May 1.
152. Nademanee A, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, DiPersio JF. Plerixafor + G-CSF vs. placebo + G-CSF for mobilization of CD34+ hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34+ cell count: Results of a subset analysis of a randomized trial. *Biol Blood Marrow Transplant* 2012; 18(10):1564-1572. Epub 2012 June 6.
153. Clarke DM, Harati D, Martin J, Rowley J, Keller J, McCaman M, Carrion M, Karnieli O, Maziarz RT, Perry R, Oh S, Stanton J. Managing particulates in cellular therapy. *Cytotherapy* 2012; 14(9):187-189. Epub 2012 Aug 17.
154. Ballen KK, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball E, Kamble R, Avigan D, Maziarz RT, Ho V, Koreth J, Alyea E, Soiffer R, Wingard J, Boussiotis V, Spitzer TR, Antin JH. Phase II trial of parathyroid hormone following double umbilical cord blood transplantation. *Biol Blood Marrow Transplant* 2012; 18(12):1851-1858. Epub 2012 Jul 2
155. Bensinger, W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Ewald B, Bilic S, Rediske J, Baeck J, Stadtmauer E. An open-label, phase I study of lucatumumab, a fully human anti-CD40 monoclonal antagonist antibody administered intravenously to patients with refractory or relapsed multiple myeloma. *Br J Haematol.* 2012; 159(1):58-66. Epub 2012 Aug 4.
156. Bacher U, Klyuchnikov ES, LeRademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson JN, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiemik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN. Conditioning regimens for allotransplants for Publications (cont.)
diffuse large B-cell lymphoma – myeloablative or reduced intensity? *Blood* 2012; 120(20):4256-4262. Epub 2012 Sep 24.
157. Denzen E, Majhail NS, Ferguson SS, Anasetti C, Bracey A, Burns L, Champlin R, Chell J, Leather H, Lill M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Snyder EL, Wiggins L, Yolin Raley DS, Murphy EA. Hematopoietic stem cell transplantation in 2020: Summary of year II recommendations of the National Marrow Donor Program's Systems Capacity Initiative. *Biol Blood Marrow Transplant* 2013; 19(1):4-11. Epub 2012 Oct 15.

158. Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: A report from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant* 2013; 19(2):173-179. Epub 2012 Nov 27.
159. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole KC, Schiller GJ, Abidi M, Anderson KC, Nishihort T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten H, Maziarz RT, Michael J, Kindwall-Keller, T, Stiff PJ, Lonial S, Krishnan A, Dispenzieri A, Hari P, on behalf of the Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. *Biol Blood Marrow Transplant* 2013; 19(5):760-766. Epub 2013 Jan 5.
160. Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J, Mody, PD, DiPersio JF, Bolwell BJ. Efficacy of upfront plerixafor + G-CSF for autologous hematopoietic stem cell mobilization non-Hodgkin's lymphoma patients with low circulating peripheral blood CD34+ cells. *Biol Blood Marrow Transplant*, 2103; 19(4):670-675. Epub 2013 Jan 17.
161. Alousi AM, Rademacher JL, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? *Blood*, 2013; 121(13):2567-2573. Epub 2013 Jan 29.
162. Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, Micallef I, Jacobsen E, McCarty J, Stiff P, Artz A, Ball ED, Berryman R, Dugan M, Joyce R, Hsu FJ, Johns D, McSweeney P. Plerixafor and G-CSF for mobilization of peripheral blood stem cells for autologous transplantation in patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma, and multiple myeloma: Results from the expanded access program. *Bone Marrow Transplant*, 2013; 48(6):777-781. Epub 2012 Nov 26.
163. Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeuser M, Ringden O, Maziarz RT, Gupta V, Papat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT. Effects of spleen status on early outcomes after hematopoietic cell transplantation. *Bone Marrow Transplant*, 2013; 48(6):825-831. Epub 2012 Dec 10.
164. Storb R, Gyurkocza B, Storer B, Sorrow M, Blume K, Niederwieser D, Chauncey T, Pulsipher M, Petersen F, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindelov L, Franke GN, Laport GG, Yeager AM, Hubel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM. Graft-vs.-host disease and graft-vs.-tumor effects in allogeneic hematopoietic cell transplantation. *J Clin Oncol*, 2013; 31(12):1530-1538. Epub 2013 Mar 11.
165. LeMaistre CF, Farnia S, Crawford S, McGuirk J, Maziarz RT, Coates J, Irwin D, Martin P, Gajewski JL. Standardization of terminology for episodes of hematopoietic stem cell patient transplant care. *Biol Blood Marrow Transplant*, 2013; 19(6):851-857. Epub 2013 Mar 21.

Publications (cont.)

166. Strasfeld L, Espinosa-Aguilar L, Gajewski JL, Stenzel P, Pimentel A, Mater E, Maziarz RT. Emergence of *Cunninghamella* as a highly pathogenic invasive mold infection in allogeneic transplant recipients. *Clinical Lymphoma, Myeloma and Leukemia*, 2013; 13(5):622-628. Epub 2013 Jul 10.
167. Hahn T, McCarthy PL, Hassebroek A, Bredesen C, Gajewski JL, Hale G, Isola L, Lazarus HM, Lee SJ, LeMaistre CF, Loberiza F, Maziarz RT, Rizzo JD, Joffe S, Parsons S, Majhail NS. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. *J Clin Oncol*, 2013; 31(19):2437-2449. Epub 2013 May 28.

168. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske T, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari P. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. *J Clin Oncol* 2013; 31(25):3100-3109. Epub 2013 Jul 29.
169. Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Perez WS, Bredeson CN, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Marks DI, Martino R, Maziarz RT, Rowlings PA, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: A study from the CIBMTR. *Bio Blood Marrow Transplant*, 2013; 19(7):1102-1108. Epub 2013 Apr 28.
170. Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen A, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN. Autologous hematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *Br J Haematol*, 2013; 162(5):648-656. Epub 2013 Jul 6.
171. McCarthy PL, Hahn T, Hassebroek A, Bredeson C, Gajewski JL, Hale G, Isola L, Lazarus HM, Lee SJ, LeMaistre CF, Loberiza F, Maziarz RT, Rizzo JD, Joffe S, Parsons S, Majhail NS. Trends in use of and survival after autologous hematopoietic cell transplantation in North America 1995-2005: Significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. *Biol Blood Marrow Transplant* 2013; 19(7):1116-1123. Epub 2013 May 6.
172. Mauskopf J, Chirila C, Graham J, Gersten I, Mullins D, Maziarz RT, Baden L, Bolanos-Meade J, Brown J, Walsh TJ, Horowitz MM, Kurtzberg J, Marr KA, Wingard JR. Cost-effectiveness analysis of voriconazole compared with fluconazole with galactomanan monitoring for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. *Am J Health Syst Pharm* 2013; 70(17):1518-1527.
173. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey T, Pulsipher MA, Benedetto B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer B, Sandmaier BM. Fludarabine/2 Gy TBI is superior to 2Gy TBI as conditioning for HLA-matched related HCT: A Phase III randomized trial. *Biol Blood Marrow Transplant*, 2013; 19(9):1340-1347. Epub 2013 Jun 11.
174. Saber W, Cutler C, Nakamura R, Zhang M, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes. *Blood*, 2013; 122(11):1974-1982. Epub 2013 Jul 11.
175. Burrows GG, van't Hof W, Newell L, Reddy A, David L, Wilmarth P, Raber A, Bogaerts A, Pinxteren J, Deans RJ, Maziarz RT. Dissection of the human multipotent adult progenitor cell (MAPC) secretome by proteomic analysis. *Stem Cells Transl Med*, 2013; 2(10):745-757. Epub 2013 Aug 27
176. Bains T, Chen AI, Lemieux A, Hayes-Lattin BM, Leis JF, Maziarz RT. Improved outcome with busulfan, melphalan, and thiotepa conditioning in autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma. *Leuk Lymphoma*, Epub 2013 Jun 24.

Publications (cont.)

177. Micallef IN, Stiff PJ, Stadtmauer EA, Bolwell BJ, Nademanee AP, Maziarz RT, Partisano AM, Marulka S, DiPersio JF. Safety and efficacy of upfront plerixafor + G-CSF vs. placebo + G-CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥ 60 and ≤ 60 years of age with non-Hodgkin's lymphoma or multiple myeloma. *Am. J. Hematol.*, 2013; 88(12):1017-1023. Epub 2013 Sep 9.
178. Bubalo J, Kullar R, Maziarz RT. A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with neutropenic fever. *Ther Adv Infect Dis*, first published on September 3, 2013 as doi:10.1177/204993611350409).

179. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson CN, Cahn J, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks D, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI. *Blood*. 2013 Dec 5;122(24):3863-70. doi: 10.1182/blood-2013-07-514448. Epub 2013 Sep 24.
180. Smith S, Okada C, Spurgeon S, Chen A, Fan G, Dunlap J, Braziel R, Maziarz RT. Diffuse large B-cell lymphoma in adults aged 75 and older: A single institution analysis of cause-specific survival and prognostic factors. *Ther Adv Hematol* 2013, 4(6):349-353
181. Burrows GG*, Maziarz RT*, Hunady K, Lehman N, Raber A, Deans RJ, van't Hof W. Human multipotent adult progenitor cells (MAPC) modulate leukocyte extravasation by transcriptional regulation of Fucosyltransferase VII (Fut7). *Cytotherapy*, 2013 Epub Oct 28.
182. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg L, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Montoto S, Hari PN. Autologous or reduced-intensity allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle cell lymphoma: Analysis of transplant timing and modality. *J Clin Oncol*. 2013 Dec 16. [Epub ahead of print]
183. Giralt S, Costa L, DiPersio J, Maziarz RT, McCarty J, Shaughnessy P, Bensinger W, Copelan E, Hosing C, Negrin R, Peterson FB, Rondelli D, Schriber J, Snyder E, Soiffer R, Devine S. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations. *Biol. Blood Marrow Transplant*, 2013 Epub Oct 17.
184. Gupta V, Malone AK, Hari PN, Ahn KW, Hu Z, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Beisen KM, Savani BN, Schouten HC, Szer J, Cahn JY, deLima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced intensity hematopoietic cell transplantation for patients with primary myelofibrosis: A cohort analysis from the Center for International Blood and Marrow Research. *Biol. Blood Marrow Transplant*, 2013 Epub Oct 23.
185. Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ. Conditioning with Treosulfan, Fludarabine and 2 Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with MDS and AML. A Prospective Extended Clinical Phase II Study. *Biol Blood Marrow Transplant*. 2014 Jan 15. pii: S1083-8791(14)00025-1. doi: 10.1016/j.bbmt.2014.01.009. [Epub ahead of print]
186. Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR, Inamoto Y, Holland HK, Aljurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortes J, Maziarz RT, Gale RP, Saber W. Does total body irradiation conditioning improve outcomes of myeloablative HLA-identical sibling transplants for chronic lymphocytic leukemia? *Biol Blood Marrow Transplant*. 2013 Dec 7. pii: S1083-8791(13)00569-7. doi: 10.1016/j.bbmt.2013.11.032. [Epub ahead of print]

Publications (cont.)

187. Li X, Brazauskas R, Wang Z, Al-Seraihy A, Baker KS, Cahn JY, Frangoul HA, Gajewski JL, Hale GA, Hsu JW, Kamble RT, Lazarus HM, Marks DI, Maziarz RT, Savani BN, Shah AJ, Shah N, Sorrow ML, Wood WA, Majhail NS. Avascular necrosis of bone following allogeneic hematopoietic cell transplantation in children and adolescents. *Biol Blood Marrow Transplant*. 2014 Apr;20(4):587-92. doi: 10.1016/j.bbmt.2013.12.567. Epub 2014 Jan 2.
188. Scott E, Dibb W, Smith S, Abar F, Kovacsovic T, Meyers G, Stentz A, Frires R, Dibb J, Heitner S, Maziarz RT. Outcomes of 35 patients with AL amyloidosis treated with high dose melphalan and hematopoietic stem cell transplantation – A single institution experience. *Clin Lymphoma Myeloma Leuk*. 2014 Feb 16. pii: S2152-2650(14)00045-7. doi: 10.1016/j.clml.2014.02.003.

189. Wirk B, Fenske TS, Hamadani M, Hu Z, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell BJ, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W. Clinical Outcomes of Hematopoietic Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. *BBMT* 2014 Mar 15. pii: S1083-8791(14)00163-3. doi: 10.1016/j.bbmt.2014.03.014. [Epub ahead of print].
190. Sorror ML, Storb R, Sandmaier BM, Maziarz RT, Pulsiper MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala SL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE. Comorbidity-Age Index: a clinical measure of biological age prior to allogeneic hematopoietic cell transplantation. *J Clin Oncol.* 2014 Oct 10;32(29):3249-56. doi: 10.1200/JCO.2013.53.8157. Epub 2014 Aug 25
191. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, Maris MB, Davis C, Deeg HJ, Lee SJ, Maloney DG, Sandmaier BM, Appelbaum FR, Gooley T. Pre-transplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. *Blood.* 2014 Jul 10;124(2):287-95. doi: 10.1182/blood-2014-01-550566. Epub 2014 May 5
192. Armand P, Kim HT, Logan B, Wang Z, Alyea EP, Kalaycio M, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf D, Rizzo D, Horowitz M, Saber W. Validation and refinement of the disease risk index for allogeneic stem cell transplantation: A study of 13,131 patients from the CIBMTR. *Blood,* 2014 Apr 17. [Epub ahead of print]
193. Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic S, Wirk B, Seftel M, Lewis I, Alyea EP, Cortes JE, Kalaycio M, Maziarz RT, Saber W. Outcomes of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia: Impact of myeloablative versus reduced-intensity conditioning regimens. *Biol Blood Marrow Transplant.* 2014 May 28. pii: S1083-8791(14)00318-8. doi: 10.1016/j.bbmt.2014.05.020. [Epub ahead of print]
194. Maziarz RT, Farnia S, Martin P, Komanduri, KV. Optimal benefits for hematopoietic stem cell transplantation: a consensus opinion. *Biol Blood Marrow Transplant.* 2014 Nov;20(11):1671-6. doi: 10.1016/j.bbmt.2014.07.007. Epub 2014 Jul 12
195. Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA, Freytes CO, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney D, Hari P. Allogeneic hematopoietic cell transplantation for primary cutaneous T cell lymphoma. *Bone Marrow Transplant.* 2014 Jul 28. doi: 10.1038/bmt.2014.161. [Epub ahead of print].
196. Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML. Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. *Biol Blood Marrow Transplant.* 2015 Jan;21(1):151-8. doi: 10.1016/j.bbmt.2014.10.006. Epub 2014 Oct.

Publications (cont.)

197. Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis J, Devine SL, Meyers G, Gajewski JL, Maertens J, Deans RJ, Van't Hof W, Lazarus HM. Prophylaxis of acute GVHD in conventional myeloablative HSCT using MultiStem® Stromal Cell Therapy: Safety after administration of single or multiple doses in a Phase I Trial. *Biol Blood Marrow Transplant.* Dec 30, 2014. pii: S1083-8791(14)01469-4. doi: 10.1016/j.bbmt.2014.12.025. [Epub ahead of print].
198. Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE. Long-term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. *Biol Blood Marrow Transplant.* 2014 Sep 21. pii: S1083-8791(14)00561-8. doi: 10.1016/j.bbmt.2014.09.006. [Epub ahead of print]

199. Copelan E, Avalos BR, Ahn KW, Zhu X, Gale R, Grunwald M, Hamadani M, Hamilton BK, Hale G, Marks D, Waller EK, Savani BP, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble R, Schouten B, Litzow MR, Aljurf M, Van Besien K, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea E, Cortes J, Maziarz RT, Kalyacio ME, Saber W. Comparison of Outcomes of Allogeneic Transplantation for CML with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan or TBI, *Biol Blood Marrow Transplant*. 2014 Dec 17. pii: S1083-8791(14)01410-4. doi: 10.1016/j.bbmt.2014.12.010. [Epub ahead of print].
200. Brammer JE, Stentz A, Gajewski J, Meyers G, Hayes-Lattin B, Leis JF, Curtin P, Kovacsovics T, Nemecek E, Subbiah N, Palmbach G, Avraham GP, Slater S, Maziarz RT. Non-myeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine and total body irradiation conditioning is effective in an elderly and infirm population. *BBMT, Biol Blood Marrow Transplant*. 2015 Jan;21(1):89-96. doi: 10.1016/j.bbmt.2014.09.024. Epub 2014 Oct 16 .
201. Scott EC, Chen A, Smith S, Barkay I, Dibb W, Dibb J, Stentz A, Frires R, Chen Y, Maziarz RT. A Retrospective Analysis of 251 Patients with High Risk Multiple Myeloma Treated with Hematopoietic Stem Cell Transplantation: Chromosome 1 Abnormalities Predict Shortened Progression Free and Overall Survival. *Journal of Blood and Lymph*, In Press.
202. ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, Syrjala KL, Martin PJ, Maloney DG, Sandmaier BM, Storb R, Sorrow ML. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. *Br J Haematol*. 2015 Aug;170(4):574-83. doi: 10.1111/bjh.13476. Epub 2015 May 5.
203. Leonard J, Newell LF, Meyers GM, Allen B, Hayes-Lattin B, Gajewski JL, Nonas S, Heitner S, Maziarz RT, Holtan SG. Chronic GVHD-associated serositis and pericarditis. *Bone Marrow Transplant*. 2015 Aug;50(8):1098-104. doi: 10.1038/bmt.2015.105. Epub 2015 May 11.
204. Vaughn J, Gooley T, Maziarz RT, Pulsipher MA, Bhatia S, Maloney DG, Sandmaier BM, Flowers ME, Storb RF, Sorrow ML. Pre-transplant Comorbidity and Post-Transplant Chronic Graft Versus Host Disease. *Br J Haematol*. 2015 Nov;171(3):411-6. doi: 10.1111/bjh.13591. Epub 2015 Jul 20.
205. Vaughn J, Sorrow ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG. Long term, sustained disease control in patients with mantle cell lymphoma with or without disease after treatment with allogeneic transplantation after nonmyeloablative conditioning. *Cancer*. 2015 Oct 15;121(20):3709-16. doi: 10.1002/cncr.29498. Epub 2015 Jul 24.
206. Burrows GG, van't Hof W, Reddy AP, Wilmarth PA, David LL, Raber A, Bogaerts A, Timmerman L, Pinxteren J, Deans RJ, Maziarz RT. Solution phase cross talk and regulatory interactions between multipotent adult progenitor cells in peripheral blood mononuclear cells. *Stem Cell Trans Med*, 2015; 4: 1-14, Oct 22. pii: sctm.2014-0225. [Epub ahead of print].
207. Riches MR, Trifilio S, Chen M, Ahn KW, Langston A, Lazarus HM, Marks DI, Martino R, Maziarz RT, Papanicolaou GA, Wingard JR, Young JH, Bennett CL. Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. *Bone Marrow Transplant*. 2015 Nov 2. doi: 10.1038/bmt.2015.263. [Epub ahead of print]
208. Munker R, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W. Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia, *Biol Blood Marrow Transplant*. 2016 Feb 19. pii: S1083-8791(16)00118-X. doi: 10.1016/j.bbmt.2016.02.013. [Epub ahead of print].
209. Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Celalettin Ustun DM, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijjiya N, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children (<18y) and Young adults (18-29y) with Chronic Myeloid Leukemia:

A CIBMTR Cohort Analysis, *Biol Blood Marrow Transplant*. 2016 Mar 7. pii: S1083-8791(16)00120-8. doi: 10.1016/j.bbmt.2016.02.015. [Epub ahead of print]

210. Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. *J Clin Oncol*. 2016 Apr 4. pii: JCO650515. [Epub ahead of print]
211. Maziarz RT. Mesenchymal Stromal Cells: Potential Roles in Graft vs Host Disease Prophylaxis and Treatment, *Transfusion*. 2016 Apr;56(4):9S-14S. doi: 10.1111/trf.13563.
212. Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas S, Chen L. Five year direct costs of pediatric patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation: an analysis from US payers' perspective. *Int J Hematologic Oncology*, ePub, Apr 27, 2016
213. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus HM, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-transplant outcomes in high-risk compared to non-high risk multiple myeloma, a CIBMTR analysis, *Biol Blood Marrow Transplant*. 2016 Aug 2. pii: S1083-8791(16)30223-3. doi: 10.1016/j.bbmt.2016.07.007. [Epub ahead of print].
214. Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller E, Maziarz RT, Wu J, Shaw B, Confer D, Horowitz M, Anasetti C. Bone marrow is associated with better patient-reported outcomes than peripheral blood 5 years after unrelated donor transplantation, *JAMA Oncology*, 2016 Aug 11. doi: 10.1001/jamaoncol.2016.2520. [Epub ahead of print].
215. Brammer JE, Saliba FM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P. Multi-Center Analysis of the Effect of Early Thymic Precursor (ETP) Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia. *Bone Marrow Transplant*. 2016 Sep 12. doi: 10.1038/bmt.2016.194. [Epub ahead of print]
216. Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR. The Prognostic Value of Serum C-reactive Protein (CRP), Ferritin, and Albumin prior to Allogeneic Transplantation for AML and MDS, *Haematologica*. 2016 Aug 4. pii: haematol.2016.145847. [Epub ahead of print]
217. Maziarz RT, Brazauskas R, Chen M, McLeod A, Martino R, Wingard JR, Aljurf M, Battwalla M, Dvorak C, George B, Guinan E, Hale G, Lazarus HM, Lee JW, Liesveld J, Ramanathan M, Reddy V, Savani B, Smith F, Strasfeld L, Taplitz RA, Ustun C, Boeckh M, Gea-Banacloche J, Lindemans C, Auletta JA, Riches M. Outcomes of allogeneic HSCT for patients with hematologic malignancies (AML, ALL, MDS, CML) with and without pre-existing fungal infections- pre-existing invasive fungal infection is not a contraindication for HSCT: a CIBMTR study. *Bone Marrow Transplantation*. *Bone Marrow Transplant*. 2017 Feb;52(2):270-278. doi: 10.1038/bmt.2016.259.
218. Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, **Maziarz R**, Sobecks R, Popat U, Alyea E, Saber W. Allogeneic Hematopoietic Cell Transplant for Adult Chronic Myelomonocytic Leukemia. *Biol Blood Marrow Transplant*. 2017 Jan 20. pii: S1083-8791(17)30203-3. doi: 10.1016/j.bbmt.2017.01.078. [Epub ahead of print].
219. Scott BL, Pasquini M, Logan B, Wu J, Devine S, Porter D, Maziarz R, Warlick E, Fernandez H, Alyea E, Hamadani M, Bashey A, Giralt S, Geller N, Leifer E, Le-Rademacher J, Mendizabal A, Horowitz M, Deeg HJ, Horwitz M, on

behalf of the Blood and Marrow Transplant Clinical Trials Network. Myeloablative vs. Reduced Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome, *JCO*, 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13

220. Scott EC, Maziarz RT, Spurgeon SE, Medvedova E, Gajewski J, Heasor- Heard S, Park B, Kratz A, Gordon M, Siegel M, Bothelo J, Loriaux M, Stadtmauer E, Amaravadi R, Vogl DT. Final results of a pilot and phase I trial of infusional cyclophosphamide and pulse dexamethasone with rapamycin and hydroxychloroquine in patients with relapsed or refractory multiple myeloma, *Haematologica*. 2017 Jul;102(7):e261-e265. doi: 10.3324/haematol.2016.162321. Epub 2017 Apr 6
221. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BP, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk B, Wood WA, Artz A. Increasing use of allogeneic cell transplantation in patients age 70 years and older in the United States. *BLOOD*, 2017 Jul 3. pii: blood-2017-03-772368. doi: 10.1182/blood-2017-03-772368. [Epub ahead of print]
222. Driscoll D, Farnia S, Kefalas P, Maziarz RT. The high cost of high tech medicine: planning ahead for market access. *Stem Cells Transl Med*. 2017 Aug;6(8):1723-1729. doi: 10.1002/sctm.16-0487
223. Holstein SA, Jung SH, Richardson PG, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith S, Hars V, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB 100104 (Alliance): a randomized phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma. *Lancet Hematology*. 2017 Aug 17. pii: S2352-3026(17)30140-0. doi: 10.1016/S2352-3026(17)30140-0. [Epub ahead of print]
224. Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas S, Eldjerou L. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. *Leukemia & Lymphoma*, 2018 May;59(5):1133-1142. doi: 10.1080/10428194.2017.1375100. Epub 2017 Sep 21.
225. Gajewski JL, McClellan MB, Majhail NS, Hari PN, Bredeson CN, Maziarz RT, LeMaistre CF, Lill MC, Farnia SH, Komanduri KV, and Boo MJ. Payment and care for hematopoietic cellular transplant patients: Toward a specialized medical home for complex care patients. *Biol Blood Marrow Transplant*. 2018 Jan;24(1):4-12. doi: 10.1016/j.bbmt.2017.09.012. Epub 2017 Sep 28..
226. Hill B, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, Saad A, Seftel M, Seo S, Szer J, Tallman M, Ustun C, Wiernik PH, Maziarz RT, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Assessment of Impact of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Hematopoietic Stem cell Transplant for Chronic Lymphocytic Leukemia (CLL). *Biol Blood Marrow Transplant*. 2017 Oct 12. pii: S1083-8791(17)30774-7. doi: 10.1016/j.bbmt.2017.10.015. [Epub ahead of print].
227. Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston J, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J., Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia HJ, Chen YB. A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti-T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT), *JCO*, *J Clin Oncol*. 2017 Oct 17;JCO2017758177. doi: 10.1200/JCO.2017.75.8177. [Epub ahead of print]
228. Burwitz BJ, Wu HL, Abdulhaqq S, Schriver-Munsche C, Swanson T, Legasse AW, Hammond KB, Junell SL, Reed J, Bimber BN, Greene JM, Webb GM, Northrup M, Laub W, Kievit P, MacAllister R, Axthelm MK, Ducore R, Lewis A,

- Colgin L, Hobbs T, Martin LD, Thomas CR, Panoskaltis-Mortar A, Meyers G, Stanton JJ, Maziarz RT, Sacha JB. Allogeneic stem cell transplantation in fully MHC-matched Mauritian cynomolgus macaques recapitulates diverse human clinical outcomes. *Nature Communications*, 2017 Nov 10;8(1):1418. doi: 10.1038/s41467-017-01631-z.
229. Saraceni MM, Scott E, Maziarz RT, Siegel MB, Mongue-Tchokote S, Jiing S, Medvedova E. Modified hyperCVAD vs Bortezomib-hyperCVAD in patients with relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2018 Jan;18(1):e77-e84. doi: 10.1016/j.clml.2017.10.008. Epub 2017 Nov 2.
230. Chen AI, Okada CY, Leonard JT, Gay N, Fan G, Dunlap JB, Raess PW, Brazier RM, Stentz A, Maziarz RT. Outcomes of R-EPOCH with or without consolidative autologous stem cell transplant for high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. *Leukemia and Lymphoma*, 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1406085. [Epub ahead of print].
231. Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes. *Clin Lymphoma, Myeloma & Leuk*, 2018 Jan;18(1):e41-e50. doi: 10.1016/j.clml.2017.10.001. Epub 2017 Oct 12.
232. Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolanos-Meade J, Flowers MED, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH. Blood and Marrow Transplant Clinical Trials Network Report on Development of Novel Endpoints and Selection of Promising Approaches for Graft-Versus-Host Disease Prevention Trials. *Biol Blood Marrow Transplant*. 2018 Jan 8. pii: S1083-8791(18)30002-8. doi: 10.1016/j.bbmt.2018.01.002. [Epub ahead of print].
233. Al Malki M, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium - HAPLO2016, San Diego, California, December 1, 2016. *Biol Blood Marrow Transplant*. 2018 Jan 12. pii: S1083-8791(18)30023-5. doi: 10.1016/j.bbmt.2018.01.008. [Epub ahead of print].
234. Micallef IN, Stiff PJ, Nadamane AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF. Plerixafor plus granulocyte colony-stimulating factor for patients with Non-Hodgkin lymphoma and multiple myeloma: Long-term follow-up report. *BBMT*, 2018 Feb 1. pii: S1083-8791(18)30056-9. doi: 10.1016/j.bbmt.2018.01.039. [Epub ahead of print].
235. Bubalo J, Mulverhill K, Meyers G, Hayes-Lattin B, Maziarz RT. A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT) A pilot trial of aprepitant with pharmacokinetic analysis for symptom management in patients undergoing high dose chemoradiotherapy and hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2018 Feb 20. doi: 10.1038/s41409-018-0106-8. [Epub ahead of print]
236. Maffini E, Maloney DG, Anderson LD, Sandmaier BM, Green DJ, Storer B, Niederwieser D, Maziarz RT, Storb R. Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström's macroglobulinemia: Evidence for a graft versus lymphoma effect. *Haematologica*. 2018 Mar 15. pii: haematol.2017.184176. doi: 10.3324/haematol.2017.184176. [Epub ahead of print]
237. Scharman CD, Maziarz RT, Shatzel JJ, Medvedova E, Stentz A, Rhyne G, Karam C, Avasare RS, Heitner SB, Scott EC. Autologous stem cell transplant in the era of bortezomib-based induction for AML amyloidosis- a single institution 11 year experience. Published on line. Science Publishing Group 2018. 1 (2) 1-15.
238. Scott EC, Hari P, Gopalakrishnan SK, Fraser R, Alvelo OD, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble R, Lazarus H, Solh M, Usmani S, Kanate A, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt G, Holmberg L, Maziarz R, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients undergoing Autologous Hematopoietic Cell Transplant: The Revised International Staging System is the most Accurate of available Prognostic Tools. *Biol Blood Marrow Transplant*. 2018 Aug 21. pii: S1083-8791(18)30478-6. doi: 10.1016/j.bbmt.2018.08.013. [Epub ahead of print].

239. Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadalla SM, Gale RP, Ganguly S, Hashmi SK, Hematti P, Hildebrandt G, Holmberg LA, Lahoud OB, Landau H, Lazarus HM, de Lima M, Mathews V, Maziarz R, Nishihori T, Norkin M, Olsson R, Reshef R, Rotz S, Savani B, Schouten HC, Seo S, Wirk BM, Yared J, Mineishi S, Rogosheske J, Perales MA. The Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 Nov 10. pii: S1083-8791(18)30699-2. doi: 10.1016/j.bbmt.2018.11.005. [Epub ahead of print].
240. Schuster SJ, Bishop MR, Tam C, Waller E, Borchmann P, McGuirk J, Jäger U, Jaglowski S, Andreadis C, Westin J, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Anak O, Pacaud L, Awasthi R, Tai F, Salles G, Maziarz RT. Juliet Investigators. Tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2018 Dec 1. doi: 10.1056/NEJMoa1804980. [Epub ahead of print].
241. Lachowiec C, Cook RJ, Hayes-Lattin B, Maziarz RT, Borate U, Traer E, Leonard J, Newell L, Dao KH, Meyers G. Allogeneic Transplantation Outcomes Amongst a Contemporary Cohort of High Risk MDS and AML Patients Age 70 and Older. *Hematology/Oncology and Stem Cell Therapy*, 2019 Mar 2. pii: S1658-3876(19)30003-2. doi: 10.1016/j.hemonc.2019.01.002. [Epub ahead of print]
242. McCune JS, Wang T, Bo-Subait K, Aljurf M, Beitinjaneh A, Bubalo J, Cahn JY, Cerny J, Chhabra S, Cumpston A, Dupuis LL, Lazarus HM, Marks DI, Maziarz RT, Norkin M, Prestidge T, Mineishi S, Krem MM, Pasquini M, Martin PJ. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyclophosphamide conditioning, *Biol Blood Marrow Transplant*. 2019 Mar 11. pii: S1083-8791(19)30150-8. doi: 10.1016/j.bbmt.2019.03.001. [Epub ahead of print]
243. Lachowiec C, Kearney M, Meyers G, Maziarz RT, Cook RJ. Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy. *Leukemia & Lymphoma*. 2019 May 6:1-4. doi: 10.1080/10428194.2019.1605512. [Epub ahead of print]
244. Newell LJ, Slater S, Allen BA, Cook R, Jacoby CJ, Kwock R, Knight R, Shoop K, Appel P, Cota B, Maziarz RT*, Meyers G*. Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors. *Cytotherapy* 2019 May 10. pii: S1465-3249(19)30386-X. doi: 10.1016/j.jcyt.2019.04.001. [Epub ahead of print] PMID:31085121
245. Press RD, Eickelberg G, Froman A, Yang F, Stentz A, Flatley EM, Fan G, Lim JY, Maziarz RT, Cook RJ. NGS-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. *Am J Hem*. 2019 May 23. doi: 10.1002/ajh.25514. [Epub ahead of print]
246. Bishop MR, Maziarz RT, Waller EK, Jaeger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, del Corral C, Tiwari T, Anak O, Awasthi R, Pacaud L, Romanov VR, Schuster SJ. Tisagenlecleucel in relapsed/refractory diffuse large B cell lymphoma patients with no active disease after bridging chemotherapy. *Blood Adv*. 2019 Jul 23;3(14):2230-2236. doi: 10.1182/bloodadvances.2019000151.
247. Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam C. Patient Reported long term Quality of Life (QoL) after Tisagenlecleucel Infusion in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). MS in Preparation.
248. Maziarz RT, Cook RJ. Recipe for a graft: T cell dose remains elusive. *Biol Blood Marrow Transplant*. 2019 Jul 22. pii: S1083-8791(19)30479-3. doi: 10.1016/j.bbmt.2019.07.023. [Epub ahead of print]
249. Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, Niederwieser D, Shizuru J, Bruno B, Pulsipher MA, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, McSweeney PA, Storb R, Sorrow ML. Phase II Trial of Nonmyeloablative Conditioning Coupled with Peri-Transplant Rituximab and Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk Chronic Lymphocytic Leukemia: Comparison to the Historical Experience. *Bone Marrow Transplant*. 2019 Sep 3. doi: 10.1038/s41409-019-0660-8. [Epub ahead of print]

250. Maziarz RT, Schuster SJ, Romanov VR, Rusch ES, Singorovitch J, Ericson SG, Maloney DG, Locke FL. Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study. Manuscript Submitted.
251. Awashti R, Pacaud L, Waldron E, Tam CS, Jager U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak O, del Corral C, Yin H, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK. Tisagenlecleucel cellular kinetics, dose and immunogenicity in relation to clinical factors in relapse/ refractory DLBCL. Submitted, BLOOD Advances.
252. Hayes-Lattin B, Bubalo J, Dunn A, Subbiah N, Moore M, Allen B, Curtin P, Slater S, Maziarz RT. Safety and tolerability of anti-bacterial prophylaxis during the post-engraftment phase after myeloablative hematopoietic stem cell transplantation. Ms in Preparation.
253. Schuster SJ, Maziarz RT, Rusch ES, Li J, Singorovitch J, Romanov VV, Locke FL, Maloney DG. Consensus grading of cytokine release syndrome in adult patients with relapsed or refractory diffuse large B-cell lymphoma treated with tisagenlecleucel in the Juliet trial. Manuscript Submitted.
254. Cooper JP, Granot N, Storb R, Gyurkocza B, Sorrow ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Peterson SL, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hubel K, Logan W, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfreay AE, Deeg HJ, Scott BL, Storer BL, Sandmaier BM. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for older and medically infirm patients with hematologic malignancies: Improved outcomes over 2 decades. Manuscript in preparation.
255. Tkacz J, Garcia J, Gitlin M, McMorro D, Snyder S, Bonafede M, Chung KC, Maziarz RT. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment by line of therapy. Submitted. Leuk & Lymphoma
256. Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, Kim DDH, Hernandez, D, Rajkhowa T, Haines K, Bonifacio G, Rine P, Purkayastha D, Fernandez HF. Midostaurin plus standard of care after allogeneic stem cell transplant in patients with *FLT3*-internal tandem duplication–mutated acute myeloid leukemia. Ms in Preparation.
257. Wu HL, Burwitz BJ, Weber W, Shriver-Munsch C, Swanson T, Northrup M, Price H, Armantrout K, Reed JS, Hammond KB, Mahyari E, Thomas A², Junell SL, Thomas CR, Hobbs TR, Martin LD, MacAllister R, Bimber BN, Slifka MK, Legasse AW, Axthelm MK, Smedley J, Lewis AD, Colgin L, Meyers G, Maziarz RT, Stanton JJ, and Sacha JB. Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications. Submitted.

Books

1. Maziarz, R.T. and Slater, S. (eds.) (2011). *Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care*. New York, NY: Springer Science + Business Media.
2. Maziarz, R.T. and Slater, S. (eds.) (2015, 2nd edition). *Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care*. New York, NY: Springer Science + Business Media.

Chapters and Reviews

1. Scott D, Maziarz R. What is the most unique form of stimulus to evoke dental pain: In: Bonic J, Albe-Fessard D, eds. *Advances in pain research and therapy*. Vol. 1. 1974:379-384.
2. Scott D, Maziarz R. "What is the basis of toothache?" (Co je podstatou zubni bolesti?) In: *Ceskoslovenska Fysiologie* 1977; 26:147-152.
3. Maziarz R, Allen H, Flavell R, Strominger J, Biro P, Burakoff S. Cytolytic T lymphocyte recognition of hybrid class I molecules. In: Streilein J, Ahmad F, Black S, Blomberg B, Veolymy R, eds. *Advances in gene technology: molecular biology of the immune system*. Proceedings of 17th Miami Winter Symposium. Vol. 2. Cambridge: Cambridge University Press. 1985:249-250.
4. Strominger JL, Fabbi M, Prendergast M, Maziarz RT, Burakoff S, Groh V. Novel subsets of human T cells (CD4⁺CD8⁺ TCR gamma/delta and CD4⁺CD8⁺ TCR alpha/beta) and T cell development. *Int J Cancer*. 1989; suppl 4:43-47.
5. Braun M, Crane S, Maziarz RT. Brefeldin A blocks phorbol ester induced target cell resistance to NK lysis. *FASEB J* 1994; 8:A769.
6. Nichols CR, Maziarz R. High-dose Chemotherapy in Patients with Germ Cell Cancer In: *High Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells: 3rd Edition*, Armitage and Antman (eds), 1999; 807-820.
7. Hayes-Lattin B, Maziarz RT, Beer T. Allogeneic stem cell transplantation for renal cell carcinoma. *Current Opinions in Oncology*, 2001. 3: 433-437.
8. Leis JM, Maziarz RT. Specific immunotherapy for the treatment of lymphoma. *Laboratory Medicine*, 2001 32: 609-616.
9. Maziarz RT, Mauro MJ. Transplantation in CML: Yes, No, Maybe So.....An Oregon Perspective. *Bone Marrow Transplantation*, 2003, 32:459-469.
10. Hayes-Lattin B, Maziarz RT. Update in the Epidemiology, Prophylaxis, and Treatment of Fungal Infections in Patients with Hematologic Disorders, Leukemia and Lymphoma, 2004, 45: 669-680.
11. Maziarz RT. Imatinib mesylate- a novel immune suppressive agent? *BLOOD*, 2004. 104: 914-915.
12. Maziarz RT. Ph+ ALL: Another success for Imatinib. *BLOOD*, 2005, 105: 3388-3389.
13. Hayes-Lattin B, Leis JF, Maziarz RT. Isolation in the Allogeneic Transplant Environment: How Protective Is It? *Bone Marrow Transplant*. 2005 Sep; 36(5):373-81. Epub 2005 Jun 13.

Chapters and Reviews (cont.)

14. Mauro MJ, Maziarz RT. Stem cell transplantation in patients with chronic myelogenous leukemia: When should it be used? *Mayo Clinic Proceedings*, 2006, 81: 404-416.
15. Maziarz RT. Transplantation for CML: lifelong PCR monitoring? *BLOOD* 2006, 107:3820 .
16. Kovacosvics T, Maziarz RT. Philadelphia chromosome- positive acute lymphoblastic leukemia: impact of imatinib treatment on induction and allogeneic stem cell transplantation, *Curr Oncol Rep*. 2006 Sep; 8(5):343-51
17. Maziarz RT. Who to transplant with CML in the era of tyrosine kinase inhibitors? *Current Opinion in Hematology*, 2008, 15(2):127-133.

18. Maziarz RT. The role of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients in the era of tyrosine kinase inhibitors. In press. "Stem Cell Transplantation", edited by H Lazarus and M Laughlin, 2009.
19. Maziarz RT. Transplantation for CML: 2010. *Blood* 2010 Mar 11;115(10):1860-1.
20. Fowler CJ and Maziarz RT. Clinical use of plerixafor in combination with granulocyte-colony stimulating factor in bone marrow transplantation. *Transplant Research and Risk Management* 2010;2 47–58.
21. Is there a need to catalyze the evolution of the application of cellular therapy? A case for commitment of a society to meet the needs of the regeneration medicine industry. White Paper Series, Stem Cells USA & Regenerative Medicine Congress 2010.
22. Maziarz RT. Overview of Hematopoietic Stem Cell Transplantation. In: "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care," edited by Maziarz RT and Slater S, 2011, pp. 3-8.
23. Appel P and Maziarz RT. The Business of Cellular Therapy and Hematopoietic Stem Cell Transplantation. In: "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care," edited by Maziarz RT and Slater S, 2011, pp. 9-20.
24. Maziarz RT and Abar F. Chronic Graft-Versus-Host Disease. In: "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care," edited by Maziarz RT and Slater S, 2011, pp. 189-212.
25. Maziarz RT and Slater S. Post-transplant Relapse. In: "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care," edited by Maziarz RT and Slater S, 2011, pp. 271-280.
26. Ishida R, Katsunori A, Kakahara K, Fukuda Y, Ohhori M, Saito Y, Kano K, Matsuda J, Asano S, Maziarz RT, Kasai M. Translin/TRAX deficiency affects mesenchymal differentiation programs and induces bone marrow failure. In: "Stem Cells and Human Diseases" edited by R. Srivastava and S. Shankar, Springer-Verlag, 2012, pp. 467-484.
27. Fleischman AG, Maziarz RT. Hematopoietic stem cell transplantation for myelofibrosis: Where are we now? *Curr Opin Hematology*, 2013; 20(2):130-136. Epub 2013 Jan 10.
28. Newell LF, Deans RJ, Maziarz RT. Adult adherent stromal cells in management of GVHD. *Expert Opinions in Biologic Therapy*, 2014 Feb;14(2):231-46. doi: 10.1517/14712598.2014.866648.
29. Maziarz RT, Chell JW, Champlin RE. Hematopoietic stem cell transplantation: financial impact on patients and payers. In "Hematopoietic stem cell transplantation: a handbook for clinicians", Second Edition, Wingard, Gastineau, Leather, Snyder, Szczepiorowski Eds. 2015: 837-851.
30. Maziarz RT. Overview of Hematopoietic Stem Cell Transplantation. In: "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care; Second Edition," edited by Maziarz RT and Slater S, 2015, pp. 1-7.
31. Appel P and Maziarz RT. The Business of Cellular Therapy and Hematopoietic Stem Cell Transplantation. In: "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care; Second Edition," edited by Maziarz RT and Slater S, 2015, pp. 9-20.
32. Maziarz RT and Bubalo J. Psychiatric Complications of HSCT. In: "Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care; Second Edition," edited by Maziarz RT and Slater S, 2015, pp. 271-280.
33. Chen AI & Maziarz RT. Hematopoietic cell transplants for central nervous system lymphomas. Edited by Lazarus HM et al, *Hematopoietic Transplants: Concepts, controversies and future directions*; 1st ed., Cambridge University Press, 2017, Chapter 45, pp 436-444.

Abstracts (partial listing):

1. Maziarz RT, Baker D, Greenberg S. (1991) TGF- β blocks phorbol ester induced polyploidy but not resistant to natural killer cell lysis, of the megakaryocytic leukemia cell line, DAMI. Sixth International Conference on Natural Killer Cell Biology, Stockholm, Sweden.
2. Macintyre EA, Ritz J, Secker-Walker LM, Maziarz RT, Kirsch IR, Strominger JL. (1991) SIL-SCL/tal^d In T-ALL occurs in α/β but not γ/δ expressing T-ALLs. Blood 78: Suppl 1, 267a.
3. Dooley D, Spurgin P, Hansen K, Hansen L, Lanier K, Maziarz RT. (1993) Mobilization of long term culture initiating cells (LTCIC) into peripheral blood (PB) by granulocyte-colony stimulating factor (G-CSF). Blood 82: Suppl 1, 292a.
4. Braun M, Crane S, Maziarz RT (1994). Brefeldin A blocks phorbol ester induced target cell resistance to NK lysis. FASEB J vol. 8, no. 5, 4463.
5. Lawton R, Vetto JT, Maziarz RT (1994). The co-expression of HLA Class I molecules and human ICAM-1 on murine fibroblasts does not overcome the species-specific defect in recognition of human alloantigen. Twelfth European Immunology Meeting, Barcelona, Spain.
6. DeLoughery TG, Edward K, Maziarz RT (1995). Red cell depletion and plasma infusion for major ABO incompatible bone marrow transplants. ISHAGE meeting, Vancouver, Canada.
7. Tittle TV, Steinkeler C, Weinberg A, Maziarz RT. The expression of the T cell activation antigen, Ox-40, in GVHD (1996) Blood 86: Suppl 1, 575a.
8. Tittle TV, Steinkeler C, Weinberg AD, Maziarz RT. Expression of the T cell activation antigen Ox-40, in GVHD (1996). American Society of Blood and Marrow Transplantation, Keystone, Colorado.
9. Tittle TV, Steinkeler CN, Weinberg A, Maziarz RT. Identification of the T cells causing acute GVHD (1996). FASEB J 10:A81435.
10. Guo H, Tittle TV, Maziarz RT. Brefeldin A-induced programmed cell death is inhibited by CED-3/ICE family protease inhibitors (1996) American Society of Hematology. Blood 88: Suppl 1, 163a.
11. List A, Stiff P, Maziarz RT, Jensen J, Liesveld J, Schuster M, Andrews DF, Karanes I, Wolff S, Litzow M. Lisofylline (LSF) reduces infection rate and improves survival in patients undergoing allogeneic bone marrow transplantation (BMT): results of a randomized, placebo-controlled trial (1996) American Society of Hematology. Blood 88: Suppl 1, 459a.
12. Abonour R, Kunkel LA, Mills B, Srour E, Gharpure V, Hromas R, Roberston M, Brouns ER, Rowley SD, Maziarz R, Oldham FB, Cornetta K. Selecting autologous CD34+ cells from mobilized peripheral blood progenitor cells (PBPC) by immunomagnetic bead separation in patients with multiple myeloma (1996). American Society of Hematology. Blood 88: Suppl 1, 605a.
13. Adkins DR, Freytes C, Maziarz R, Brown RA, Beck E, Khoury H, Bachier C, LeMaistre CF, DiPersio J. Outcomes of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) in stage III-B inflammatory breast cancer (1997) ASCO.
14. Holmberg LA, Demirer T, Schiffman K, Rowley SD, Buckner CD, Goodman G, Maziarz R, Appelbaum F, Bensinger WI. High dose busulfan, melphalan, and thiotepa (BUMELTT) followed by autologous peripheral blood stem cells (PBSC) rescue in patients with advanced stage III/IV ovarian cancer (1997). American Society of Hematology. Blood 90: Suppl 1, 383a.
15. Araten D, Bessler M, Nafa K, Longo L, Karadimitris F, Castro-Malaspina H, Chase A, Childs B, Kutlar A, Maziarz R, Tsataalas C, Weiss M, Jhanwar S, Luzzatto L. Chromosomal abnormalities in paroxysmal nocturnal hemoglobinuria (PNH) American Society of Hematology. (1997) Blood 90: Suppl 2, 4b.

Abstracts (partial listing) cont.

16. Tittle TV, Weinberg A, Maziarz RT. A comparison of OX40 and IL-2R (CD25) expression in acute GVHD (1997) American Society of Hematology. Blood 90: Suppl 2, 320b.
17. Tittle TV, Weinberg AD, Maziarz RT. T cell Activation during acute GVHD. (1998) FASEB J. 12: A584.
18. Saund N, Law CL, Leis J, Maziarz RT, Druker B, Bonyhadi M. A novel autologous T cell immunotherapeutic approach for the treatment of B-cell Lymphocytic leukemia (B-CLL) (2000) AAI, Seattle, WA.
19. Hoffelt SC, Holland JM, Liem BJ, Maziarz RT, Marquez CM. Use of 1400 Centigray total body irradiation in allogeneic bone marrow transplants. (2000) Radiologic Society of North America.
20. Bonyhadi M, Saund N, Druker B, Streeter P, Maziarz RT, Leis J. Xcellerate: a novel autologous T cell immunotherapeutic approach for the treatment of B-cell lymphocytic leukemia (B-CLL). (2000) Leukemia 2000 meeting, Houston, TX.
21. Tittle TV, Streeter PR, Caldwell J, Maziarz RT. CD4+ T Cell Subsets with Antagonistic Roles in Acute Graft-Versus-Host Disease (2000). American Society of Hematology. Blood 96:11, 768a.
22. Bonyhadi M, Saund N, Chana H, Tam V, Nguyen H, Habecker P, Streeter P, Druker B, Maziarz RT, Leis J. Xcellerate: An Autologous T Cell Immunotherapeutic Approach for Treating of B-Cell Lymphocytic leukemia (B-CLL) (2000). American Society of Hematology. Blood 96:11, 837a.
23. Leis J, Hansen KS, Brunvand M, Fleming WH, Curtin PT, Menashe JI, Gruenberg DR, Seelig F, Kratz AC, Stepan DE, Lanier KS, Kerr MM, Subbiah N, Hansen LK, Maziarz RT. Phase II/Study of Combination High-Dose Therapy with Busulfan, Thiotepa, and Total Body Irradiation (TBI) for the Treatment of Aggressive Multiple Myeloma (2000). American Society of Hematology. Blood 96:11, 372b
24. Cornetta K, Sledge G, Yanovich S, Rosenfeld C, Chabannon C, Burtness B, Lotz JP, Maziarz R, Williams S, Somlo G, Bitran J, Mitsky P. High dose chemotherapy and stem cell transplant in breast cancer: a randomized multicenter study of CD34 selection. American Society of Clinical Oncology. J Clin Onc (2001) 20:16A.
25. Hoffelt S, Holland JM, Liem BJ, Maziarz RT, Marquez CM. Total body irradiation in allogeneic bone marrow transplantation: a comparison of 6mV and 18mV photons (2001). American Society of Clinical Oncology, San Francisco, CA. J Clin Onc 20:19a.
26. Karamlou K, Grant C, Capdeville R, Druker BJ, Maziarz RT. Kinetics of Response to Gleevec in Chronic Myelogenous Leukemia Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Patients. American Society of Hematology. Blood 98:590a.
27. Streeter PR, Tam VL, Dooley DC, Druker BJ, Leis JF, Reik RA, Maziarz RT. Vaccine Development in Chronic Myelogenous Leukemia: Optimization of Leukemic Dendritic Cell Generation. American Society of Hematology. Blood 98:267b.
28. Maziarz RT, Chauncey TR, Capdeville R, Druker BJ, Seelig F. Growth Factor Mobilization of CD34+ PBSC in CML Patients Treated with Imatinib (STI571). American Society of Hematology. Blood 98:738a.
29. Leis J, Stepan D, Curtin P, Peng B, Ford J, Schubach S, Fleming W, Druker BJ, Maziarz RT. Low Penetration of Imatinib (STI571) into the CSF Indicates the need for Standard CNS Prophylaxis in Patients with CML Lymphoid Blast Crisis and Philadelphia Chromosome Positive ALL. American Society of Hematology. Blood 98:140a.

Abstracts (partial listing) cont.

30. Leis J, Primack S, Schubach S, Capdeville R, Curtin P, Stepan DE, Fleming WH, Druker BJ, Maziarz RT. Management of Lifethreatening Pulmonary Leukostasis with Single Agent Imatinib (STI571) during CML Blast Crisis. American Society of Hematology. Blood 98:261b.
31. Ruffner KL, Radich JP, Bryant E, Maziarz RT, Rosamilia M, Druker BJ, Chauncey TR. Serial Cytogenetic and Quantitative Molecular Monitoring of Disease Burden in a Patient on Imatinib (STI571) for CML-AP undergoing G-CSF Mobilization of Peripheral Blood Stem Cells (PBSC). American Society of Hematology. Blood 98:321a.
32. Winston DJ, Maziarz RT, Chandrasekar P, Lazarus H, Goldman M, Leitz G, Territo MC. Long-term Antifungal Prophylaxis in Allogeneic Bone Marrow Transplant Patients: A Multicenter, Randomized Trial of Intravenous/Oral Itraconazole Versus Intravenous/Oral Fluconazole. American Society of Hematology. Blood 98:479a.
33. Mehdizadehkashi Z, Streeter PR, Reik RA, Druker BJ, Buchdunger E, Maziarz RT, Dooley DC. GM-CSF and/or IL-3 Overcome STI571 (GLEEVEC)-Mediated Growth Inhibition of C-KIT⁺ BCR-ABL⁻ Cells. American Society of Hematology. Blood 98:619a.
34. Frassoni F, Labopin M, Bacigalupo A, Gluckman E, Rocha V, Bruno B, Lazarus H, Devine S, Holland K, McCarthy P, Curtin P, Maziarz R, Shpall E, Moseley AM. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hemopoietic stem cell transplant, reduce acute and chronic graft versus host disease: a matched pair analysis. Presidential Symposium, 28th Annual meeting of the European Group for Blood and Marrow Transplantation (EBMT), 2002.
35. Bonyhadi M, Leis JF, Grosmaire L, Rasmussen A, Xu J, Roehrs H, Ferrand C, Markham E, Leshinsky N, Lindgren R, Wierda W, Kipps TJ, Maziarz RT, Tibergien P, Berenson RJ, Frohlich M. Autologous T Cell Therapy for B-CLL (2002). American Society of Hematology. Blood 100:206a.
36. Maziarz RT, Zhang X, Streeter PR. CD25 expression distinguishes functionally distinct alloreactive CD4⁺CD134⁺ T cell subsets in acute GVHD(2002). American Society of Hematology, Blood 100:250a.
37. Mauro MJ, Deininger MW, O'Dwyer ME, Maziarz RT, Walker T, Kurilik G, Druker BJ. American Society of Hematology. Phase I/II study of arsenic trioxide (Trisenox) in combination with Imatinib Mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase (2002). American Society of Hematology, Blood 100:781a.
38. Deininger MW, Schleunig M, Sayer HG, Greinix H, Fischer T, Olavarria E, Maziarz RT, Martinez J, Niederwieser D. Allografting after Imatinib Therapy. No evidence for increased transplant-related mortality and favorable results in patients transplanted in remission. A retrospective study by the EBMT. American Society of Hematology, Blood 100:783a.
39. Zhang X, Schon CN, Maziarz RT, Streeter PH. Donor-derived CD4⁺ 134⁺ 25⁺ cells from animals with acute Graft-Versus-Host-Disease differentially regulate T cell immune responses. American Society of Hematology, Blood 100:824a.
40. Maziarz RT, Zhang X, Streeter PR. CD25 Expression Distinguishes Functionally Distinct Alloreactive CD4⁺CD134⁺ T Cell Subsets in Acute GVHD. IBMTR 2003.
41. Eldredge D, Nail L, Maziarz RT. Caregiving strain following autologous BMT. IBMTR 2003.
42. Streeter PR, Zhang X, Schon C, Maziarz RT. Separable Alloreactive CD4⁺ T Cells Exhibit Differential Tissue Associations and Functions in Acute Graft-Versus-Host Disease. AAI 2003, Denver, CO.
43. Zhang X, Schon C, Maziarz RT, Streeter PR. GVHD-associated regulatory T cells are eliminated by depletion of donor-derived naturally occurring regulatory T cells prior to transplantation. AAI 2003, Denver, CO.

Abstracts (partial listing) (cont.)

44. Mauro MJ, Druker BJ, Kuyl J, Kuilik G, Maziarz RT. Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of Bcr-Abl. ASCO, 2003.
45. Medis R, Marlowe M, Partel R, Tomines E, Curtin P, Maziarz R, Norman D, Endres RO. PCR-SSP typing of an apparently homozygous A31 individual reveals the serologically undetected HLA-A*2411N allele. ASHI, 2003.
46. Maris MB, Sandmaier BM, Storer B, Stuart M, Agura E, Hegenbart U, Pulsipher M, Maziarz RT, et al. TID compared to BID mycophenolate mofetil (MMF) improves donor chimerism and engraftment rates without increasing postgrafting toxicities after unrelated peripheral blood stem cell (PBSC) transplantation (HCT) with nonmyeloablative conditioning. ASBMT, 2004.
47. Burroughs LM, Maris MB, Sandmaier FM, Leisenring WJ, Stuart M, Niderwieser D, McSweeney PA, Chauncey T, Maziarz RT, et al. HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). ASBMT, 2004.
48. Eldredge DH, Nail LM, Maziarz RT, Archbold P. Identifying classes of caregiving activities helping family caregivers do it all better. National Cancer Nursing Research Meeting, FLA, 2005.
49. Maris MB, Sandmaier BM, Storer B, Shizuru J, Maloney D, Agura E, Niederwieser D, Pulsipher M, Maziarz RT, et al. Unrelated donor peripheral blood stem cell (PBSC) transplantation using nonmyeloablative conditioning and mycophenolate mofetil (MMF) TID results in high engraftment rates. American Society of Hematology 2004, Blood 104:503a.
50. Norasetthada L, Maris MB, Sandmaier BM, Gooley T, Forman S, Agura E, Maziarz RT, et al. HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative hematopoietic cell transplantation (HCT) for patients with refractory and relapsed aggressive non-Hodgkin lymphoma. American Society of Hematology 2004, Blood 104:634a.
51. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Monic JS, Maziarz RT, Agura E, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. American Society of Hematology 2004, Blood 104:231a.
52. Liu Hui, Wang Jin, Maziarz RT, Epner EM. Long distance cyclin D1 activation in B cell malignancies: Role of RNA polymerase II. American Society of Hematology 2004, Blood 104:316a.
53. Epner EM, Liu H, Jin W, Huang J, Nichols CR, Maziarz RT. Cyclin D1 deregulation in mantle cell lymphoma: tethering of the cyclin D1 promoter and 3' immunoglobulin enhancers by CTCF and nucleophosmin. American Society of Hematology 2004, Blood 104:430a.
54. Dugan MJ, Akard LP, Thompson JM, Nademanee A, Maziarz RT, Bensinger WL, Liesveld J, Badel K, Dehner C, Gibney C, Calandra G, Jansen J. Treatment with AMD3100 in multiple myeloma or Non-Hodgkin's lymphoma patients to increase the number of peripheral blood stem cells when given with a mobilizing regimen of chemotherapy and G-CSF. American Society of Hematology 2004, Blood 104:782a.
55. Streeter PR, Zhang X, Maziarz RT. Functional separation of GVHD-derived and naturally occurring CD4 + CD25 + regulatory T cells. American Society of Hematology 2004, Blood 104:886a.
56. Hayes-Lattin B, Bubalo J, Dunn A, Subbiah N, Allen B, Balleisen S, Curtin P, Jacoby C, Leis JF, Mauro MJ, Simic A, Schubach S, Maziarz RT. Safety and tolerability of anti-bacterial prophylaxis during the post-engraftment phase after myeloablative hematopoietic stem cell transplantation. American Society of Hematology 2004, Blood 104:357b.

Abstracts (partial listing) (cont.)

57. Hayes-Lattin B, Mehtah P, Dunn A, Subbiah N, Leis JF, Simic A, Allen B, Balliesen S, Curtin PT, Epner E, Fleming WH, Jacoby C, Mauro MJ, Nichols CR, Schubach S, Maziarz RT. Survival after autologous transplantation to treat diffuse large B-Cell lymphoma with a history of CNS involvement, bone marrow involvement, or histologic transformation. American Society of Hematology 2004, Blood 104:394b.
58. Streeter PR, Zhang X, Maziarz RT. GVHD-derived CD4+CD25+ T cells exhibit regulatory activities that are distinct from naturally occurring regulatory T cells. International Society for Cellular Therapy 2005. Cytotherapy 7: (supp 1), #134.
59. Leis JF, Hansen KS, Curtin PT, Hayes-Lattin BM, Lanier KS, Stanton NR, Callway CD, Fowler CJ, Dunn AM, Gruenberg D, Mauro MJ, Segal GM, Hansen LK, Menashe JI, Kovacovics TJ, Simic A, Maziarz RT. Prognostic models for predicting outcomes after autologous stem cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin's Diseases: How predictive are they? American Society of Hematology 2005, Blood 106:465b.
60. Kovacovics-Bankowski M, Streeter PR, Hewett E, Van't Hof WJ, Deans RG, Maziarz RT. Multipotent adult progenitor cells (MAPC) are immunoprivileged and demonstrate immunosuppressive properties on activated T cell population. American Society of Hematology 2005, Blood 390b.
61. Huang JZ, Bakke AC, Fan G, Brazier R, Gatter KM, Maziarz RT, Leis JF, Zhong Y. A novel multiparameter flow cytometric cytotoxicity assay detects p53 deletion as the major cause of in vitro resistance to fludarabine in B-cell chronic lymphocytic leukemia. American Society of Hematology 2005, Blood 195b.
62. Sandmaier BM, Maris MG, Maloney DG, Gooley TA, Shizuru JA, Niederwieser DW, Chauncey TR, Sahebi F, Agura E, Maziarz RT, Bruno B, Pulsipher M, Langston AA, Wade J, McSweeney PA, Epner E, Bethge W, Forman SJ, Blume KG, Storb R. Hematopoietic cell transplants (HCT) from HLA-matched related MRD and unrelated (URD) donors for patients with hematologic malignancies using low-dose TBI conditioning. American Society of Hematology 2005, Blood 194a.
63. Baron F, Storb R, Storer B, Maloney D, Maris M, Niederwieser D, Shizuru J, Chauncey T, Bruno B, Forman S, McSweeney P, Maziarz R, Pulsipher M, Agura E, Sorrow M, Wade J, Sandmaier B. Allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning after failed myeloablative HCT: Factors affecting outcomes. American Society of Hematology 2005, Blood 333a.
64. Kerbauy F, Maris M, Storer B, Maloney D, Niederwieser D, Agura E, Pulsipher M, Chauncey T, Maziarz R, Forman S, Langston A, Wade J, Scott B, Deeg J, Storb R, Sandmaier BM. Efficacy of nonmyeloablative hematopoietic cell transplant (HCT) in secondary myelodysplastic syndrome (MDS) and its impact on the primary disease. American Society of Hematology 2005, Blood 234a.
65. Maris M, Sandmaier BM, Storer B, Agura E, Wade J, Maziarz RT, Forman S, Shizuru J, Chauncey T, Kahl C, Langston A, Niederwieser D, Storb R, Maloney DG. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. American Society of Hematology 2005, Blood 329a.
66. Anaissie E, Schuster MQ, Hurd D, Bensinger W, Mason J, McCarty JM, Rifkin R, Maziarz RT, Bowell B, Mehta J, Mangan K, Skikne B, Abboud C, Chao N, Stadtmauer E, Fernandez H, Lazarus H, Westervelt P, Halvorsen Y, Gerwien R, Annino V, Hahne W. A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velfermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AH SCT). American Society for Blood and Marrow Transplant 2006, Biology of Blood and Marrow Transplantation 12; 2 (Suppl 1) 21.

Abstracts (partial listing) (cont.)

68. Franke GN, Hegenbart U, Niederwieser D, Sandmaier BM, Maris MG, Shizru JA, Stuart M, Greiniz H, Cordonnier C, Rio B, Gratwohl A, Lange T, Poenisch W, Grommisch L, Al-Ali H, Storer B, Maloney D, Petersdorf E, McSweeney P, Chauncey T, Agura E, Epner E, Maziarz RT, Petersen F, Bruno B, Storb R. Treatment for acute myelogenous leukemia by low dose total body irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors. American Society for Blood and Marrow Transplant 2006, Biology of Blood and Marrow Transplantation 12; 2 (Suppl 1) 31.
69. Hayes-Lattin B, Leis JF, Curtin PT, Dunn A, Epner E, Fleming WH, Kovacovics T, Mauro MJ, Moore M, Simic A, Subbiah N, Maziarz R. Outcomes associated with a steroid-containing acute GVHD prophylaxis regimen for matched unrelated donor (MUD) hematopoietic stem cell transplantation. American Society for Blood and Marrow Transplant 2006, Biology of Blood and Marrow Transplantation 12; 2 (Suppl 1) 68.
70. Leis JF, Hansen KS, Curtin PT, Hayes-Lattin B, Lanier KS, Gruenberg D, Mauro MJ, Segal GM, Menashe JI, Kovacovics TJ, Simic A, Maziarz RT. The failure of prognostic models (PM) for Hodgkins Disease (HD) to predict outcomes after autologous stem cell transplantation (ASCT) American Society for Blood and Marrow Transplant 2006, Biology of Blood and Marrow Transplantation 12; 2 (Suppl 1) 95.
71. Kovacovics-Bankowski M, Streeter PR, Van't Hof WJ, Deans RJ, Maziarz RT. Multipotent adult progenitor cells (MAPC) are non immunogenic and display immunosuppressive properties on activated T cells. American Society for Blood and Marrow Transplant 2006, Biology of Blood and Marrow Transplantation 12; 2 (Suppl 1) 106.
72. Eldredge DH, Nail LM, Grant M, Maziarz RT. Family caregiving processes indirectly influence HSCT recipient QOL. American Society for Blood and Marrow Transplant 2006, Biology of Blood and Marrow Transplantation 12; 2 (Suppl 1) 113.
73. Bubalo JS, Leis JF, Curtin PT, Simic A, Subbiah N, Fowler C, Dunn A, Grant B, Maziarz RT. A phase II randomized open-label study anti-CMV hyperimmune globulin vs. standard IGIV for prevention of cytomegalovirus (CMV) reactivation in hypogammaglobulinemic adult allogeneic hematopoietic stem cell transplants (AHSCT). American Society for Blood and Marrow Transplant 2006, Biology of Blood and Marrow Transplantation 12; 2 (Suppl 1) 170.
74. Kovacovics T, Hayes-Lattin B, Riegert K, Subbiah N, Curtin PT, Leis JF, Mauro MM, Epner EE, Fleming WH, Meyers GH, Deininger MW, Dunn A, Maziarz RT. Validation of the hematopoietic cell transplantation-co-morbidity index (HCT-CL) for non-relapse mortality (NRM) and survival after matched unrelated donor SCT. American Society for Blood and Marrow Transplant 2007, Biology of Blood and Marrow Transplantation 13; 2 (Suppl 2) 257.
75. Sorror ML, Storer B, Sandmaier BM, Maris MB, Shizuru J, Niederwieser D, Agura E, Chauncey T, Maziarz R, Pulsipher M, McSweeney P, Wade J, Bruno B, Langston A, Blume K, Storb R, Maloney, DG. Longer follow up of patients (PTS) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT). American Society for Blood and Marrow Transplant 2007, Biology of Blood and Marrow Transplantation 13; 2 (Suppl 2) 368.
76. Anderson, LD, Sandmaier, BM, Maris MB, Niederwieser D, Agura E, Maziarz RT, Chauncey TR, Storb R, Maloney DG. Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for refractory Waldenstrom's macroglobulinemia (WM): Evidence for a Graft-Versus-WM effect. American Society of Hematology 2006, Blood 862a.
77. Baron F, Sandmaier BM, Storer B, Maris M, Langston A, Niederwieser DW, Petersdorf E, Bethge W, Maziarz RT, McSweeney P, Pulsipher M, Wade JC, Chauncey T, Shizuru J, Woolfrey A, Maloney DG, Storb RF. Postgrafting immunosuppression with prolonged mycophenolate Mofetil (MMF) and truncated cyclosporine (CSP) failed to reduce the incidence of Graft-Versus-Host disease (GVHD) after unrelated donor hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning. American Society of Hematology 2006, Blood 888a.

Abstracts (partial listing) (cont.)

78. Rezvani AR, Sandmaier BM, Storer B, Maris M, Agura E, Maziarz R, Wade JC, Chauncey T, Forman SJ, Niederwieser DW, Shizuru J, Langston A, Pulsipher M, Storb RF, Maloney DG. Outcomes of allogeneic hematopoietic stem cell transplantation (HCT) after non-myeloablative conditioning in relapsed, refractory, or transformed indolent non-Hodgkin lymphoma. American Society of Hematology 2006, Blood 891a.
79. Siegel DS, Drishnan A, Lonial S, Chatta G, Alsina M, Jagannath S, Richarson P, Hohl RJ, Lust JA, Bensinger W, Carrum G, Moreb J, Simic A, Barlogie B, Maziarz RT, Anderson KC, Lin J, Lowe A, Vetticaden S, Zhu J. Phase II trial of SCIO-469 as monotherapy (M) or in combination with Bortezomib (MB) in relapsed multiple myeloma (MM). American Society of Hematology 2006, Blood 1022a.
80. Patel KM, De Paula LP, Holland JM, Maziarz RT, Marquez CM. Extramedullary leukemia: The role of radiation therapy. American Society of Hematology 2006, Blood 225b.
81. Leis JF, Newton A, Post MT, Hayes-Lattin BM, Maziarz RT, Taplitz RA. Vancomycin-resistant enterococcus (VRE) colonization is associated with a high rate of bacteremia and early mortality in transplant/leukemia patients. American Society of Hematology 2006, Blood 421b
82. Maziarz RT, Dunn A, Hansen L, Hansen K, Leis JF, Hayes-Lattin BM, Kovacsovics T, Calandra G, Fowler C. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and AMD3100: An institutional experience. American Society of Hematology 2006, Blood 461b.
83. Kovacsovics T, Park B, Hayes-Lattin B, Leis JF, Curtin PT, Meyers G, Epner E, Maziarz RT. Applying the hematopoietic cell transplantation-comorbidity index (HCT-CI) in myeloablative MUD transplants predicts NRM and OS using a modified 2-tier scoring system. American Society of Hematology, 2007, Blood 591a.
84. Rotta M, Storer B, Sahebi F, Shizuru JA, Bendetto B, Lange T, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Agura ED, Chauncey T, Appelbaum FR, Sorrow ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG. Long-term outcome of autologous follow by Nonmyeloablative allografting from HLA-identical sibling for multiple Myeloma (MM). American Society of Hematology 2007, Blood 889a.
85. Rezvani AR, Norasetthada L, Gooley T, Sorrow M, Forman SJ, Agura E, Chauncey T, Maziarz RT, Maris M, Shizuru J, Bruno B, Wade JC, Lange T, Yeager A, Sandmaier BM, Storb RF, Maloney DG. Outcomes of allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning in relapsed diffuse large B-cell lymphoma (DLBCL). American Society of Hematology 2007, Blood 892a.
86. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, Mendizabal AM, Leather H, Confer DL, Baden LR, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, DiPerson JF, Boeckh M, Marr KA. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. American Society of Hematology 2007, Blood 55a.
87. Burroughs L, O'Donnell PO, Sandmaier BM, Storer B, Luznik L, Symons H, Maris M, Blume KG, Niederwieser DW, Bruno B, Maziarz RT, Pulsipher M, Petersen F, McSweeney PA, Chauncey T, Agura E, Wade JC, Storb RF, Fuchs EJ, Maloney DG. Comparison of allogeneic hematopoietic cell transplantation (HCT) after Nonmyeloablative conditioning with HLA-matched related (MRD), unrelated (URD), and related haploidentical (Haplo) donors for relapsed of refractory Hodgkins lymphoma (HL). American Society of Hematology 2007, Blood 58a.
88. DiPersio JF, Micallef I, Stiff PJ, Bolwell BJ, Maziarz RT, Angell J, Bridger G, Calandra G, 3101 Investigators. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD 3100 (Plerixafor) + G-CSF in non Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. American Society of Hematology 2007, Blood 185a.

Abstracts (partial listing) (cont.)

89. Micallef I, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Angell J, Bridger G, Calandra G on behalf of the 3101 Investigators. Successful stem cell mobilization rescue by AMD3100 (Plerixafor) + G-CSF for patients who failed primary mobilization: Results from the phase III (3101-NHL) study. American Society of Hematology 2007, Blood 185a.
90. Lee S, Maziarz R, Kukreja M, Wang T, Giralt S, Szer J, Woolfrey A, Arora M, on behalf of the Writing Committee, CIBMTR. Impact of prior therapy with imatinib mesylate on the outcome of hematopoietic cell transplantation (HCT) for chronic myeloid leukemia (CML). American Society of Hematology 2007, Blood 227a.
91. McHenry M, Hayes-Lattin B, Maziarz RT. Impact of health insurance on time to approval and time to transplant among patients receiving hematopoietic stem cell transplantation. Bio Blood Marrow Transplant 14: 2 (Supp 2) 146.
92. Rotta M, Storer B, Sahebi F, Shizuru JA, Benedetto B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey T, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG. Long-term outcome of nonmyeloablative allografting from HLA-identical sibling for multiple Myeloma (MM). Bio Blood Marrow Transplant 14:2 (Suppl 2) 170.
93. Bubalo JS, Ciszewski AO, Kovacovics TJ, Meyers G, Mauro M, Epner E, Jones N, Hayes-Lattin B, Deininger M, Curtin PT, Leis JF, Maziarz RT. A phase II open label pilot trial of empiric Daptomycin treatment for hematology-oncology patients with febrile neutopenia (FN). Bio Blood Marrow Transplant 14:2 (Suppl 2) 269.
94. Nemecek ER, Ly B, Kovacovics T, Maziarz RT, Baumgart J, Sanders JE, Deeg HJ. Treosulfan plus fludarabine for allogeneic hematopoietic cell transplantation (HCT) in patients with acute leukemia and myelodysplastic syndrome. Bio Blood Marrow Transplant 14:2 (Suppl 2) 278.
95. Kovacovics T, Park B, Hayes-Lattin B, Dunn A, Curtin PT, Leis JF, Epner EE, Meyers G, Maziarz RT. Applying the hematopoietic cell transplantation-comorbidity index (HCT-CI) in myeloablative MUD transplants predicts NRM and OS using a modified 2-group scoring system. Bio Blood Marrow Transplant 14:2 (Suppl 2) 285.
96. Myers G, Dunn A, Kovacovics T, Fleming W, Epner E, Hayes-Lattin B, Mauro M, Deininger M, Bubalo J, Maziarz R. Busulfan, Fludarabine and total body irradiation followed by allogeneic peripheral blood stem cell transplantation is an effective treatment for hematologic malignancies with acceptable toxicity in a higher-risk population. Bio Blood Marrow Transplant 14:2 (Suppl 2) 318.
97. Bubalo JS, Kovacovics TJ, Meyers G, Mauro M, Epner E, Hayes-Lattin B, Deininger M, Curtin PT, Leis JF, Maziarz RT. Conazepam plus levetiracetam (CL) for the prevention of busulfan-induced seizures: A single center experience. Bio Blood Marrow Transplant 14:2 (Suppl 2) 467.
98. Gyurkocza B, Storb RF, Storer B, Chauncey T, Niederwieser D, Shizuru J, Langston A, Pulsipher M, Bredeson C, Maziarz RT, Bruno B, Peterson F, Maris M, Agura E, Yeager AM, Bethge WA, Sahebi F, Vindelov L, McSweeney PA, Applebaum FR, Maloney DG. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with de novo secondary acute myeloid leukemia. American Society of Hematology 2008, Blood 112(11):61.
99. Schriber JR, Agovi, MA, Ballen KK, Bacigalupo A, Hale GA, Gupta V, Lazarus HM, Litzow MR, Marks DI, Giller RH, Maziarz RT, Bornhauser M, Isola LM, Bredeson C, Rizzo JD. Second unrelated donor (URD) transplant as a rescue strategy for 122 patients with primary non engraftment: Results from the CIBMTR. American Society of Hematology 2008, Blood 112(11):295.
100. Cortes J, Seiter K, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey B, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown, Jr. A, Moore JO. Superiority of Rasburicase versus allpurinol on serum uric acid control in adult patients with hematological malignancies at risk of developing tumor lysis syndrome: Results of a randomized comparative phase III study. American Society of Hematology 2008, Blood 112(11):340.

Abstracts (partial listing) cont.

101. Rotta M, Storer B, Sahebi F, Shizuru JA, Bruno B, Lange T, McSweeney PA, Pulsipher M, Hari P, Maziarz RT, Agura E, Chauncey T, Appelbaum F, Bensinger W, Sandmaier B, Storb R, Maloney DG. Tandem auto/alloHCT for newly diagnosed multiple myeloma (MM) patients. American Society of Hematology 2008, Blood 112(11):412.
102. DiPersio JF, Micallef INM, Stiff PJ, Bolwell BJ, Maziarz RT, Bridger G, Calandra G. 12 Months report from the Phase 3 study of Plerixafor+G-CSF vs. placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. American Society of Hematology 2008, Blood 112(11):414.
103. Sorrow ML, Storer B, Sandmaier BM, Maris M, Chauncey T, Maziarz RT, Pulsipher M, Shizuru J, Niederwieser D, Agura E, Wade JC, Langston AA, Storb RF, Maloney DG. Sustained graft-versus-lymphoma effect among patients (pts) with Mantle Cell Lymphoma (MCL) given nonmyeloablative allogeneic hematopoietic cell transplantation. American Society of Hematology 2008, Blood 112(11):747.
104. Sorrow ML, Storer B, Sandmaier BM, Maloney DG, Franke G, Shizuru J, Chauncey T, Agura E, Maziarz RT, Sahebi F, Langston AA, Wade JC, Maris M, Bruno B, Yeager AM, Pulsipher M, Petersen F, Bethge WA, McSweeney PA, Niederwieser D, Blume KG, Storb RF. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for patients (pts) aged ≥ 60 years. American Society of Hematology 2008, Blood 112(11):753.
105. Stiff PJ, Micallef INM, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, Bridger G, Calandra G, Angell J, DiPersio JF. Transplanted CD34+ cell dose is associated with long-term platelet count following autologous hematopoietic stem cell transplant in patients with non-Hodgkin's lymphoma and multiple myeloma. American Society of Hematology 2008, Blood 112(11):758.
106. Nemecek ER, Sorrow ML, Doney KC, Scott BL, Kovacovics TJ, Maziarz RT, Woolfrey AE, Sanders J, O'Donnell PV, Guthrie K, Deeg HJ. A regimen of treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation (HCT) for high-risk hematologic malignancies is associated with low treatment-related mortality. American Society of Hematology 2008, Blood 112(11):1028.
107. Micallef, INM, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Angell J, Bridger G, Calandra G. Comparison of graft durability among lymphoma patients who received Plerixafor in combination with G-CSF for primary versus failed mobilization. Bio Blood Marrow Transplant 15: 2 (Supp 2), 11.
108. Abar F, Leis JF, Jacoby CE, Mishra M, Bubalo JS, Curtin PT, Hayes-Lattin BL, Meyers G, Slater SE, Subbiah N, Maziarz RT. Denileukin difitox (ONTAK) for the treatment of advanced steroid-refractory GVHD: A Single Institution Experience. Bio Blood Marrow Transplant 15:2 (Supp 2), 129.
109. DiPersio JF, Micallef IN, Nademanee AP, Stiff PJ, Stadtmauer EA, Maziarz, RT, Bolwell BJ, Angell J, Bridger G, Calandra G. Results of two phase III, multicentre, randomized, placebo-controlled trials of plerixafor + G-CSF versus G-CSF + placebo for mobilization and engraftment of non-Hodgkin's lymphoma and multiple myeloma patients undergoing autologous transplantation. Bone Marrow Transplant 43(Suppl. 1): S104, 2009.
110. Micallef IN, DiPersio JF, Nademanee AP, Stiff PJ, Stadtmauer EA, Maziarz RT, Bolwell BJ, Angell J, Bridger G, Calandra G. Efficacy of plerixafor plus G-CSF compared to G-CSF plus placebo for mobilization of CD34+ haematopoietic progenitor cells in patients older than 60 years with non-Hodgkin's lymphoma or multiple myeloma. Bone Marrow Transplant 43(Suppl. 1): S105, 2009.
111. Stiff PJ, Micallef IN, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, Calandra G, Bridger G, DiPersio JF. Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous haematopoietic stem cell transplant in patient with non-Hodgkin's lymphoma and multiple myeloma. Bone Marrow Transplant 43(Suppl. 1): S114, 2009.

Abstracts (partial listing) cont

112. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, Nelson V, Kovacovics T, Leis J, Calandra G, Maziarz RT. Rescue from failed growth factor and/or chemotherapy haematopoietic stem cell mobilization with C-GSF and plerixafor: a single-centre experience. Bone Marrow Transplant 43(Suppl. 1): S114, 2009.

113. Maziarz RT, Micallef IN, Stiff P, Bolwell BJ, Marulka S, Calandra GC, DiPersio JF. Plerixafor plus G-CSF is an effective regimen to mobilize hematopoietic stem cells in NHL patients with circulating peripheral blood CD34+ cells/ul <10. American Society of Hematology 2009, Blood 114(22):19.
114. Bolwell BJ, Nademanee AP, Stiff P, Stadtmauer E, Maziarz RT, Micallef IN, Marulka S, Gandhi P, DiPersio JF. Mobilization with plerixafor (Mozobil) plus G-CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G-CSF: results from two randomized placebo-controlled trials in patients with multiple myeloma or non-Hodgkin's lymphoma. American Society of Hematology 2009, Blood 114(22):1248.
115. Nemecek ER, Guthrie K, Sorrow M, Hilger R, Doney K, Scott B, Kovacsovics T, Maziarz R, Woolfrey A, Sanders J, Sickel E, Borruel-Rector J, O'Donnell P, Witherspoon R, Appelbaum F, Deeg HJ. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk haematologic malignancies. Results of a phase I/II multicentre study in the United States. Poster Presentation at the European Bone Marrow Transplant 2010 Congress, Vienna, Austria.
116. Maziarz RT, Wang Z, Zhang MJ, Laport GG, Lazarus HM, Montoto S, Hari PN. CNS remission predicts survival after autologous hematopoietic stem cell transplantation (AHCT) for non-Hodgkin lymphoma (NHL) with pre-existing CNS involvement: a CIBMTR analysis. Biol Blood Marrow Transplant 2010; 16 (Supp 2): S166.
117. Strasfeld L, Espinoza L, Green J, Graeme F, Meyers G, Ball E, Castro J, Mulrone C, Curtin P, Maziarz R, Taplitz R. Novel H1N1 influenza A (S-OIV) infection in recipients of hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16 (Supp 2): S174.
118. Micallef INM, Maziarz RT, van Rhee F, Horowitz M, Hill J, Stewart K, Mody P, Huebner D, Shaughnessy P. Efficacy of plerixafor plus G-CSF in hematopoietic stem cell (HSC) remobilization in patients with amyloidosis. Biol Blood Marrow Transplant 2010; 16 (Supp 2): S203.
119. Meyers G, Subbiah N, Palmbach G, Kovacsovics T, Abar F, Hayes-Lattin B, Gajewski J, Dunn A, Jacoby C, Slater S, Allen B, Maziarz R. Reduced intensity allogeneic hematopoietic stem cell transplantation can achieve both disease control and very good outcomes in elderly (>60) patients with hematologic malignancies. Biol Blood Marrow Transplant 2010; 16 (Supp 2): S284.
120. Meyers G, Subbiah N, Palmbach G, Dunn A, Abar F, Hayes-Lattin B, Gajewski J, Kovacsovics T, Slater S, Jacoby C, Allen B, Maziarz R. Addition of busulfan to fludarabine and total body irradiation conditioned allogeneic hematopoietic stem cell transplantation enhances donor T-cell engraftment and optimized disease control. Biol Blood Marrow Transplant 2010; 16 (Supp 2): S289.
121. McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giral S, Stadtmauer EA, Richardson PG, Weisdorf DJ, Vij R, Moreb JS, Callender NS, van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Hars V, Postiglione J, Jiang C, Bennett E, Barry SS, Bressler L, Kelly M, Sexton M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C. Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. American Society of Hematology 2010, Blood 116(21):37.
122. Maziarz RT, Zhang MJ, Wang Z, Laport GG, Lazarus HM, Montoto S, Hari P. CNS remission at the time of autologous stem cell transplantation improves outcome for patients with non-Hodgkin's lymphoma with pre-existing CNS involvement: A CIBMTR analysis. American Society of Hematology 2010, Blood 116(21):371.

Abstracts (partial listing) cont

123. Sorrow ML, Storer B, Sandmaier BM, Franke GN, Laport GG, Chauncey T, Agura E, Maris MT, Wade J, Pulsipher MA, Maziarz RT, Sahebi F, McSweeney P, Bruno B, Vindelov L, Yeager AM, Rezvani A, Niederwiser DW, Blume KG, Storb RF, Maloney DG. Outcomes following relapse of non-Hodgkin's lymphoma (NHL) or chronic

lymphocytic leukemia (CLL) after nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related or unrelated donors. American Society of Hematology 2010, Blood 116(21):1292.

124. Sorror ML, Storer B, Sandmaier BM, Braunert L, Laport GG, Chauncey T, Bredeson C, Maziarz RT, Pulsipher MA, Agura E, Maris MT, Vindelov L, Sahebi F, McSweeney P, Bruno B, Langston A, Storb RF, Maloney DG. Impacts of cytogenetic abnormalities and prior alemtuzumab on outcomes of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) give nonmyeloablative allogeneic hematopoietic cell transplantation. American Society of Hematology 2010, Blood 116(21): 2364.
125. Gyurkocza B, Storb RF, Storer BE, Chauncey T, Lange T, Laport GG, Langston A, Pulsipher MA, Bredeson C, Maziarz R, Bruno B, Petersen F, Maris M, Agura E, Yeager AM, Bethge WA, Sahebi F, Appelbaum FR, Maloney DG, Estey EH, Sandmaier BM. A relapse risk score to predict acute myeloid leukemia relapse after nonmyeloablative allogeneic hematopoietic cell transplantation based on pre-transplant variables. American Society of Hematology 2010, Blood 116(21):3450.
126. Akpek G, Pasquini MC, Agovi MA, Logan B, Cooke KR, Maziarz RT, Gupta V, Lazarus HM, Hale GA, Marks DI, Maharaj D, Popat U, Carabasi M, Bornhaeuser M, Bolwell BJ, Ringden O, Ballen KK, Rizzo JD, McCarthy PL. Spleen status and engraftment after allogeneic hematopoietic stem cell transplantation (HCT). American Society of Hematology 2010, Blood 116(21):3486.
127. Ballen KK, Arora M, Zhu X, Agovi M, Kalaycio M, Maziarz RT, Cortes JE, Woolfrey A, Horowitz MM, Saber W. Results of allogeneic transplantation for polycythemia vera and essential thrombocythemia. American Society of Hematology 2010, Blood 116(21):3514.
128. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Johnson L, Maziarz RT, Pulsipher M, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Carter SL, Horowitz MM, Confer DL. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with Filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT/CTN) protocol 0201, a phase III, prospective, randomized trial. American Society of Hematology 2011, Blood 118(21):3.
129. Sorror ML, Ostronoff F, Storb R, Bhatia S, Maziarz RT, Pulsipher MA, Maris MT, Deeg HJ, Martin PJ, Appelbaum FR, Maloney DG, Sandmaier BM, Storer B. Multi-institutional validation of the predictive power of the hematopoietic cell transplantation comorbidity index (HCT-CI) for HCT outcomes. American Society of Hematology 2011, Blood 118(21):69.
130. Sorror ML, Storb R, Martin PJ, Shatia S, Maziarz RT, Pulsipher MA, Maris MT, Deeg HJ, Appelbaum FR, Maloney DG, Sandmaier BM, Gooley TA. Impact of pre-transplant comorbidities on the rate of- and mortality- following acute graft versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). American Society of Hematology 2011, Blood 118(21):76.
131. Sorror ML, Storb R, Sandmaier BM, Bhatia S, Maziarz RT, Pulsipher MA, Maris MT, Deeg HJ, Appelbaum FR, Maloney DG, Martin PJ, Storer B. Impact of comorbidities on early and late mortalities after allogeneic hematopoietic cell transplantation (HCT). American Society of Hematology 2011, Blood 118(21):153.
132. Ostronoff F, Storer B, Storb R, Bhatia S, Maziarz RT, Pulsipher MA, Maris MT, Deeg HJ, Martin PJ, Appelbaum FR, Maloney DG, Sandmaier BM, Sorror ML. Interaction of age and comorbidities and their impact on hematopoietic cell transplantation (HCT) outcomes. American Society of Hematology 2011, Blood 118(21):305.

Abstracts (partial listing) cont

133. Maziarz RT, deVos T, Bachier C, Goldstein SC, Leis JF, Perry R, Deans R, Van't Hof WJ, Lazarus HM. Prophylaxis of acute GVHD using stromal cell therapy: Preliminary results after administration of single or multiple doses of MultiStem® in a phase I trial. American Society of Hematology 2011, Blood 118(21):867.

134. Battiwalla M, Ellis K, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani BN, Aljurf M, Cairo MS, Drobyski WR, George B, Hahn T, Khera N, Litzow MR, Loren AW, Saber W, Arora M, Urbano-Ispizua A, Cutler CS, Flowers MED, Spellman S. HLA DR15 antigen status does not impact graft-versus-host disease or disease-free survival in HLA-matched sibling transplantation for hematologic malignancies. American Society of Hematology 2011, Blood 118(21):1337.
135. Bains T, Chen AI, Lemieux A, Hayes-Lattin B, Leis JF, Maziarz RT. Improved outcome with Busulfan, Melphalan, and Thiotepa conditioning (BuMelTt) in autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma. American Society of Hematology 2011, Blood 118(21):1344.
136. Kornblit B, Storer B, Storb RF, Hari P, Vucinic V, Maziarz RT, Chauncey T, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hubel K, Storek J, Maloney DG, Sandmaier BM. A randomized phase III trial investigating 2Gy TBI vs. Flu/2 Gy TBI conditioning for HLA-matched related donor hematopoietic cell transplantation (HCT): Tempo of CD3 and NK cell engraftment determines relapse and progression free survival in patients with hematologic malignancies. American Society for Blood and Marrow Transplantation 2012, Biol Blood Marrow Transplant 18(2, suppl 2):S214.
137. Bains T, Lemieux A, Abar F, Maziarz RT, Chen AI. Long term engraftment is associated with survival after autologous hematopoietic stem cell transplantation in multiple myeloma. American Society for Blood and Marrow Transplantation 2012, Biol Blood Marrow Transplant 18(2, suppl 2):S256.
138. Newell LF, Leeborg N, Dong ZM, Perets-Avraham G, Deans R, Chauncey TR, Maziarz RT. Multipotent adult progenitor cells (MultiStem®) enhance bone marrow recovery after ablative allogeneic stem cell transplant. American Society for Blood and Marrow Transplantation 2012, Biol Blood Marrow Transplant 18(2, suppl 2): S264.
139. Maziarz RT, Devos T, Bachier C, Goldstein SC, Leis J, Cooke KR, Perry R, Deans RJ, Van't Hof WJ, Lazarus HM. Prophylaxis of acute GVHD using MultiStem® stromal cell therapy: Preliminary results after administration of single or multiple doses in a phase I trial. American Society for Blood and Marrow Transplantation 2012, Biol Blood Marrow Transplant 18(2, suppl 2):S264.
140. Leis JF, Sabloff M, Sobecks RM, Maziarz RT, Ahn KW, Zhu X, Kalaycio ME, Cortes J, Saber W, On behalf of the CIBMTR Chronic Leukemia Working Committee. Outcomes of allogeneic hematopoietic cell transplantation (HCT) in chronic lymphocytic leukemia (CLL): Impact of myeloablative (MA) vs reduced-intensity conditioning (RIC) regimens, and impact of total body irradiation (TBI)-based MA versus chemotherapy (CT)-based MA conditioning. American Society for Blood and Marrow Transplantation 2012, Biol Blood Marrow Transplant 18(2, suppl 2):S290.
141. Perets-Avraham P, Bains T, Lemieux A, Slater S, Kovacsovics T, Curtin P, Gajewski J, Meyers G, Maziarz RT. Improved outcome of elderly patients after reduced intensity allogeneic hematopoietic cell transplantation (HCT). American Society for Blood and Marrow Transplantation 2012, Biol Blood and Marrow Transplant 18(2, suppl 2): S347.
142. Myers L, Burmeister J, Mater E, Murray S, Curtin PT, Gajewski JL, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Slater S, Maziarz RT. An institutional perspective on the efficacy of donor leukocyte infusions for patients with post-transplant relapse. American Society for Blood and Marrow Transplantation 2012, Biol Blood Marrow Transplant 18(2, suppl 2): S350.
143. Hamilton BK, Ahn KW, Zhu X, Avalos B, Bolwell BJ, Gale RP, Cortes JE, Kalaycio M, Maziarz RT, Saber W. Lower transplant-related mortality and improved survival for patients with AML in first CR receiving BuCy compared to Cy/TBI as myeloablative preparation for allogeneic transplantation: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). American Society of Hematology, 2012.

Abstracts (partial listing) cont

144. Cutler C, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes JE, Kalaycio M, Horowitz MM. Comparison of outcomes after related and unrelated hematopoietic cell transplantation in adults with myelodysplastic syndromes: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). American Society of Hematology, 2012.

145. Gupta V, Ahn KW, Zhu X, Hari P, Maziarz RT, Cortes JE, Kalaycio M, Saber W. Lille scoring system rather than DIPSS is a better predictive of overall mortality after allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis using reduced intensity conditioning: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). American Society of Hematology, 2012.
146. Smith SD, Okada C, Chen AI, Spurgeon SE, Fan G, Dunlap JB, Leeberg N, Brazier RM, Maziarz RT. Prognostic features, treatments and disease-specific mortality among patients with diffused large B-cell lymphoma over the age of 75: A single-center retrospective analysis. American Society of Hematology, 2012.
147. Scott EC, Smith SD, Chen AI, Leeberg N, Bains T, Stentz A, Frires R, Dibb W, Dibb J, Allen B, Kratz A, Daffe R, Chen Y, Maziarz RT. Outcomes of 252 patients with high risk multiple myeloma treated with hematopoietic stem cell transplantation: Identification of risk factors associated with early relapse, shortened progression free and overall survival. American Society of Hematology, 2012.
148. Maziarz RT, McLeod A, Chen M, Gea-Banaloché J, Szabolcs P, Boeckh MJ, Tombyln M. Outcomes of allogeneic HSCT for patients with hematologic malignancies (AML, ALL, MDS, CML) with and without pre-existing fungal infections: A CIBMTR Study. American Society for Blood and Marrow Transplantation 2013, Biol Blood Marrow Transplant 19(2, suppl. 2):S125.
149. Scott EC, Kovacovics T, Smith S, Abar F, Stentz A, Frires R, Dibb J, Dibb W, Heitner S, Maziarz RT. HDM/SCT for AL amyloidosis – A single institution 12 year experience. American Society for Blood and Marrow Transplantation 2013, Biol Blood Marrow Transplant 19(2, suppl. 2):S188.
150. Holtan SG, Newell LF, Meyers G, Chen AI, Hayes-Lattin B, Gajewski JL, Slater S, Nemecek E, Brazier R, Fan G, Maziarz RT. Predictive classification of chronic GVHD status by immune reconstitution testing. American Society for Blood and Marrow Transplantation 2013, Biol Blood Marrow Transplant 19(2, Suppl. 2):S292.
151. Leonard J, Holtan SG, Heitner S, Nonas S, Allen B, Chen AI, Newell LF, Meyers G, Hayes-Lattin B, Gajewski JL, Slater S, Maziarz RT. Chronic GVHD-associated serositis and pericarditis. American Society for Blood and Marrow Transplantation 2013, Biol Blood Marrow Transplant 19(2, Suppl. 2):S333.
152. Maziarz RT, Newell JF, Bogaerts A, Pinxteren J, Deans RJ, Burrows GG. Dissection of the human multipotent adult progenitor cell (MAPC) secretome by proteomic analysis. American Society for Blood and Marrow Transplantation 2013, Biol Blood Marrow Transplant 19(2, Suppl. 2):S350.
153. Armand P, Kim HT, Logan B, Wang Z, Alyea EP, Kalaycio M, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf D, Rizzo D, Horowitz M, Saber W. Validation and refinement of the disease risk index for stratification of patients undergoing allogeneic stem cell transplantation: A study of 13,131 patients from the CIBMTR. American Society of Hematology, 2013 pending.

FORMAL PRESENTATIONS AND LECTURES

1991

1. Brigham and Women's Hospital, Boston, MA: Hematology/Medical Oncology Grand Rounds "The Immunobiology of the Natural Killer Cell".
2. The Sixth International Conference on Natural Killer Cell Biology - Stockholm, Sweden: "TGF Beta Blocks Phorbol Ester Induced Polyploidy but not Resistant to Natural Killer Cell Lysis, of the Megakaryocytic Leukemia Cell Line, DAMI".
3. Oregon Health Sciences University Hematology/Medical Oncology Grand Rounds: "The Immunobiology of the Natural Killer Cell."
4. Boston University Medical Center Hematology Grand Rounds: "The Immunobiology of the Natural Killer Cell."

1992

1. Hematology/Medical Oncology Research Rounds of Oregon Health Sciences University: "The Role of Adhesion Molecules in Immune Effector: Target Cell Interactions."
2. OHSU Department of Microbiology/Immunology Research Rounds; "The Role of Adhesion Molecules in Immune Effector: Target Cell Interactions."
3. OHSU Medical School - MS2 Hematology Course: "Acute Myelogenous Leukemia."
4. OHSU Medical School - MS2 Hematology Course: "Chronic Myelogenous Leukemia."
5. OHSU Medical School - MS1 Immunology Course: "Tumor Immunology."
6. Portland VA Medical Center Research Rounds: "A Unique Translocation in a T-Cell Leukemia with the Gamma/Delta T-Cell Receptor."
7. Oregon Health Sciences University Medical Grand Rounds: "Allogeneic Bone Marrow Transplantation."

1993

1. OHSU Medical School - MS2 Hematology Course: "Pathophysiologic Considerations of Neutrophils and Monocytes."
2. OHSU Medical School - MS2 Hematology Course: "Molecular Leukemogenesis."
3. OHSU Hematology/Medical Oncology Research Rounds: "MHC Class I: Peptide Interactions."
4. Reed College Immunology Course: "Adhesion Molecules."
5. Reed College Immunology Course: "Natural Killer Cells."
6. OHSU Department of Pathology Research Rounds: "The Immunobiology of MHC Class I Antigens."
7. OHSU Medical School - MS1 Cancer Biology Course: "Tumor Immunology."
8. OHSU Hematology/Medical Oncology Research Rounds: "Tumor Immunology."
9. Albany Hospital, Albany, OR: Medical Grand Rounds, "Autologous Bone Marrow Transplantation."

1994

1. OHSU Medical School - MS2 Hematology Course: "Bone Marrow Transplantation"
2. OHSU Graduate School - Con 711.0 - "Hematopoiesis and Ontogeny of the Immune System"
3. OHSU Hematology/Medical Oncology Research Rounds: "Multiple Myeloma"
4. Reed College Immunology Course: "Adhesion Molecules"
5. Reed College Immunology Course: "Tumor Immunology"
6. OHSU Graduate School - Mb612: "Cell Trafficking: Adhesins and Addressins"
7. OHSU Graduate School - Mb612: "Tumor Immunology."
8. OHSU Medical School - MS1 Cancer Biology Course: "Tumor Immunology"
9. Tuality Hospital, Hillsboro, OR - Medical Grand Rounds: "Autologous Bone Marrow Transplantation."
10. OHSU Combined Solid Organ Transplant Conference - "Stem Cell Transplantation"

1995

1. OHSU Medical School - MS2 Hematology Course: "Bone Marrow Transplantation"
2. Legacy Portland Hospitals - Seminar for Radiation Oncology Professionals - "Allogeneic Bone Marrow Transplants"
3. OHSU Hematology/Medical Oncology Research Conference - "Management of Allogeneic Bone Marrow Transplant Patients."

FORMAL PRESENTATIONS AND LECTURES

1995 (cont.)

4. OHSU Combined Solid Organ Transplant Conference – “Bone Marrow Transplantation: Cell Therapies - Present and Future.”
5. Reed College Immunology Course: “Adhesion Molecules.”
6. Reed College Immunology Course: “Tumor Immunology.”
7. OHSU Morbidity and Mortality Rounds: “Respiratory Failure after Bone Marrow Transplantation for Aplastic Anemia”
8. Department of Medicine, OHSU, Resident Teaching Rounds: “Indications for Bone Marrow Transplant.”
9. Portland Bone and Mineral Research Club: “The Skeleton and Bone Marrow Transplantation”
10. Salem Hospital Tumor Board, Salem, Oregon: “Indications for Bone Marrow Transplants”

1996

1. OHSU Medical School - MS2 Hematology Course: “Bone Marrow Transplantation”
2. OHSU Combined Solid Organ Transplant Conference: “Graft versus Host Disease”
3. NW Leadership Summit - Meeting the Challenge of Breast and Cervical Cancer – “Hematopoietic Transplantation - Current and Future Prospects.”
4. OHSU Graduate School - Mb612 – “Adhesion Molecules”
5. Sommer Memorial Lecture – “Blood and Marrow Transplantation: Experimental Procedure or Standard of Care.”
6. AASTROM BIOSCIENCES, Inc. – “Autologous Hematopoietic Stem Cell Transplantation for CML: an Overview.”
7. Eugene, Oregon – “Update on PBSC Transplants”

1997

1. OHSU Medical School - MS2 Hematology Course: “Bone Marrow Transplantation”
2. OHSU Surgical Grand Rounds: “Autologous Stem Cell Transplants for Breast Cancer”
3. ISHAGE (Applications of Flow Cytometry in Blood and Marrow Stem Cell Transplantation Meeting) - Plenary Lecture: “T cell Activation in GVHD”
4. National Blood Brain Barrier Disruption - Third Annual Meeting: “Stem Cell Transplants - Potential Application in Primary or Secondary CNS Hematologic Malignancy”
5. Northwest Marrow Transplant Program – “Complications of Marrow Transplantation”
6. Portland BMT Support Group – “Long Term Effects of Bone Marrow Transplantation”

1998

1. Central Oregon Cancer Care Conference: ‘Current Research in Bone Marrow Transplant’
2. Central Oregon Oncology Conference: ‘Protective Agents in the Use of High Dose Therapy’
3. Northwest Marrow Transplant Program Lecture: AProtective Agents in the Use of High Dose Therapy
4. OHSU Medical School - MS2 Hematology Course: “Bone Marrow Transplantation”
5. OHSU Hematology Grand Rounds: “Indications for Bone Marrow Transplantation”
6. FASEB Mini-Symposium: Graft vs Host Disease: “A comparison of OX40 and IL-2R (CD25) expression in acute GVHD” San Francisco, AAI meeting.
7. Invited Oncology Lecture: “ Current Indications for Blood and Marrow Transplants”, Rogue Valley Medical Center and Providence Hospital, Medford, OR
8. Mercy Medical Center Tumor Board: “Current Indications for Blood and Marrow Transplants”, Klamath Falls, OR
9. Osiris Therapeutics, Inc: “CD 134 (OX40) Expression as a Marker of T cell Activation in Acute GVHD.”
10. OHSU, Medical Resident Rounds: ‘Current Indications for Blood and Marrow Transplants’

1999

1. Invited Oncology Lecture: “Current Indications for Blood and Marrow Transplants”, Corvallis, OR.
2. Hematology Update: ASH, 1998 “Bone Marrow Transplantation”
3. OHSU Medical School - MS2 Hematology Course: “Bone Marrow Transplantation”
4. OHSU Hematology Grand Rounds: “Basic Tenets of Immunobiology.”
5. Leukemia Society of America: “Advances in Leukemia Research.” Medford, OR.
6. Northwest Marrow Transplant Survivor’s Conference: “Long term complications of Allogeneic Bone Marrow Transplantation”, Beaverton, OR
7. Northwest Marrow Transplant Program Lecture:”Complications of Stem Cell Infusions”

FORMAL PRESENTATIONS AND LECTURES

1999(cont.)

8. Frontiers in Medicine: "Hope and Healing; Progress in Bone Marrow Transplantation Therapy" Eugene, OR
9. Northwest Marrow Transplant Program: Controversies in Stem Cell Transplantation Conference: "Overview of Care and Treatment Options in CML." Portland, OR
10. St. Alphonsus Hospital Medical Grand Rounds: "Advances in Bone Marrow Transplantation." Boise, ID.

2000

1. Hematology Update: ASH, 1999: "Bone Marrow Transplant", Portland, OR.
2. OHSU Medical School - MS2 Hematology Course: "Bone Marrow Transplantation."
3. Chimeric Therapies Investigator Meeting. "Immune Reconstitution Post-allogeneic Transplantation", San Diego, CA
4. St. Charles Hospital Tumor Board: "Non-Myeloablative Allogeneic Transplantation", Bend, OR
5. ISEH Corporate Symposium: Plenary Lecture: "Mesenchymal Stem Cells in Allogeneic Transplantation" ISEH, Tampa, FL
6. OHSU BMT Seminar Series: "Indications for High Dose Myeloablative Therapy with Stem Cell Rescue"
7. OHSU BMT Seminar Series: "HLA biology and immunogenetics"
8. ASH Corporate Symposium: "Mesenchymal stem cells in unrelated transplantation: Immunological roles", ASH, San Francisco, CA.
9. Legacy Good Samaritan Hospital Tumor Board: "Nonmyeloablative stem cell transplantation", Portland, OR.

2001

1. Hematology Update: ASH, 2000: "Bone Marrow Transplantation", Portland, OR.
2. Hematology Research in Progress: "Mesenchymal Stem Cells: Biology and Clinical Implications"
3. Hematology/ Oncology Grand Rounds: "Immunology for the Oncologist/ Hematologist"
4. NWMTP Blood/ Marrow Transplant Conference: "Update from ABMTR/ IBMTR"
5. OHSU Medical School - MS2 Hematology Course: "Bone Marrow Transplantation".
6. OHSU Organ Transplantation Grand Rounds: "Update on Bone Marrow Transplantation with Attention to Cell Therapies"
7. Leukemia and Lymphoma Society of Oregon: "Multiple Myeloma"
8. ISHAGE Plenary Lecture: "Mesenchymal cells in allogeneic bone marrow transplantation", ISHAGE Annual Meeting, Quebec City, Canada
9. NWMTP Stem Cell Conference: "Transplantation for Leukemia and Lymphoma"
10. NWMTP Stem Cell Conference: "Overview of Stem Cell Therapy"
11. Salem Hospital Medical Grand Rounds: "Stem Cells: Current and Future Indications for Regenerative Cell Therapies"
12. Kaiser Permanente, Hematology/ Medical Oncology Grand Rounds: "Non-myeloablative stem cell transplantation"
13. OHSU Hospital Medical Grand Rounds: "Cell Therapy: Current and Future Applications"
14. ASH Scientific Simultaneous Session: "Growth Factor Mobilization of CD34⁺ PBSC in CML Patients treated with STI571", Orlando, FL

2002

1. Hematology Update: ASH, 2001: "Bone Marrow Transplantation", Portland, OR.
2. OHSU Medical School - MS2 Hematology Course: "Bone Marrow Transplantation,"
3. Molecular Therapy Seminar Series: "Targeted therapy in Hematologic Malignancies," Abbott Laboratories, Worcester, MA.
4. NWMTP Regional Conference: "Transplantation for patients with CML in the era of targeted Therapies," Portland, OR
5. NWMTP Survivors Conference: "The Latest Developments in Stem Cell Therapy," Portland, OR
6. OHSU M & M: "Hypercoagulable States; Multiple Myeloma," Portland, OR
7. OHSU Oncology Nursing Conference: "Stem Cell Transplantation," Portland, OR
8. Northwest Oncology Meeting: "Acute Leukemia 2002," Portland, OR
9. Tumor Board Conference, "Immunochemotherapy in Relapsed Acute Myeloid Leukemia (AML): Targeted Versus Non-Specific Treatment," St. Joseph's Regional Medical Center, Lewiston, ID.

FORMAL PRESENTATIONS AND LECTURES

2002 (cont.)

10. OHSU Department of Medicine, Morbidity and Mortality Conference: "Acute Renal Failure, spontaneous tumor lysis syndrome and AML," Portland, Oregon.
11. Fifteenth Annual National Marrow Donor Program Council Meeting: "Gleevec: Current Indications, Stem Cell Transplants and the Future," Minneapolis, Minnesota.
12. Invited Lecturer, "Targeted Therapy for Acute Myeloid Leukemia," Yakima Regional Cancer Care Center, Yakima, WA.
13. OHSU Pediatric Hematology/ Oncology Grand Rounds: "Gleevec: Current Indications, Stem Cell Transplants and the Future", Portland, OR.
14. Oregon Branch, Leukemia and Lymphoma Society: "Long-term effects of Bone Marrow Transplantation."
15. Legacy-Good Samaritan Hospital Tumor Board: "Reduced intensity allogeneic stem cell transplantation", Portland, OR.

2003

1. Hematology Update: ASH, 2002: "Bone Marrow Transplantation", Portland, OR.
2. Mayo Clinic Transplant Grand Rounds: "Imatinib mesylate, stem cell transplantation and the future of treatment for CML patients," Rochester, Minnesota.
3. OHSU Hematology/Medical Oncology Grand Rounds: "High Grade Lymphoma"
4. OHSU Medical School - MS2 Hematology Course: "Bone Marrow Transplantation,"
5. OHSU Combined Organ Transplant Grand Rounds: "Reduced Intensity Stem Cell Transplantation: On the Road to Tolerance," Portland, OR.
6. United Resource Networks, "Blood/Marrow Transplantation for Adults: the importance of timely transplant referrals; the role of clinical trials; treatable diseases; complications and outcomes", Portland, OR.
7. Invited Lecturer, "Imatinib mesylate: its uses, indications and its role in transplantation for CML," Medford, OR.
8. Roswell Park Cancer Institute Medical Grand Rounds, "Transplantation for Hematologic Malignancies: Optimal Management of Disease with Targeted Therapy," Buffalo, NY.
9. OHSU Hematology/ Medical Oncology Grand Rounds: "Bone Marrow Transplantation: Insights into the Major Histocompatibility Complex".
10. Invited Lecturer, "New Approaches in Anti-fungal Therapy," U. S. Oncology, Portland, OR.
11. Invited Lecturer, "Mesenchymal Stem Cells in Human Stem Cell Transplantation," American Association of Blood Banking", San Diego, CA.

2004

1. Invited Lecturer, "The Impact of Imatinib on Transplantation for Chronic Myelogenous Leukemia, IBMTR/ASBMT Annual Meeting, Orlando, FL
2. OHSU Leukemia/Lymphoma Conference: "AMD3100 in stem cell mobilization"
3. OHSU Medical School - MS2 Hematology Course: "Bone Marrow Transplantation," Portland, OR
4. Invited Lecturer, "Acute Graft vs Host Disease : current state of treatment and management," Ligand Pharmaceuticals, San Diego, CA.
5. OHSU Leukemia/Lymphoma Conference: "Acute Graft vs Host Disease"
6. NWMTP Regional Tx Conference: "Transplantation for Acute Non-Lymphocytic Leukemia"
7. Medical Grand Rounds, St. Vincent's Medical Center: "New approaches in anti-fungal therapy," Portland, OR.
8. OHSU Leukemia/Lymphoma Conference: "Reduced intensity transplantation: the OHSU experience"
9. Oncology Grand Rounds, Legacy- Good Samaritan Medical Center: "Infections in patients with hematologic malignancies", Portland OR.
10. Invited Lecturer, Oregon Leukemia & Lymphoma Society, "Understanding Graft vs Host Disease", Portland, OR.
11. OHSU Oncology Nursing Education Seminar: "Bone Marrow Transplantation", Portland, OR.
12. OHSU Heme/ Med Onc Fellows Conference: "Fundamentals of Bone Marrow Transplantation- Graft vs Host Disease"
13. OHSU Heme/ Med Onc Fellows Conference: "Aggressive and Highly Aggressive Lymphomas"
14. OHSU Leukemia/Lymphoma Conference: "The molecular etiology of Dyskeratosis congenita"

FORMAL PRESENTATIONS AND LECTURES

2005

1. Medical Grand Rounds, St. Luke's Medical Center: "Infections in the immune compromised host, with special attention to fungal infections", Boise ID
2. Medical Grand Rounds, Mercy Medical Center: "Infections in the immune compromised host, with special attention to fungal infections", Boise ID
3. OHSU Combined Organ Transplant Rounds: "Infections in the immune compromised host, with special attention to fungal infections", Portland, OR
4. Hematology Update: ASH, 2004: "Bone Marrow Transplantation", Portland, OR.
5. Tumor Board, Sacred Heart Hospital: "Infections in the immune compromised host, with special attention to to fungal infections", Eugene, OR.
6. OHSU Graduate School Course in Cancer Biology: "Cancer Therapeutics", Portland, OR.
7. OHSU Leukemia/Lymphoma Conference: "FDA and the Regulation of Cell Therapy"
8. OHSU Leukemia/Lymphoma Conference: "Aplastic anemia: management decisions – transplant vs immune suppressive therapy"
9. St. Luke's Mountain States Tumor Institute, 11th Annual High Dose Therapy and Stem Cell Transplantation Conference: "Treatment Options for Multiple Myeloma: Too many to choose from?", Boise, ID.
10. OHSU Leukemia/ Lymphoma Conference: "ABO Incompatible Hematopoietic Stem Cell Transplantation".
11. OHSU Critical Care Conference: "Hyperleukocytosis and leukostasis: Management of the ANLL patient".
12. Athersys, Inc., Invited Lecturer: "Clinical Presentation and Immunobiology of Graft vs Host Disease- the impact of alternative stem cell transplantation", Cleveland, Ohio.
13. Case Comprehensive Cancer Center Grand Rounds: "Acute Graft vs Host Disease: Clinical observations and investigations", Cleveland, Ohio
14. Case Comprehensive Cancer Center Blood Club Seminar: "Immunobiology of Graft vs Host Disease", Cleveland, Ohio
15. Pfizer- Sponsored BMT Advisory Board: "Management of Invasive Fungal Infections", San Diego, CA
16. National Marrow Donor Program Annual Council Meeting: "Graft vs Host Disease", Minneapolis, Minnesota
17. OHSU Critical Care Conference: "The Management of bronchiolitis obliterans, the pulmonary manifestation of chronic GVHD"
18. OHSU Oncology Nursing Education Program: "Complications of allogeneic transplantation: acute and chronic GVHD"
19. Providence Hospital Oncology Lecture: "Management of invasive fungal infections", Medford, OR.
20. Invited lecture, Portland Medical Oncology: "Fungal infections in the immune compromised host", Portland, OR.

2006

1. Hematology Update: ASH, 2005: "Bone Marrow Transplantation", Portland, OR.
2. Tokyo CML Seminar 2006: "Allogeneic Stem Cell Transplantation for CML in the Imatinib Era", Tokyo, Japan.
3. 1493rd Meeting of Keio Medical Society: "Allogeneic Stem Cell Transplantation for CML in the Imatinib Era: a decision analysis for treatment selection", Keio University School of Medicine, Tokyo, Japan.
4. Invited Lecturer: 21st Hokuyu Hospital Seminar in Hematology, "CML: a new management model for a chronic disease", Sapporo, Japan.
5. Hematology/ Oncology Grand Rounds, Salem Hospital: "Indications for Stem Cell Transplantation: 2006", Salem, OR
6. Fred Hutchinson Cancer Research Center Mini-transplantation Symposium: "CD134 T cell subsets in acute GVHD", Seattle, WA.
7. Fred Hutchinson Cancer Research Center Mini-transplantation Symposium: "Immunologic Analysis of Multipotential Adult Progenitor Cells", Seattle, WA.
8. OHSU Leukemia/Lymphoma Conference: "Reduced intensity transplantation"
9. OHSU Combined Organ Transplant Rounds: "Update on Hematopoietic Stem Cell Transplantation for Treatment of Patients with Hematologic Malignancies", Portland, OR.
10. OHSU Critical Care Conference: "The management of invasive aspergillus pulmonary infections".
11. OHSU Leukemia/Lymphoma Conference: M & M- "Splenic rupture during transplantation for systemic amyloidosis".
12. Leukemia/ Lymphoma Society Regional Patient Conference "Graft vs Host Disease- the Pluses and Minuses", Medford, OR.
13. Leukemia/ Lymphoma Society Regional Patient Conference: "Graft vs Host Disease", Portland, OR.

FORMAL PRESENTATIONS AND LECTURES

2006 (cont.)

14. ASHI Continuing Education Lecture- National Teleconference: “Graft vs Host Disease”, sponsored by Georgetown Medical Center, Washington DC.
15. OHSU Hematology/ Medical Oncology Grand Rounds: “Indications for Bone Marrow Transplantation”, Portland, OR.
16. Hematology/ Oncology Grand Rounds, Salem Hospital: “The management of GVHD”, Salem, OR.
17. NWMTP Biennial Transplant Conference, “Management of GVHD”, Portland, OR.
18. OHSU Bioethics Grand Rounds: “Bone Marrow Transplantation for the Uninsured?”, Portland, OR.

2007

1. Hematology Update: ASH, 2006: “Bone Marrow Transplantation”, Portland, OR.
2. OHSU Hematology/ Medical Oncology Grand Rounds: “Complications of Bone Marrow Transplantation”, Portland, OR.
3. Continuing Medical Education Lecture: “Advances in Fungal Therapy”, Portland, OR.
4. OHSU Leukemia/Lymphoma Conference: “Lymphoplasmacytic lymphoma”, Portland, OR.
5. Fred Hutchinson Cancer Research Center Mini-transplantation Symposium: “Results of a pilot trial of busulfan, TBI-200 and fludarabine for conditioning prior to allogeneic HSCT in the elderly or infirm”, Seattle, WA.
6. OHSU Heme/ Med Onc Fellows Conference: “Fundamentals of Bone Marrow Transplantation, Portland, OR.
7. Hematology Grand Rounds: Mayo Clinic “Advances in Management of Graft vs Host Disease”, Scottsdale, AZ.
8. Invited lecture, Scottsdale Hematology Community : “Fungal infections in the immune compromised host”, Scottsdale, AZ.
9. National Marrow Donor Program Annual Council Meeting: “Transplantation for CML in the Imatinib Era”, Minneapolis, MN.
10. Invited lecture, Bend Hematology/ Oncology: “Infections in the immune compromised host”, Bend, OR.
11. CHM BMT Morbidity & Mortality conference: “IPS as cause of death in HSCT patients”, Portland, OR.
12. OHSU Medical Resident’s Teaching Conference: “Non-Hodgkin’s Lymphoma”, Portland, OR.

2008

1. Leukemia/ Lymphoma Society Regional Patient Conference: “Non-Hodgkin’s Lymphoma”, Medford, OR
2. Medical Grand Rounds: “ Stem cell transplantation”, Sky West Medical Center, Klamath Falls, OR
3. Hematology Update: ASH, 2007: “Bone Marrow Transplantation”, Portland, OR.
4. Hematology update, ASH 2007: “Update in the Management of CLL”, Portland, OR.
5. 5th Annual Hematology & Medical Oncology Retreat: “Bench to bedside: MAPC in human transplantation”, Portland, OR
6. OHSU Leukemia/Lymphoma Conference: “BMT CTN: State of the Science, 2008”
7. Leukemia/ Lymphoma Society Regional Patient Conference: “Multiple Myeloma”, Lake Oswego, OR.
8. OHSU Combined Organ Transplant Grand Rounds: “MAPC as adjuncts to therapy during allogeneic hematopoietic stem cell transplantation”, Portland, OR.
9. OHSU Medical School - MS2 Hematology Course: “Hematopoietic Stem Cell Transplantation,” Portland, OR
10. Portland Citywide Oncology Journal Club: “Updates from the Tandem Transplantation Meetings: BMT CTN and the State of the Science”, Portland, OR.
11. Invited lecture, Eugene, OR Hematology/Oncology: “Infectious Complications of the Hematologic Malignancy Patient”
12. Seattle VAMC Transplant Rounds: “Transplantation for CML in the Imatinib Era”, Seattle, WA.
13. InterLink Health Services, National Medical Roundtable Teleconference: “Transplantation for CML in the Imatinib Era”, Portland, OR
14. Invited Lecture: “An Update of Transplant Options for Patients with Multiple Myeloma”, Corvallis, Or.
15. OHSU Leukemia/Lymphoma Conference: “The Radiation Injury Treatment Network”, Portland, Or.
16. OHSU Heme/ Med Onc Fellows Conference: “Indications for Bone Marrow Transplantation, Portland, OR.
17. OHSU Heme/ Med Onc Fellows Conference: “Stem Cell Transplantation, Part II: Complications of procedure, Portland, OR.
18. OHSU Leukemia/Lymphoma Conference: “New approaches to the management of aGVHD”, Portland, OR.
19. Invited Lecture: “An Update of Transplant Options for Patients with Multiple Myeloma”, Bend, OR.

FORMAL PRESENTATIONS AND LECTURES

2008 (cont.)

20. Cedars- Sinai Medical Center Stem cell Transplantation Grand Rounds: “New directions in the management of acute graft versus host disease”. Los Angeles, CA.
21. Invited lecture: “Management of opportunistic infections in the transplantation patient”, Los Angeles, CA

2009

1. Hematology Update: ASH, 2008: “Emerging trends in hematopoietic stem cell transplantation”, Portland, OR
2. Leukemia/ Lymphoma Society Regional ONS Education Conference, “Advances in Blood and Marrow Transplantation”, Portland, OR
3. Willamette McKenzie Hospital Medical Grand Rounds: “Stem cell transplantation and the promise of regeneration medicine”, McMinnville, OR.
4. OHSU Medical School - MS2 Hematology Course: “Hematopoietic Stem Cell Transplantation, Portland, OR
5. NWMTP 6th Biennial HSCT Conference: “Patient selection and eligibility”, Portland, OR
6. NWMTP 6th Biennial HSCT Conference: “Chronic GVHD management and other long term care of the transplant survivor”, Portland, OR.
7. Salem Heme/Onc Grand Rounds: “Current status of HSCT in the management of the patient with multiple myeloma”, Salem, OR.
8. Invited lecture, Hematology/ Oncology Associates “Current status of HSCT in the management of the patient with multiple myeloma”, Medford, OR
9. Advisory Board, Genzyme: “Stem cell mobilization challenges and clinical impact ”, Denver CO
10. Advisory board, Genzyme: “Proven versus predicted poor stem cell mobilizers: defining hard to mobilize patient populations”, Denver CO
11. Invited Lecture, “Current status of HSCT in the management of the patient with multiple myeloma- An update from the BMT CTN”, SW Washington Medical Center, Vancouver, WA
12. Invited Lecture, “Current status of HSCT in the management of the patient with multiple myeloma- An update from the BMT CTN”, Good Samaritan Hospital Cancer Center, Corvallis, OR
13. OHSU Medical Grand Rounds: “Medical preparedness for nuclear terrorism: the role of the radiation injury treatment network (RITN), Portland, OR
14. National Advisory Board, Sanofi-Aventis, Inc. “Results of a phase III study on rasburicase”. Chicago, IL
15. East Coast Advisory Board, Sanofi-Aventis, Inc. “Results of a phase III study on rasburicase, Dallas, Tx.
16. West Coast Advisory Board, Sanofi-Aventis, Inc. “Results of a phase III study on rasburicase, Dallas, Tx.
17. Invited Lecture, Mountain States Tumor Institute, “Current status of HSCT in the management of the patient with multiple myeloma- An update from the BMT CTN”, Boise, ID.
18. St .Alphonsus Hospital H/O rounds: “Current status of HSCT in the management of the patient with multiple myeloma- An update from the BMT CTN”, Boise, ID.
19. Invited lecture, “Stem cell mobilization”, UC Davis Medical Center, Sacramento, CA.
20. American Society of Hematology Scientific Session on Stem cell mobilization, “Plerixafor plus G-CSF is an effective regimen to mobilize hematopoietic stem cells in NHL patients with circulating peripheral blood CD34+ cells/ul <10”, New Orleans, LA

2010

1. Hematology Update: ASH, 2009: “Emerging trends in hematopoietic stem cell transplantation”, Portland, OR
2. Seattle VAMC Heme/Onc Grand Rounds: “Current status of HSCT in the management of the patient with multiple myeloma”
3. Scientific Session on Autologous Stem Cell Transplantation, Tandem Transplant Meetings “CNS Remission Predicts Survival after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma with Pre-existing CNS Involvement: A CIBMTR Analysis”, Orlando, FL
4. Invited Lecture, Scientific Advisory Board, “Current Strategies in Hematopoietic Stem Cell Mobilization”, Orlando, FL
5. OHSU Hem/Onc Training Forum for Novartis, Inc: “Patient selection and disease indications for hematopoietic stem cell transplantation”, Portland, OR

FORMAL PRESENTATIONS AND LECTURES

2010(cont.)

6. 16th Annual blood brain barrier consortium meeting: CNS Remission Predicts Survival after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma with Pre-existing CNS Involvement: A CIBMTR Analysis, Sunriver OR
7. Portland Citywide Hematology Journal Club: “Updates in HSCT- insights from the Tandem Transplant meetings, 2010”, Portland, OR.
8. Invited Lecture, UCSF Stem Cell Transplant Program, “Current Strategies in Hematopoietic Stem Cell Mobilization”, San Francisco, CA
9. BMT M & M: Adenovirus infections in the Blood & Marrow Transplant Patient, Portland, OR
10. OHSU Medical School - MS2 Hematology Course: “Hematopoietic Stem Cell Transplantation,” Portland, OR
11. Inflammatory Bowel Disease Athersys Research Meeting: “GVHD: defining the scope of the problem”, New York, NY
12. Invited Lecture, “Current status of HSCT for management of patients with multiple myeloma”, Longview, WA.
13. Portland Emergency Medical Disaster System Team: “Medical preparedness for nuclear terrorism: the role of the radiation injury treatment network (RITN)”, Portland, OR
14. Sanofi- Aventis National Advisory Board, “Results of a phase III study on rasburicase efficacy in control of hyperuricemia”. Chicago, IL
15. Stem Cells USA and Regenerative Medicine Congress: “Finding an industry voice for regenerative medicine”, Philadelphia, PA.
16. Hematopoietic Stem Cell Transplantation in 2020: NMDP System Capacity Initiative Symposium: “The system need for expanded outpatient allogeneic stem cell transplantation procedures ”, Chicago, IL.
17. Hematopoietic Stem Cell Transplant for Advanced Practice Clinicians- 2010 Portland Conference: “Getting blood from a stone: The art of stem cell mobilization and collection”, Portland, OR.
18. Hematopoietic Stem Cell Transplant for Advanced Practice Clinicians- 2010 Portland Conference: “Work Force Shortages in Transplantation: Opportunities for Advanced Practice Providers?”
19. Hematopoietic Stem Cell Transplant for Advanced Practice Clinicians- 2010 Portland Conference: “The secondary disease of transplant: Acute GVHD”, Portland, OR.
20. ASBMT Corporate Council Meeting: “How Industry, NIH and Academia can Collaborate to Facilitate Cellular Therapy Trials”, Kiawah Island, SC.
21. CHM Strategic Planning Meeting, Knight Cancer Institute: “Work force issues and influence on care systems for hematopoietic stem cell transplant programs”.
22. American Society of Hematology Scientific Session on Autologous Stem Cell Transplantation for Lymphoma, Leukemia, Myeloma: “CNS Remission at the Time of Autologous Stem Cell Transplantation Improves Outcomes for Patients with Non-Hodgkin Lymphoma with Pre-existing CNS Involvement”, Orlando FL

2011

1. Cardiology Research Center, Providence St. Vincent’s Medical Center: “Can adherent stromal stem cells provide efficacious adjunctive therapy in hematopoietic stem cell transplantation?” Portland, OR
2. Hematology Update: ASH, 2010: “Updates in Hematopoietic Stem Cell Transplantation: 10 things from ASH to share with you”, Portland, OR
3. BMT CTN: “CTN trials as source of RRT assessments in the modern era”, Honolulu, HI.
4. Tandem Transplant Meetings Scientific Symposia: “Can adherent stromal stem cells provide efficacious adjunctive therapy for hematopoiesis in HSCT?”. Honolulu, HI.
5. Invited Lecture:Athersys, Inc. “Stromal stem cells in hematopoietic stem cell transplantation: unmet needs and opportunities”. Cleveland, OH.
6. Investigators meeting, Teva Pharm. “Novel cord blood transplant therapies”., Miami, FL
7. OHSU Nursing Education Lecture Series: “Graft vs Host Disease: Friend or foe?” Portland, OR.
8. Invited Lecture: “Stem cell transplantation for multiple myeloma and other hematologic malignancies: an update on indications in 2011”. Coos Bay, Or.
9. OHSU Hematology/ Medical Oncology Grand Rounds : “Hematopoietic Stem Cell Transplantation: Indications and Complications”, Portland, OR.

10. NWMTP Biennial Transplant Conference: "Current status and future horizons for autologous transplantation used in the treatment of multiple myeloma patients". Portland, Oregon.
11. NWMTP Biennial Transplant Conference: "Clinical Management Challenges in the Long Term Transplant Survivor". Portland, OR.
12. Oregon Physicians Assistant Annual Meeting: "Advances in the care of the patient with acute myeloid leukemia". Salem, OR.
13. OHSU Medical School - MS2 Hematology Course: "Introduction to Hematopoietic Stem Cell Transplantation," Portland, OR.
14. Cedars-Sinai Medical Center- Stem Cell Transplant Grand Rounds. "Getting blood from a stone: The art of stem cell mobilization and collection", Los Angeles, CA.
15. Invited Lecture, Genzyme-sponsored, for the American Association for Apheresis "Getting blood from a stone: The art of stem cell mobilization and collection", Scottsdale, AZ.
16. Genzyme Advisory Board, "Stem Cell Mobilization and Transplantation for NHL in 2011: Ensuring Access to Transplant", Boston, MA.
17. BMT CTN, "Survey of non-core affiliate centers: Perceptions of the BMT CTN", Crystal City, VA.
18. ISCT: NMDP Workshop on Reimbursement for Stem Cell Therapies: "The view from the field: the nuts and bolts of reimbursement of healthcare delivery ", Minneapolis, Mn.
19. National Marrow Donor Program System Capacity Initiative Symposium Year II, "HCT in 2020 Financial Working Group," Minneapolis, MN
20. Plenary Lecture: International Society for Cellular Therapy North American Regional Meeting 2011, "MSC Dose Response – State of the Art," Charlottesville, VA.
21. Stem Cell Mobilization Consensus meeting: "Phase III trial results of plerixafor and its impact on stem cell mobilization", New York, NY
22. Invited Roundtable Forum, HSCT program, Hershey Medical Center: "Stem cell mobilization", Hershey, PA
23. Novartis CML Phase 5 Practicum, OHSU, "Stem Cell Transplant for Ph+ Leukemias", Portland, OR
24. Invited Lecture: "Stem cell transplantation for multiple myeloma: new futures", Bend, OR
25. Stem Cell Meeting on the Mesa: "Public and private pathways for reimbursement of cellular therapy", La Jolla, CA
26. Alder Biopharmaceuticals, Inc.: "Graft vs Host Disease- results of antibody trials". Bothell, WA.
27. ASH Spotlight Session: "MSC and GVHD", San Diego, CA.

2012

1. Invited Lecture, Millenium Pharmaceuticals-sponsored, "Overall survival in previously treated multiple myeloma: The role of bortezomib", Hood River, OR.
2. OHSU Hematology Symposium, ASH Update, 2011: "Hematopoietic stem cell transplantation- future directions", Portland, OR
3. ASBMT BMT Pharmacists Plenary Lecture, "Expanding applications of cellular therapy: use in brain injury, diabetes mellitus, HIV, myocardial infarction, and beyond", San Diego, CA.
4. Novartis CML Phase 5 Practicum, OHSU, "Stem Cell Transplant for Ph+ Leukemias", Portland, OR
5. 8th Stem Cell Research and Regenerative Medicine Summit Meeting, "Adult mesenchymal stromal cells: refocused effort in hematopoiesis and GVHD", Boston, MA.
6. OHSU Medical School - MS2 Hematology Course: "Introduction to Hematopoietic Stem Cell Transplantation," Portland, OR.
6. OHSU Nursing Education Lecture Series: "Expanding applications of Cellular Therapies", Portland, OR.
7. FHCRC 2012 Mixed Chimerism Meeting: "MAPC as prophylaxis for aGVHD: results of phase I study", Seattle, WA.
8. Invited Lecture, Millenium Pharmaceuticals-sponsored, "Overall survival in previously treated multiple myeloma: The role of bortezomib", Lewiston, ID.
9. ISCT Plenary Lecture : "Achieving Reimbursement for Regenerative Medicine: Building Collaboration with Payors", Seattle WA.
10. Alder Pharmaceuticals: " MAPC as prophylaxis for aGVHD: results of a phase I study", Bothell, WA.
11. HFMA Plenary Lecture: "Partnering with Payers for Product Line Growth: A collaborative initiative to remove financial barriers to HCT", Las Vegas, NV.
12. BMT CTN, "Follow-up survey: non-core affiliate centers: Recommendations for the BMT CTN", Crystal City, VA.
13. OHSU Hematology/ Medical Oncology Grand Rounds: "Blood & Marrow Transplant Emergencies", Portland, OR.
14. Novartis Hematology and Medical Oncology Practicum, OHSU, "Introduction to Hematopoietic Stem Cell Transplantation", Portland, OR.

15. OHSU Nursing Education Lecture Series: "Blood & Marrow Transplant Emergencies", Portland, OR.
16. NMDP System Capacity Initiative Symposium: "Financial Working Group: Implementation Update and Succession Planning", Minneapolis, MN
17. OHSU Nursing Education Lecture Series: "Getting blood from a stone- the art of stem cell mobilization", Portland, OR.
18. IBC Cell Therapy Clinical Development: "Obstacles in implementation of regenerative medicine technologies", Arlington, VA.
19. Mountain States Tumor Institute: "Stem cell mobilization strategies", Boise, ID.
20. Sacred Heart Hospital Cancer Program: "Stem cell mobilization strategies and applications to autologous HSCT", Spokane, WA
21. CHM Lecture Series: "New research activities within the BMT CTN", Portland, OR
22. Merle West Cancer Center, Sky Lakes Medical Center: "Transplantation for myeloma: where is it now?", Klamath Falls, OR
23. Stem Cells on the Mesa, Sanford-Burnham Institute: "Overcoming obstacles for commercialization for clinical application of stem cell therapies", San Diego, CA.
24. 2nd NIH conference on prevention and treatment of relapse after allogeneic HSCT: "Flt3 inhibitors for prevention and treatment of relapse of Flt3 mutated AML patients undergoing allogeneic HSCT", Bethesda, MD.
25. CHM Grand Rounds: "Meeting review- 2nd NIH conference on prevention and treatment of relapse after allogeneic HSCT", Portland, OR.

2013

1. CHM Grand Rounds: "Adult Mesenchymal stromal cells: refocused efforts in hematopoiesis and GVHD", Portland, OR
2. Hematology Update: ASH Update, 2012: "Hematopoietic stem cell transplantation- future directions", Portland, OR
3. Peace Health Cancer Rounds: "Stem Cell Transplantation- where are we and where are we going?", Vancouver, WA.
4. Tandem Transplant Meetings: Scientific Sessions- "CIBMTR IN09-01 Outcomes of allogeneic hematopoietic stem cell transplantation for patients with hematologic malignancies with and without pre-existing fungal infections", Salt Lake City, UT.
5. John Muir Hospital: "Transplantation 2020: is it too late to build a transplant program?", Walnut Creek, CA.
6. NWMTP Biennial Transplant Conference: "Current & future applications for HSCT". Portland, Oregon
7. Novartis Hematology and Medical Oncology Practicum, OHSU, "Hematopoietic Stem Cell Transplantation for CML in the TKI Era", Portland, OR.
8. OHSU Medical School, Hematology Yr II: "Introduction to Hematopoietic Stem Cell Transplantation," Portland, OR
9. ISCT Commercialization Track: "Perspectives on cell therapy reimbursement from the front lines of medicine "The good, the bad, and the ugly", Auckland, New Zealand.
10. Salem Cancer Institute: Knight Cancer Institute Symposium on Myeloma: "Management of renal failure in multiple myeloma", Lake Oswego, OR.
11. Solid Organ Tx Grand Rounds: "Stromal Cells as Adjunctive Therapy for Hematopoietic Stem Cell Transplantation", Portland, OR.
12. Novartis Hematology and Medical Oncology Practicum, OHSU, "Hematopoietic Stem Cell Transplantation for CML in the TKI Era", Portland, OR.
13. NMDP Payer Forum 2013: "Transplant Benefits Impact: positive and negative", Chicago, IL.
14. Invited Lecture, St. Joseph's Med Center: "Building a transplant center- starting from the ground floor", Tacoma, WA.
15. International Society for Cellular Therapy North American Regional Meeting 2013: Scientific Session -"Solution phase cross talk and regulatory interactions between multipotent adult progenitor cells, and peripheral blood mononuclear cells", Philadelphia, PA.
16. International Society for Cellular Therapy North American Regional Meeting 2013: "Perspectives on Reimbursement: The view from a transplanters's eye", Philadelphia, PA.
17. 2013 HSCT for Advance Practice Providers Conference: "Stem Cells: They Aren't Just for Transplant Anymore", Portland, OR
18. 2013 HSCT for Advance Practice Providers Conference: "Introduction to Immunology", Portland, OR.
19. Invited Lecturer: "Perspectives on stem cell therapy reimbursement from the front lines of medicine "The good, the bad, and the ugly", Dartmouth Medical Center, Hanover, NH.
20. Invited Lecturer: "Getting blood from a stone- the art of stem cell mobilization", Dartmouth Medical Center, Hanover, NH
21. CHM Grand Rounds: "BMT CTN: What's beyond the horizon?", Portland, OR

2014

1. Hematology Update: ASH Update, 2013: "Hematopoietic stem cell transplantation- future directions", Portland, OR
2. OHSU Medical School, Hematology Yr II: "Introduction to Hematopoietic Stem Cell Transplantation," Portland, OR
3. CHM Grand Rounds: "Transplantation for refractory malignancy", Portland, OR
4. 15th Biannual BMT and Hem Malignancies Conference: "Future of Hematopoietic Stem Cell Transplantation", Boise, ID
5. CHM Grand Rounds: "Transplantation for high grade myelodysplasia", Portland, OR
6. OHSU Transplant Survivor conference, 2014: "Snapshots on the edge of life: reflections from a BMT ward", Portland, OR
7. OHSU Medical School, Hematology/Immunology Yr I: "Introduction to Hematopoietic Stem Cell Transplantation," Portland, OR
8. OHSU Medical School, Hematology/Immunology Yr I: "Introduction to Immunology- the Allogeneic Response," Portland, OR

2015

1. Hematology Update: ASH Update, 2014: "Hematopoietic stem cell transplantation- State of the science", Portland, OR
2. Lincoln City Hospital Cancer Rounds: "Stem Cell Transplantation- where are we and where are we going?", Lincoln City, OR
3. Phacilitate Annual meeting: "Determining utilization of regenerative medicine cellular products: a physician perspective, Washington DC
4. BMT CTN Steering Committee meeting: "Survey of non-core affiliate centers: Perceptions of the BMT CTN", San Diego, CA
5. ASBMT Tandem Tx Meeting: Plenary Session "An overview: how much is one life worth? Identifying costs and determining value measures in HSCT", San Diego, CA
6. NWMTP Biennial Transplant Conference: "Transplant Community – who are we? (ASBMT, CIBMTR, BMT CTN, FACT, etc)". Portland, Oregon
7. NWMTP Biennial Transplant Conference: "There is a Donor for Everyone: Cord Blood and Haplo-identical Transplants". Portland, Oregon
8. NWMTP Biennial Transplant Conference: "CAR-T cells and the management of relapsed, refractory ALL". Portland, Oregon
9. OHSU Medical School, Hematology Yr. II: "Introduction to Hematopoietic Stem Cell Transplantation," Portland, OR
10. American Society for Gene & Cell Therapy: Commercialization workshop- "How we make choices: private and public payor support for orphan diseases" New Orleans, LA.
11. International Society for Cell Therapy: "Reimbursement for novel cellular therapies- a ground floor view". Las Vegas, NV.
12. OHSU Vaccine and Gene Therapy Institute/ Oregon Primate Center: "Graft-versus-Host Disease", Beaverton, Oregon.
13. BMT Infonet Webinar: "Transplants 101: An introduction to bone marrow, stem cell and cord blood transplantation".
14. Northwest Advanced Practice Providers Oncology Summit: "Hematologic malignancies and their financial impact on health care", Portland, OR.
15. OHSU Physician Assistant Training Program: "Hematopoietic stem cell transplantation", Portland, OR.
16. American Association for Blood Banks: "Mesenchymal stromal cells: potential roles as therapeutics for GVHD prophylaxis and treatment", Anaheim, CA.
17. National Marrow Donor Program Council Meeting: "Stem cell transplantation: perspectives on reimbursement in the modern era", Minneapolis, MN.
18. Knight Cancer Institute OHSU Traveling CME: "Advances in stem cell transplantation", Corvallis, OR.
19. Knight Cancer Institute Translational Oncology Grand Rounds: "Mesenchymal Stromal Cells: Graft vs Host Disease Prophylaxis and Treatment", Portland, OR.
20. ASH Scientific Sessions: "Five year direct cost of pediatric patients with ALL undergoing allogeneic stem cell transplantation: an analysis from US payers' perspective, Orlando, FL.

2016

1. Hematology Update: ASH Update, 2015: "Hematopoietic stem cell transplantation", Portland, OR
2. Health economics invited lecture: "Down the rabbit hole: misadventures in coding land", Roswell Park Cancer Institute, Buffalo, NY

3. Medical grand rounds: "Stem cell transplantation: perspectives on reimbursement in the modern era", Roswell Park Cancer Institute, Buffalo, NY
4. Tandem Tx meeting: "Health economics: HCT as a model system", Honolulu, HI
5. Tuality Hospital Tumor Board: "Immunotherapy comes of age: CAR-T for large cell lymphoma", Hillsboro, OR.
6. Novartis National Advisory Board: "Midostaurin: Data Gaps in treatment approaches to AML", Atlanta, GA.
7. DKMS/CancerCare Teleconference: "HCT as a Treatment Option for Blood Cancers", National webinar, USA
8. CHM Grand Rounds: "Keeping a finger on the pulse of BMT CTN- trials planned or in development ", Portland, OR.
9. BMT Journal club: "Alternate donor transplantation", Portland, OR.
10. CHM Nursing Education Rounds: "Stem cell mobilization strategies: optimal pathways in patient care", Portland, OR.
11. BMT Journal Club: "HCT and ICU- defining outcome pathways", Portland, OR.
12. OHSU Heme Onc Grand Rounds: "Innovations in cellular therapy", Portland, OR.
13. Cell & Gene Therapy Bioprocessing & Commercialization Summit: "Understanding cell therapy and physician choice in the new world of value based reimbursement", Boston, MA.
14. OHSU BMT M & M's: "Management of Hepatitis B + transplant recipients", Portland, OR.
15. NMDP Advisory Group on Finances In HCT: "Back to the Basics: HCT & the Money Problem", Minneapolis, MN.
16. CHM Grand Rounds: "Brass Tacks: The costs of transplantation and determinations of value", Portland, OR
16. Haploidentical Transplantation 2016: "Role of inducible suicide switch in cellular immunotherapy", San Diego, CA.
17. Amer Soc Hematology, Novartis investigator forum: "Results of Radius: a phase II randomized trial of standard of care with/ without midostaurin to prevent relapse after allogeneic HSCT in patients with FLT3-ITD mutated AML" San Diego, CA.
18. OHSU BMT Education Rounds: "Invasive fungal infections in the immune compromised patient", Portland, OR.

2017

1. OHSU BMT Education Rounds: "Engraftment syndrome", Portland, OR.
2. Hematology Update: ASH 2016: "Stem cell transplantation & cellular therapy: Now more than ever", Portland, OR
3. ASBMT Tandem Tx meeting: "Defining our financial floor: funding for HCT in US under the ACA", Orlando, FL.
4. OHSU BMT Education Rounds: "Allogeneic tx for MDS: an evolution in application", Portland, OR.
5. NWMTP Biennial Stem Cell Tx Conference: "Expanding applications for cellular therapy in the management of patients with hematologic malignancies", Portland, OR.
6. SWOG BMT Committee: "Prevention of relapse after allogeneic HCT- novel approaches", San Francisco, CA
7. OHSU BMT Education Rounds: "Prevention of relapse after allogeneic HCT- novel approaches", Portland, OR
8. OHSU BMT Education Rounds: "ATG and its application as GVHD prophylaxis", Portland, OR
9. Xconomy meeting on Cancer Immunotherapy: "Can CAR-T be tamed?", Seattle, WA
10. KCI CAR-T & Immuno-oncology Summit: "CAR-T for adult lymphomas & leukemias", Portland, OR
11. KCI CAR-T & Immuno-oncology Summit: "Value assessments & reimbursement models for CAR-T cellular therapy", Portland, OR
12. OHSU BMT Education Rounds: "CAR-T for large cell lymphoma: a detailed examination of Kite & Novartis multicenter phase II trials for advanced disease", Portland, OR.
13. OHSU CHM Grand Rounds: "Transplantation for the elderly? Or Transplantation is for the elderly.", Portland, OR.
14. 33rd Annual ROSE insurance conference: "Cost of Cancer Care", Minneapolis, MN.
15. Emmanuel Hospital Resident Rounds: "Cancer care: growth and limitations", Portland, OR.
16. Keith Hansen Memorial Lecture, Emmanuel Hospital Med Grand Rounds: "Cell therapy: from transplantation to organ regeneration", Portland, OR.
17. OHSU BMT Education Rounds: "Transplantation for Mantle Cell Lymphoma", Portland, Or.
18. SWOG BMT Committee: "Measurement modalities of minimal residual disease in myeloid malignancies", Chicago, IL.
19. CHM Grand Rounds: "How good of a hematologist are you? A morphologic review of pathology", Portland OR.
20. Society for Immunotherapy: Scientific session: "Report on the economics of adoptive cell therapy", Washington, D.C.
21. Investigator's Meeting, Fate Therapeutics, American Society of Hematology: "PROTECT: results of a phase I GVHD prophylaxis study of graft engineered PBSC allografts", Atlanta, GA.

2018

1. Hematology Update: ASH 2017: "Technology meets Transplantation: Updates in BMT & CAR-T Cellular Therapy", Portland, OR
2. CHM Grand Rounds: "Clinical M & M Presentation -GVHD & Sepsis", Portland, OR
3. ASBMT Value & Health Economic Interest Group Meeting- "Value measures of Chimeric antigen receptor T cell

- therapy”, Salt Lake City, UT
4. Institute for Clinical & Economic Review (ICER)- Chimeric antigen receptor T cell therapy for B cell cancers: Effectiveness & Value: “Commentary re: FDA approval of CAR-T therapy in absence of randomized controlled trials for patients with advanced hematologic malignancies”, Oakland, CA.
 5. Canadian cell and Gene therapy strategy workshop, ISCT annual meeting: “Risk sharing models for reimbursement in cellular therapy”, Montréal, Canada.
 6. Knight Oncology Quality Committee: “Sepsis- impact on outcomes of stem cell transplant recipients”, Portland, OR
 7. OHSU BMT & Cellular Therapy Education Rounds: “Axicabtagene ciloleucil- efficacy and toxicity experiences”, Portland, OR
 8. OHSU BMT & Cellular Therapy Education Rounds: “Herpes zoster- post transplant complications and prevention”, Portland, OR
 9. CancerCare National Teleconference: “Novel management strategies for GVHD: new therapies, new trials, new horizons”. National webinar, USA.
 10. OHSU BMT & Cellular Therapy Education Rounds: “Ruxolitinib for the treatment of patients with steroid refractory GVHD”, Portland, OR
 11. Novartis National Meeting: “Advanced DLBCL management: where we were, where we are going”, Whippany, NJ.
 12. Novartis National Meeting: “Assessing value & quality in care delivery: the migration toward patient reported outcome”, Whippany, NJ.
 12. Fourth international workshop on the biology, prevention, and treatment relapse after hematopoietic stem cell transplantation: “The economics of cellular therapy”, Chicago IL.
 13. Society for Adolescent & Young Adult Oncology: “The economics of CAR-T therapy”, Newport Beach, CA.
 14. American Cancer Society Cancer Action Network (Oregon): “Perspectives on CAR-T therapy from the front lines of medicine”, Portland, Or.
 15. 17th Biennial BMT & Hem Malig Conference: “The cost of cancer care: the viewpoint of a cell therapist”, Boise, ID
 16. OHSU Knight Cancer Outreach Series: “Advances in T cell immunotherapy”, Salem, OR.
 17. OHSU BMT & Cellular Therapy Education Rounds: “Repeat transplant procedures after relapse in myeloma patients after HSCT”, Portland, OR
 18. ASH Scientific Sessions: Radius, a phase 2 randomized trial investigating standard of care +/- midostaurin after allogeneic stem cell transplant in FLT3-ITD mutated AML”, San Diego, CA.
 19. OHSU BMT & Cellular Therapy Education Rounds: “Novel investigational approaches for the management of aGVHD after allogeneic stem cell transplantation”, Portland, OR.

2019

1. OHSU BMT & Cellular Therapy Education Rounds. “Prophylactic and therapeutic donor leukocyte infusions”, Portland, OR
2. Novartis Canada Meeting. “Advanced DLBCL management: where we were, where we are going”, Victoria, BC
3. Novartis Canada Meeting. “Chimeric antigen receptor T cell therapy – toxicity and efficacy”, Victoria, BC
4. Novartis Canada Meeting. “Chimeric antigen receptor T cell therapy- real world experiences”, Victoria, BC
5. Dept of Neurology Journal club. “Stem cell transplantation for multiple sclerosis”, Portland, OR
6. Hematology Update: ASH 2017: “Cellular Therapy: Updates in BMT & CAR-T Cellular Therapy”, Portland, OR
7. ISCT Commercialization Signature Series- Achieving Global CGT Adoption: “Is the market prepared to adopt cell and gene therapy products- reimbursement models”, Miami, FL.
8. OHSU Graduate School, Cell & Gene Therapy. “Chimeric antigen T cell therapy”, Portland OR.
9. OHSU Graduate School, Cell & Gene Therapy- Journal Club. “TET2 disruption and clonal CART expansion”, Portland, OR
10. Tuahly Hospital Mediical Grand Rounds. “The emergence of immune effector cell therapy for the treatment of hematologic malignancies”, Hillsboro OR.
11. Transplant & Cellular Therapy Meeting Scientific Sessions: “Long-term Follow-up of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of JULIET Study”. Houston, TX.
12. Transplant & Cellular Therapy Meeting Scientific Sessions: “Radius: a phase 2 randomized trial investigating standard of care +/- midostaurin after allogeneic stem cell transplant in FLT3-ITD mutated AML”, Houston TX.
13. CHM Grand Rounds: “Chimeric antigen receptor T cell therapy”, Portland, OR.
14. EBMT Lymphoma Scientific Session: “Consensus CRS and neurological events regrading of “JULIET”: Phase II prospective study of tisagenlecleucel therapy in patients with relapsed/refractory diffuse large B-cell lymphoma”, Frankfurt, Germany.

15. EBMT Cellular Therapy Educational Session: “Strategies for optimizing CAR-T cell therapy in patients with DLBCL in the real world: management of neurological and long term cytopenias”, Frankfurt, Germany.
16. Community Oncology Alliance: Plenary lecture: “CAR-T: Exploring Clinical Efficacy & Toxicity, Value Assessments, Reimbursement Issues & Challenges”, Orlando, FL.
17. American Society of Gene & Cellular Therapy: The emergence of cell and gene therapy: the costs of care”, Washington DC
18. Citywide Journal Club: “Efficacy & Toxicity of Tisagenlecleucel for relapsed/refractory large cell lymphoma”, Portland, OR
19. Univ of Pennsylvania- CAR-T & the rise of Cellicon Valley Symposium. “The view from the ground floor: the cost of care for cellular therapy, Philadelphia, PA.
20. Fate Therapeutics- Invited Scientist: “Prophylaxis strategies for acute GVHD”, San Diego, CA
21. Fate Therapeutics- Invited Lecture: “The evolving management of immune effector cell therapy”, San Diego, CA.